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Abstract 
 
Antibiotic treatments are known to disturb the composition and metabolic activity of the 
human gut microbiota and, therefore, may lead to gut disorders. In this thesis, it was 
investigated whether and by which mechanisms galacto-oligosaccharides (GOS), a 
prebiotic known to stimulate the growth of bifidobacteria and to positively influence 
human health, may counter the  negative effects of antibiotics on the microbiota.  
First, a high throughput approach combining the in vitro fermentation screening platform 
with a phylogenetic microarray read-outs was shown to be reliable to simultaneously 
analyse the effects of several often-used antibiotics on the intestinal microbiota. Then, 
using the same approach, the recovery of the composition and metabolic activity of the 
microbiota treated with four selected antibiotics upon GOS addition was shown to be 
antibiotic and dose dependant. The addition of GOS to an amoxicillin (AMX)-treated 
microbiota was considered successful as, after a decrease of the level of Bifidobacterium 
species, the recovery of mainly Bifidobacterium longum, was observed. The growth of 
bifidobacteria and the production of the beneficial butyrate tended to be higher upon 
addition of small GOS (dimers-trimers) than upon large GOS in non-treated microbiota 
(tetramers to hexamers). On the contrary in AMX-treated microbiota, the growth of 
bifidobacteria and production of butyrate tented to be higher upon addition of large GOS 
than upon addition of small GOS. The positive results of GOS on AMX-treated microbiota 
during in vitro experiments were evidenced in a double-blind randomized parallel 
intervention study involving 12 healthy adults.  
Overall, the addition of GOS, especially the large oligosaccharides, allowed the recovery of 
B. longum and, subsequently, stimulated the activity of the microbiota through cross-
feeding after an AMX treatment.  
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Project outline 
In the beginning of the 20th century, public health improved tremendously due to better 
sanitation, better hygiene and medical discoveries on the treatment of disease, such as 
penicillin (1928), the first antibiotic. Nowadays, human health is also a reflection of what 
people eat. The diet can influence the incidence of certain disorders, such as coronary 
heart diseases, diabetes and obesity. Recently, it has been shown that a number of these 
health disorders can be related to the composition and metabolic activity of the bacteria 
present in the gut, the gut microbiota. The gut microbiota, comprising more bacteria than 
our body has cells, has become in the last decades a key towards human health to be 
unveiled.  
One occasion of disturbance in the gut microbiota is the use of antibiotics. Despite their 
positive action to treat infectious diseases, antibiotic also alter the composition and 
metabolic activity of the gut microbiota and may, therefore, lead to gut disorders. On the 
contrary, prebiotics that are known to stimulate beneficial bacteria are thought to be a 
means to prevent the side effects of antibiotics on the microbiota. This thesis focuses on 
understanding when and how prebiotics can help to counter the side effects of antibiotics 
on the human gut microbiota. 
 
Gut microbiota  
The gut comprises the small intestine and the large intestine, also called colon. The small 
intestine is the first part of the gut, where most of the food compounds are digested and 
absorbed into the blood. The colon is the last part of the human gastrointestinal tract. 
Different regions can be distinguished: The ascending colon, the transverse colon, the 
descending colon, the sigmoid colon and rectum (Figure 1).1, 2 The main functions of the 
colon includes the absorption of electrolytes and water, the accumulation and excretion 
of waste material3 as well as protective, trophic and metabolic functions through the 
presence of a bacterial ecosystem, the gut microbiota.4, 5 The concentration of bacteria in 
the gut is increasing from the small intestine (104-107 cells g-1) to the colon (1010-1012 
cells.g-1) (Figure 1).2  
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Figure 1: Schematic representation of the human gut and amount of bacteria per gram of 
intestinal contents (adapted from Payne et al 2). 
Microbiota composition  
The colonic or gut microbiota is a complex microbial ecosystem, which comprises a large 
number and variety of bacteria, up to 1012 bacteria for every gram of gut content and 
more than 1000 different species.2, 6 The microbiota is dominated by anaerobic bacteria, 
which are usually either saccharolytic or proteolytic.7 These bacteria mainly belong to two 
phyla, the Firmicutes and Bacteroidetes, whereas the Proteobacteria, Verrucomicrobia, 
Actinobacteria, Fusobacteria and Cyanobacteria are present in minor proportions.8 The 
main two phyla represent about 90% of the total population. The main phylogenetic 
cluster belonging to the Firmicutes is the class of Clostridia, while the main phylogenetic 
cluster belonging to the Bacteroidetes is the genus of Bacteroides. Furthermore, the 
phylum of Actinobacteria includes important members of the gut microbiota, such as the 
beneficial gram positive Bifidobacterium genus.9, 10 Bifidobacterium spp. represent 3% to 
6% of the total bacterial cell count in adults.10, 11  
It has been suggested that the human gut microbiota has a dominant core of bacteria.12, 13 
In adults, three clusters, named “enterotypes”, have been identified by the variation in the 
levels of genera and named after the most dominant one: Bacteroides (enterotype 1), 
Prevotella (enterotype 2) and Ruminococcus (enterotype 3).14 Despite a common core of 
bacteria, the diversity of the microbiota at species level remains highly individual 
dependant.8 For each individual, the microbiota composition is highly resilient and stable 
over periods of life.15 The stability is suggested to be due to the functional redundancy of 
certain groups of bacteria, for instance the Bacteroides sp. that show redundancy in their 
genomes to degrade polysaccharides. 10, 16  
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Microbiota metabolic activity  
The metabolic activity of the microbiota refers to the degradation and fermentation of the 
non-digested compounds reaching the colon by the complex microbiota. The main 
substrates reaching the colon are from dietary origin, including  resistant starch, non-
starch polysaccharides, non-digestible oligosaccharides,17 and also minor concentrations 
of proteins, peptides and amino acids.4 Due to the diversity of the substrates reaching the 
colon, a synergy between the bacterial groups is in place to achieve partial or complete 
degradation of the substrates.18, 19 Released disaccharides and monosaccharides are 
further fermented into organic acids (OA), which can be intermediate OA, such as lactate 
and succinate, and short chain fatty acids (SCFA), such as acetate, butyrate and 
propionate. Intermediate OA and acetate serve as growth substrate for other bacteria,18, 
20, 21 while SCFA are absorbed into the blood through the portal vein. The SCFA production 
is strongly dependant on the substrate source, the species and amount of bacteria present 
and the gut transit.22  Overall, the different bacterial groups of the gut microbiota appear 
to work in a coherent and efficient network of cross-feeding species and, therefore, to 
ensure the functioning of the gut microbiota (Figure 2).17 
 
 
Figure 2: Diagram illustrating the sequential degradation of dietary carbohydrates and the 
intermediate and final metabolites formed by the gut microbiota (reprinted from Scott et al17). 
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Gut microbiota and its relevance to health 
The gut microbiota may have an effect on health because of the nature of the bacteria 
itself. Bacteria have been reported to have either or both a beneficial and a harmful effect 
on host health (Figure 3)3. For example, Bifidobacterium spp. are known to have several 
benefits on health, such as lowering blood cholesterol level, producing vitamins and 
restoring the normal intestinal microbiota after antibiotic therapy.23 On the contrary, 
Clostridium difficile is known to induce diarrhoea or severe inflammation of the colon.24 
Furthermore, compounds resulting from the bacterial fermentation may influence the 
host’s health as well.3 Saccharolytic fermentation results in end-products that have 
benefits for the host. Propionate has been shown to inhibit cholesterol synthesis, while 
butyrate has been proposed to lower the risk of colon cancer and to play a major positive 
role in the chronic intestinal inflammations.22 Overall, SCFA decrease the pH in the colon 
and, therefore, limit pathogen colonisation.3 On the contrary, proteolytic fermentation 
results in metabolites, such as ammonomia, phenols, indoles and amines, that are toxic.22 
The proteolytic fermentation mostly takes place in the distal colon, which is a part of the 
colon reported to be the main site of chronic gut disorders, such as bowel cancer and 
ulcerative colitis.4 
 
Figure 3: Generalized scheme of the composition and health effects of predominant faecal 
bacteria (adapted from Gibson et al3). 
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Finally, the gut microbiota may have a health impact because it acts as a protective 
barrier. The microbiota diversity helps to resist to the potential intestinal pathogen 
colonisation.4 Possible mechanisms involved in colonisation resistance are e.g. acids 
production that lower the gut pH, competition for adhesion site and for nutrients, 
production of toxic metabolites and antagonistic compounds, and enhancement of the 
immune system.25 Recent studies have highlighted the fact that an imbalanced gut 
microbiota is characteristic for many chronic gut-related diseases (e.g. inflammatory 
bowel disease and colon cancer)9, 26 and systemic diseases (e.g. allergy, diabetes and 
obesity).27, 28 Conversely, certain functional foods reaching the gut microbiota have shown 
promise in reducing the risk of developing these diseases.29 Orienting the microbiota 
composition towards a beneficial microbiota seems to be a key towards human health.  
 
Variation in the microbiota composition 
Although the bacterial composition and activity of the human gut microbiota is relatively 
stable over life-time, age-related changes can be distinguished.30 Furthermore, the 
microbiota can vary with factors such as diet and antibiotic therapy.31 
 
Influence of age 
Bacterial colonisation of the gastrointestinal tract of babies occurs during the delivery 
process. The first colonisers are facultative anaerobic organisms, such as Escherichia coli 
and streptococci. These bacteria metabolise the oxygen present, thereby reducing the 
environment into anaerobic conditions.32 Further colonisation mainly occurs upon feeding. 
Overall, babies have a lower number of bacteria per gram of faeces and a reduced 
diversity as compared to adults. One of the main component of this “simple” microbiota is 
the genus Bifidobacterium that represent about 50% of the total bacteria in breast fed 
babies.33 The gut microbiota gradually develops during the first year of life upon intake of 
solid food. The gut microbiota is considered to be mature at the age of 2 years.34, 35 At 
adult age, the microbiota is a complex ecosystem, unique to each individual, highly 
resilient and stable in time.15, 36 With ageing, the physiology and metabolism of the 
individual alter, resulting in a shift in the microbiota composition with a decrease in 
bacterial diversity rather than a decrease in total number of bacteria.30 These changes are 
likely the reason for the higher incidence of chronicle gut disorders in elderly.37  
The relative proportions of the various health beneficial Bifidobacterium species also differ 
with age, and each age group has its characteristic species. Predominant species in breast-
fed infants are Bifidobacterium breve, Bifidobacterium longum and Bifidobacterium 
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infantis.32 In adults, B. longum and Bifidobacterium adolescentis are most often present,23, 
38 while in elderly, the relative proportion of B. adolescentis increases considerably.39 
 
Influence of antibiotic 
Antibiotic treatments are known to disrupt the microbiota and may cause short term side 
effects, such as Antibiotic-Associated-Diarrhoea (AAD).40 Clostridium difficile infection 
accounts for nearly one third of the AAD cases. The etiology for the other AAD cases is 
diverse or unknown.24 On long term, antibiotic treatments can lead to Inflammatory 
Bowel Disease (IBD) and Crohn’s disease.41 In infants, the use of antibiotics in the neonatal 
period may result on a long term impact on the microbiota due to the inadequate gut 
colonisation and development.42-44 Gut alterations in early life might even have long term 
consequences, such as eczema, allergic rhinitis and Inflammatory Bowel Diseases.28  
 
Influence of diet and prebiotics  
The diet can influence the microbiota composition since the non-digestible parts reach the 
colon to be fermented by bacteria.45 A well-known example is the increased diversity of 
the microbiota of formula-fed babies as compared to breast-fed babies.32 Modulation of 
the microbiota through the diet may be of interest in order to achieve a more beneficial 
intestinal bacterial community. Ingestion of probiotics is a way to increase the 
concentration of specific beneficial bacteria in the colon. However, the percentage of 
probiotics that survive the acidic conditions of the stomach and settle in the gut 
microbiota is rather low. Hence, the use of probiotics is questioned.3 Another option to 
specifically stimulate the beneficial bacteria already settled in the host’s large intestine is 
the use of prebiotics. A prebiotic is defined as “selectively fermented ingredients that 
allow specific changes, both in the composition and/or activity in the gastrointestinal 
microflora that confer benefits upon host well-being and health”46. Prebiotics are routinely 
used for their ability to selectively promote bifidobacteria.47, 48 
 
In this thesis, we focussed on the changes occurring in adult microbiota due to antibiotics 
and prebiotics as adults have a mature microbiota, stable within individuals.  
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Antibiotics 
Classification and intake of antibiotics in Europe 
Antibiotics are antibacterial agents that are used to treat bacterial infections. The main 
classes of antibiotics used in Europe are penicillin, tetracycline, quinolone, cephalosporin 
and macrolide-lincosamide.49 Antibiotics belonging to these classes can have a specific 
spectrum of action towards gram positive bacteria or gram negative bacteria, or have a 
broad spectrum of action. Antibiotics are classified as bactericidal if they kill bacteria and 
as bacteriostatic if they prevent bacterial growth.50 
In Europe, the median consumption of antibiotics was 18,97 Defined Daily Doses per 1000 
inhabitants per day in 2010. The use of antibiotic differs for out-patient use (ambulatory 
care) and for hospital use.49 The distribution of the classes of antibiotic used in the 
Netherlands in 2009 is shown as example in figure 4.51  
 
Figure 4: Dutch antibiotic consumption in the Netherlands for hospital and out-patient use (Based 
on the SWAB/RIVM NethMap report 200951). 
The Netherlands is one of the countries where the least antibiotics are prescribed (11.39 
Defined Daily Doses per 1000 inhabitants per day in 2009). The type of antibiotic used is, 
nevertheless, representative for European countries.51 The most commonly used 
antibiotics are penicillin, macrolide—lincosamide and quinolone for both out-patient and 
hospital use. Tetracycline is most often used for out-patient, while cephalosporin is mostly 
used for hospital use. The use of cephalosporin for out-patient is, however, lower in the 
Netherlands than in most other European countries. In the Netherlands, the mostly used 
antibiotics per class are doxycycline for the tetracycline class, amoxicillin for the penicillin 
class, ciprofloxacin and norfloxacin for the quinolone class and clarithromycin, 
azithromycin and clindamycin for the macrolide-lincosamide class.51  
Hospital use tetracyclines
penicillins
cephalosporins
macrolides-
lincosamides
quinolones
others
Out-patient use
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Impact of antibiotics on the gut microbiota 
Even though antibiotics are important to treat infectious diseases all over the body, a side 
effect is that antibiotics kill or inhibit bacteria that are not targeted, especially the ones 
being part of the gut microbiota.40, 52 The impact on the non-targeted microbial 
populations depends on the spectrum of action, the mode of administration (oral vs. 
intravenous), the dose and the absorption rate in the upper gastrointestinal tract.53 
Antibiotic treatments induce a decrease in the total amount of bacteria54-56 and/or a shift 
in the microbiota composition.57, 58 Antibiotics affect directly certain bacteria, but other 
species that depend on the secondary metabolites may be affected indirectly as well.52 
The disruption of the microbiota due to antibiotic treatments therefore result in metabolic 
changes, such as decrease of SCFA and a reduced fermentation of carbohydrates.59 Even 
though antibiotics are important tools against infectious diseases, strategies are required 
to counter the side effects on the gut microbiota. 
 
Resilience of the gut microbiota 
After disruption, the microbiota has the ability to return to its initial composition, so called 
“resilience”. Several studies showed that a resilience of the microbiota within a month in 
healthy adults.41, 54 Another study, which followed the evolution of the microbiota per 
individual, also showed a recovery of 89% of the initial microbiota composition in 60 
days.40 One subject, however, still had less than 70% similarity to the initial microbiota 
composition after 2 months. Long term impact on the microbiota has also been suggested 
elsewhere.60 The latter study reported a difference in the level of Bacteroides upon a        
7-day clindamycin treatment that was still detected after 2 year post-treatment.  
 
Galacto-oligosaccharides as prebiotics 
Many food oligosaccharides and polysaccharides are prebiotic candidates, but only inulin, 
fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), lactulose and recently xylo-
oligosaccharides have been accepted as prebiotics.61, 62 In this thesis, the focus is on GOS.  
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GOS structure 
Commercially available GOS are produced by trans-galactosylation of lactose by β-
galactosidases from yeast, fungi or bacteria.63 During the trans-galactosylation process, a 
complex mixtures of oligosaccharides is produced with different degrees of polymerisation 
(DP) and glycosidic linkages.63 The DP varies from 2 to mostly 8. Possible linkages are β(1-
2), β(1-3), β(1-4) and β(1-6) and β(1-1). Due to the diversity of glycosidic linkages, several 
isomeric oligosaccharides are present in each DP fraction64 (Figure 5).  
 
 
Figure 5:  Example of possible GOS isomers per degree of polymerisation (DP).65 
 
The enzymes and conditions used during GOS production determine the abundance of the 
different oligosaccharides in the final product. Enzymes originating from Aspergillus 
oryzae mainly form β-(1-6)-linkages (Oligomate products); enzymes from Bifidobacterium 
bifidum mainly form β-(1-3)-linkages (Bimuno) and enzymes from Bacillus circulans and 
Cryptococcus laurentii mainly form β-(1-4)-linkages (Vivinal® GOS and Cup-Oligo)64, 66 
With advanced analytical tools, all dimers and a number of trimers structures of the 
Vivinal® GOS (FrieslandCampina Domo) have been identified and quantified (Table 1).65 
The galacto-oligosaccharides present in the mixture are predominantly reducing 
oligosaccharides, with [β-D-Gal-(1-4)-β-D-Gal-(1-4)]n-D-Glc being the most abundant 
representatives for oligosaccharides of DP≥3.65  
 
 
Glucose
Galactose
DP3
DP5
DP4
DP2
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Table 1: Structures and relative abundance of DP2 and DP3 compounds in Vivinal® GOS.65 
DP 2 (37.4 % (w/w) in Vivinal® GOS) 
 Compound % (w/w)  in DP2 
 β-D-Gal-(1<->1)-β-D-Glc 7 
 β-D-Gal-(1->4)-D-Glc (lactose) 27 
 β-D-Gal-(1->6)-D-Glc (allo-lactose) 15 
 β-D-Gal-(1->4)-D-Fru (lactulose) 5 
 β-D-Gal-(1->3)-D-Gal 1 
 β-D-Gal-(1->4)-D-Gal 3 
 β-D-Gal-(1->3)-D-Glc  26 
 β-D-Gal-(1->2)-D-Glc 16 
   
DP 3 (22.1 % (w/w) in Vivinal® GOS) 
 Compound % (w/w)  in DP3 
 β-D-Gal-(1->4)-β-D-Gal-(1->4)-D-Glc 
+ β-D-Gal-(1->4)-β-D-Gal-(1->4)-Fru 
45 
 β-D-Gal-(1->4)-β-D-Gal-(1->6)-D-Glc  
or β-D-Gal-(1->6)-β-D-Gal-(1->4/6)-D-Glc 
15 
 β-D-Gal-(1->4)-β-D-Gal-(1->6)-D-Glc  
or β-D-Gal-(1->6)-β-D-Gal-(1->4/6)-D-Glc 
9 
 β-D-Gal-(1->4)-β-D-Gal-(1->3)-D-Glc 8 
 β-D-Gal-(1->6)-[β-D-Gal-(1->2]-D-Glc 5 
 β-D-Gal-(1->4)-β-D-Gal-(1->2)-D-Glc 9 
 other 9 
Gal: galactose, Glc: glucose, Fru: Fructose 
 
The typical structure of β-glycosidic linkages between the saccharide units prevents GOS 
from being hydrolysed by the human digestive enzymes secreted in the upper 
gastrointestinal tract.67 GOS are, therefore, non-digestive oligosaccharides and reach the 
colon where they can be fermented by the gut microbiota and reveal their prebiotic 
properties. 
 
Prebiotic application 
GOS is added to products mostly for their health promoting properties. The main market 
for the health promoting properties of GOS is in infant milk formula and infant food.68 The 
most known health promoting effect of GOS is its bifidogenic property. GOS was proven 
during in vitro fermentations and in vivo trials to be a selective substrate for modulating 
specifically bifidobacteria within the gut microbiota.69, 70 A recent study using a 13C-
labelling technique unambiguously showed that Bifidobacterium longum, Bifidobacterium 
bifidum, Bifidobacterium catenulatum, Lactobacillus gasseri and Lactobacillus salivarius 
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specifically fermented 13C-GOS.71 The bifidogenic effect was reported to be observed 
between 5g to 15g per day.48, 61 An excess of GOS consumption (estimated to >20g/human 
body) might result in transient osmotic diarrhoea.66 Besides specific stimulation of 
bifidobacteria and to a lesser extent lactobacilli, GOS fermentation is reported to reduce 
the growth of pathogens69, 72 and the adherence of pathogens to tissue cells.73 In vivo 
studies reported other health related impacts in humans, such as enhance calcium 
absorption and protection against gut infection.61, 74, 75 
 
Prebiotics to counter the side effects of antibiotics 
The use of prebiotics, alone or in combination with probiotics, to prevent from antibiotic-
associated gut diseases or to recover from an antibiotic treatment has already been 
suggested.31, 61, 76 However, only a few studies have been performed and the results are 
contradictory in nature regarding the efficacy to limit the risk of antibiotic-associated 
diarrhoea and the impact on the microbiota composition (Table 2). Intake of a synbiotic 
(FOS + B. longum or L. acidophilus) during a treatment of cefpodoxime proxetil 
successfully limited the decrease of lactobacilli and prevented the growth of Clostridium 
difficile.77 Also, supplementation of FOS during and after an various antibiotic treatments 
(30 days) resulted in an increase of bifidobacteria and in a reduced risk of relapse of 
C. difficile-associated-diarrhea.78 In contradiction to these positive results, addition of 
Inulin, FOS and GOS during an in vitro fermentation using clindamycin treatment were 
shown to induce a loss of bifidobacteria and a loss of colonisation resistance against C. 
difficile.79 Also, FOS supplementation (12g/day) during and after various antibiotic 
treatments did not help to prevent AAD in elderly even though the number of 
bifidobacteria remained stable in the supplemented groups while it dropped in the 
placebo group.80 At last, non-conclusive results have also been reported: No change in the 
diarrhoea frequency was reported in infants treated with amoxicillin and receiving FOS 
and Inulin (70:30 w/w ratio), although a promising increase of bifidobacteria was 
reported.56 Discrepancies in literature (Table 2) regarding the effect of prebiotic addition 
on antibiotic-treated microbiota might be explained by the variability in study parameters 
among the studies. Parameters, such as type of prebiotics and antibiotics, dosages and 
age of subjects are known to have a high impact on the microbiota composition.81  
  
12 
 
General introduction 
  
Ta
bl
e 
2:
 O
ve
rv
ie
w
 o
f s
tu
di
es
 in
vo
lv
in
g 
pr
eb
io
tic
s t
o 
pr
ev
en
t/
re
co
ve
r f
ro
m
 a
nt
ib
io
tic
-a
ss
oc
ia
te
d 
di
ar
rh
oe
a.
   
AI
M
  
O
ut
co
m
e 
 A
nt
ib
io
tic
 
Pr
eb
io
tic
 
 
&
 R
ef
er
en
ce
 
re
ga
rd
in
g 
ai
m
 
Ty
pe
 +
 d
os
ag
e 
Du
ra
tio
n 
Ty
pe
 +
 d
os
ag
e 
Du
ra
tio
n 
Ta
rg
et
 
De
cr
ea
se
 d
ia
rr
ho
ea
 
fr
eq
ue
nc
y5
6  
Fa
ilu
re
 
Am
ox
ic
ill
in
 
(5
0m
g/
kg
/d
ay
) 
7 
da
ys
 
FO
S:
In
ul
in
  
(7
0:
30
) 
(2
.2
5 
g/
d)
 
3 
w
ee
ks
 a
ft
er
 A
T 
In
fa
nt
s 
In
 v
iv
o 
Pr
ev
en
tio
n 
of
 A
AD
80
 
Fa
ilu
re
 
Br
oa
d 
sp
ec
tr
um
 
Va
rie
s 
FO
S 
(1
2g
/d
) 
Du
rin
g 
AT
  
+ 
1 
w
ee
k 
af
te
r 
>6
5y
 
In
 v
iv
o 
Pr
ev
en
tio
n 
of
 re
la
ps
e 
of
 C
DA
D7
8  
Su
cc
es
s 
N
ot
 
ap
pl
ic
ab
le
 
N
ot
  
ap
pl
ic
ab
le
 
FO
S 
(1
2g
/d
) 
30
 d
ay
s a
ft
er
 A
T 
Ill
 su
bj
ec
ts
 
In
 v
iv
o 
Pr
ev
en
tio
n 
of
 C
DA
D7
7  
Su
cc
es
s 
Ce
fp
od
ox
im
e 
pr
ox
et
il 
(2
00
m
g/
da
y)
 
7 
da
ys
 
B.
 lo
ng
um
/  
   
   
L.
 a
cid
op
hi
lu
s  
+ 
FO
S 
(1
5g
/d
) 
Du
rin
g 
AT
  
+ 
2 
w
ee
ks
 a
ft
er
 
He
al
th
y 
ad
ul
ts
 
In
 v
iv
o 
Pr
ev
en
tio
n 
of
 C
DA
D7
7  
Fa
ilu
re
 
Ce
fp
od
ox
im
e 
pr
ox
et
il 
(2
00
m
g/
da
y)
 
7 
da
ys
 
FO
S 
(1
5g
/d
) 
Du
rin
g 
AT
  
+ 
2 
w
ee
ks
 a
ft
er
 
He
al
th
y 
ad
ul
ts
 
In
 v
iv
o 
Co
lo
ni
sa
tio
n 
re
sis
ta
nc
e 
 a
ga
in
st
 C
.d
iff
ici
le
79
 
Fa
ilu
re
 
Cl
in
da
m
yc
in
 
(2
0μ
g/
m
l) 
48
h 
FO
S 
GO
S 
   
 (1
0g
/L
)  
   
In
ul
in
 
Du
rin
g 
AT
 
He
al
th
y 
ad
ul
ts
 
in
oc
ul
um
 
In
 v
itr
o 
AA
D:
 a
nt
ib
io
tic
-a
ss
oc
ia
te
d 
di
ar
rh
oe
a,
 C
DA
D:
 C
lo
st
rid
iu
m
 d
iff
ici
le
 a
ss
oc
ia
te
d 
di
ar
rh
oe
a,
  
AT
: 
An
tib
io
tic
 t
re
at
m
en
t, 
GO
S:
 G
al
ac
to
-o
lig
os
ac
ch
ar
id
es
, 
FO
S:
 
Fr
uc
to
-o
lig
os
ac
ch
ar
id
es
 
 
13 
 
Chapter 1 
 
Fermentation models 
Investigating the human microbiota composition and activity requires digesta from 
different locations of the colon. The access to the colon is, however, limited for practical 
and ethical reasons. Several model systems have, therefore, been developed to study the 
microbiota.1 In vitro models range from simple batch system to pH-controlled multistage 
continuous culture systems and use pure cultures, defined mixed-cultures and/or faecal 
material as inoculum. Main limitations are the overgrowth of non-representative 
microbial population over fermentation time and the difficulty to reproduce the dynamic 
conditions of the colon, such as absorption of compounds and interactions with the host 
cells.9 Nevertheless, in vitro models are often used as they are relatively inexpensive and 
high-throughput. Furthermore, in vitro models allow studying the microbial activity, such 
as dietary component fermentation and SCFA production in time, and give a first 
indication of the impact on the microbiota composition.2, 82 
Because the in vitro models do not allow to mimic the colon conditions, the effects 
studied in in vitro models need to be confirmed in in vivo models.1 Animal models are of 
great value to investigate the effect of controlled diet or a specific compound, such as 
drugs and toxins, on the microbiota and subsequently its host. The main limitation is, 
however, that the intestinal tracts of animals differ from that of humans. Human studies 
using healthy volunteers, patients or sudden death victims remain the best model to study 
the microbiota in relation to the host health.1 
 
Diagnostic tools to describe the gut microbiota 
The most commonly used techniques with their advantages and limitations are described 
below and summarized in table 3. Bacteria from the gut microbiota were first studied by 
plate count analysis. Culturing on specific media in combination with phenotypic 
characteristics enables identification of some bacteria. However, this method is time 
consuming and around 80% of the bacteria are not cultivable.9, 83 New methods based on 
nucleic-acid-based analysis have been developed. They provide evidence that bacteria 
numbers and diversity are underestimated by the plate count method. These molecular 
approaches focus on 16S ribosomial RNA (rRNA) gene as target molecule. This sequence is 
common to bacteria, while it presents variation depending on the species or groups. 
Therefore, specific primers can be designed on the basis of variable regions of this 
sequence to detect specific species or larger groups of bacteria.84-86 These new 
14 
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technologies give opportunity to elucidate the complexity of the microbiota ecosystem by 
providing powerful tools able to study diversity and dynamic of the microbiota.9 
Sequencing techniques (cloning and sequencing of SSU rRNA, and pyrosequencing) 
provide the most detailed phylogenetic information. However, these techniques require 
extensive bioinformatic analyses and are costly.87 Fingerprinting methods, such as 
denaturing gradient gel electrophoresis (DGGE), are often used to compare microbial 
communities and monitor their dynamics. The main drawbacks of these methods are the 
poor detection of low abundant bacteria and a difficult quantification of the detected 
bacteria due to the comigration of many phylotypes, especially in case of complex 
ecosystem as the gut microbiota.87 More suitable methods for quantification are 
fluorescence in situ hybridisation (FISH) and quantitative polymerase chain reaction 
(qPCR). They can be used to target either large or specific bacterial groups. One limitation 
of the techniques is the specificity of the primers used and the limitation to detect only 
known bacterial groups.87  
All these above approaches are relatively low throughput. In contrast, phylogenetic 
microarray microarrays allow high-throughput analyses of thousands of microbes and 
provide insights on the microbiota composition in relation to gut health and disease.9 The 
limitations of phylogenetic microarray analyses, as for other culture-independent 
technologies, depend on the isolation of nucleic acids and subsequent polymerase chain 
reaction (PCR) amplification of SSU rRNA genes. Another limitation of the phylogenetic 
microarrays is that no link between microbiota diversity and functionality can be 
established.9 New tools, including stable isotope probing and meta’omics approaches, 
have been developed to address knowledge gaps on gut microbiota composition and have 
started to reveal core metabolic functions of the gut microbiota. These tools remain, 
however, costly and required laborious data analysis.9, 87  
Regarding the aim this thesis, we have chosen to screen the changes in the microbiota 
composition using a high-throughput tool, namely the phylogenetic microarray, and to 
confirm changes in most influenced group using a quantitative tool, namely the qPCR.  
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Thesis outline 
As stated above, only a limited number of studies have been performed to investigate the 
effect of prebiotics on antibiotic-treated microbiota and results were not consistent. 
Therefore, the aim of this thesis was to understand whether and by which mechanisms 
the prebiotic GOS could help to counter the side effects of antibiotics on the human gut 
microbiota. We hypothesised that the recovery of the microbiota upon GOS addition will 
be antibiotic dependant since antibiotics have different spectrum of actions. Furthermore, 
the prebiotic GOS will help to recover the balance of the human microbiota by stimulating 
bifidobacteria, and, subsequently, stimulating other bacterial groups through cross-
feeding.  
In chapter 2, a new high-throughput approach is introduced to monitor the impact of 
antibiotics on the human microbiota: In vitro fermentations were run using a screening-
platform and the microbiota composition was determined using a phylogenetic 
microarray. The reliability of the method was first verified and, subsequently, an overview 
of the effects of seven antibiotics on adult intestinal microbiota was obtained. Four 
antibiotics were selected based on their mode of action, classification and specific impact 
on the microbiota. 
In chapter 3, the impact of addition of the prebiotic GOS on the adult gut microbiota 
treated with the 4 selected antibiotics was investigated in vitro on both the microbiota 
composition and activity. The results were compared using the high-throughput approach 
described in chapter 2.  
A specific combination of prebiotic-antibiotic, GOS-Amoxicillin, was further studied in 
chapters 4 and 5. In chapter 4, GOS was fractionated based on the size of the 
oligosaccharides and each fraction was in vitro fermented using amoxicillin-treated 
microbiota. The contribution of each fraction to the recovery of the microbiota 
composition and activity was investigated. In chapter 5, the combination of GOS-
Amoxicillin was studied in a human study, including 12 healthy adults. This preliminary 
trial investigated whether results obtained in vitro so far could also be observed in vivo.  
In chapter 6, the results obtained in the research are discussed and their impact on future 
research on gastro-intestinal health after antibiotic treatment is reflected. 
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Chapter 2 
High-throughput analysis of the impact of antibiotics 
on the human intestinal microbiota composition  
 
 
Abstract 
Antibiotic treatments can lead to a disruption of the human microbiota. In this in vitro 
study, the impact of antibiotics on adult intestinal microbiota was monitored in a new 
high-throughput approach: a fermentation screening-platform was coupled with a 
phylogenetic microarray analysis (Intestinal-chip). Faecal inoculum from healthy adults 
was exposed in a fermentation screening-platform to seven widely-used antibiotics during 
24h in vitro fermentation and the microbiota composition was subsequently determined 
with the Intestinal-chip. Phylogenetic microarray analysis was first verified to be reliable 
with respect to variations in the total number of bacteria and presence of dead (or 
inactive) cells. Intestinal-chip analysis was then used to identify and compare shifts in the 
intestinal microbial composition after exposure to low and high dose (1 μg.ml-1 and 
10 μg.ml-1) antibiotics. Observed shifts on family, genus and species level were both 
antibiotic and dose dependent. Stronger changes in microbiota composition were 
observed with higher doses. Shifts mainly concerned the bacterial groups Bacteroides, 
Bifidobacterium, Clostridium, Enterobacteriaceae, and Lactobacillus. Within bacterial 
groups, specific antibiotics were shown to differentially impact related species. The 
combination of the in vitro fermentation screening platform with the phylogenetic 
microarray read-outs has shown to be reliable to simultaneously analyse the effects of 
several antibiotics on intestinal microbiota. 
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Introduction 
The human intestinal microbiota, a complex ecosystem mainly dominated by anaerobic 
bacteria, plays an important role in the health of its host.1 Under normal conditions, the 
composition of the microbiota is relatively stable for long periods of time,2 but this can 
change due to external factors, such as antibiotic treatments. 
Antibiotics are used to treat specific bacterial infections. However, these agents are also 
known to kill or inhibit bacteria which are not primarily targeted, such as resident 
commensal gut microbiota.3 The extent of the impact on the non-targeted microbial 
populations depends on the spectrum of  action, the mode of administration (oral vs. 
intravenous), the dose and the absorption rate.4 A disruption of the microbiota due to 
antibiotic treatments can lead in 5-35% of the cases to Antibiotic-Associated-Diarrhoea 
(AAD), with Amoxicillin and Clindamycin having the highest impact.5 
Increasingly, changes in the microbiota composition are correlated with health disorders.6-
8 Such correlations between microbiota composition and health disorders can be detected 
from in vivo studies. These studies, however, are rather expensive and have a low-
throughput. Moreover, comparison of the outcomes of different studies is difficult since 
many parameters in the study designs differ. In this perspective, in vitro screening-
platforms are considered useful tools to perform multiple fermentations in a high-
throughput. Furthermore, to establish correlations between microbiota composition and 
human gut diseases, it has been suggested to use new high-throughput analytical tools 
like phylogenetic microarrays.8 Such phylogenetic microarray have been developed and 
validated for e.g. oral and intestinal microbiota.9, 10 Combining the use of in vitro 
screening-platforms with intestinal microarray analysis appear to be promising to increase 
fermentation-throughput and compare straightforwardly the resulting bacterial 
fingerprints obtained under similar conditions.  
Phylogenetic DNA microarrays enable quick determination of microbiota composition. 
However, the DNA array read-outs might be influenced by factors induced by the 
antibiotic treatment, such as variation in the total cell number11 and presence of nucleic 
acids derived from dead (or inhibited) cells.12 Reliability of the microarray read-outs still 
has to be tested on complex human microbiota in case of antibiotic treatments. In this 
study, we addressed the use of a phylogenetic microarray to monitor the changes in the 
human intestinal microbiota after antibiotic treatment during 24h in vitro fermentation in 
screening-platforms. First, the reliability of the I-chip readouts was addressed with respect 
to the variation in cell numbers and presence of dead cells. Secondly, an overview of the 
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impact of seven widely-used antibiotics on the microbiota composition was shown under 
comparable conditions. 
 
Material and methods 
Antibiotics 
Amoxicillin (AMX) (≥90%), Azithromycin (AZM) (≥98% HPLC), Cefadroxil (CFR), 
Ciprofloxacin (CIP) (≥98% HPLC), Clindamycin hydrochloride (CLI) (≤2 mol/mol EtOH), 
Doxycycline (DOX) (≥98% TLC), and Erythromycin (ERY) (≥85%) were obtained from Sigma-
Aldrich (St Louis, MO, USA). Their characteristics are presented in table 1.  
 
Table 1: Characteristics of antibiotics used including class, type, mode of action and impact on 
antibiotic-associated-diarrhoea.  
a AAD: Antibiotic-Associated-Diarrhoea 
 
 
 
Class Name Type Mode of action AADa 
frequency 
Penicillin 
 
Amoxicillin Bacteriolytic Inhibition peptidoglycan 
biosynthesis3  
High5 
Tetracycline 
 
Doxycycline Bacteriostatic Translation inhibition3  Low5 
Macrolide- 
Lincosamide 
 
Erythromycin 
 
Bacteriostatic Translation inhibition3  Low13 
Azithromycin 
 
Bacteriostatic Translation inhibition3  Low13 
Clindamycin 
 
Bacteriostatic Translation inhibition3  High 5 
Quinolone Ciprofloxacin Bacteriolytic Replication and 
transcription inhibition3  
 
Low 5 
Cephalosporin Cefadroxil Bacteriolytic Inhibition of peptidoglycan 
biosynthesis14  
 
Medium / 
High5 
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Microarray construction and validation of the intestinal microbiota 
representing microarray 
The intestinal microbiota representing microarray was constructed as described for the 
oral microbiota microarray by Crielaard et al.9 Instead of primers for oral bacterial species, 
primers for intestinal bacterial species were selected based on scientific literature, 
sequence databases and 454 sequencing of faecal material, resulting in a DNA based 
microarray enabling the detection of more than 400 bacterial targets from the human 
large intestinal microbiota. The selected targets included primers that are specific at 
family, genus and species level. Several groups of bacteria, e.g. Bacteroides, 
Bifidobacterium, Enterobacteriaceae, Clostridium and Lactobacillus are targeted. These 
groups are known to be the main bacterial groups in the human intestinal microbiota.15 
The intestinal microarray (I-chip) performance was validated for the same criteria as 
mentioned by Crielaard et al.9 
 
Experimental set up and sampling 
Intestinal microbiota were cultured by in vitro fermentations in microtiterplate (96 wells - 
1.5 ml volume per well). The culture medium was based on the modified standard ileal 
efflux medium (SIEM) composition16 and modified as follow (g.l-1): pectin (0.047), xylan 
(0.047), arabinogalactan (0.047), amylopectin (0.047), starch (0.392), casein (24.0), Tween 
80 (17.0), bactopepton (24.0), ox-bile (0.4) and cysteine (0.2). All medium components 
were provided by Tritium Microbiology (Veldhoven, The Netherlands). The pH was 
adjusted to 5.8. 
A standardized pool of adult faecal inoculum was prepared as validated by Minekus et al.16 
This pool approach was especially relevant in our study since it limited inter-individual 
variations and increased the probability to have a larger representation of potential 
bacterial species in the human colon. The faecal samples used to produce the 
standardized inoculum were from eight healthy European adults (25-45 years old) who 
neither received antibiotic treatments in the 2 months before donation nor consumed 
prebiotics or probiotics the week before donation. After storage at -80°C in 12% glycerol, 
the standardized faecal inoculum was incubated in the adapted SIEM under anaerobic 
conditions overnight (37°C; 300 rpm) in order to activate the bacteria. This pre-culture 
step was found not to significantly modify the microbiota composition and activity as 
determined by I-chip analysis (data not shown).  
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For antibiotic exposure experiments, SIEM, antibiotics (1 μg.ml-1 or 10 μg.ml-1) and pre-
cultured inoculum (0.1% v/v) were mixed in each well. The fermentation was conducted 
under anaerobic conditions at 37° for 24h. Inoculated SIEM without antibiotic was used as 
a blank. Each specific fermentation condition was performed 5 times. After 24h of 
fermentation, collected samples were split in three parts. One part was directly stored at -
20°C for DNA isolation. A second part was immediately treated with propidium monoazide 
(PMA) (Biotium, Hayward, CA, USA) as described by Nocker et al12 with a final 
concentration of 50 μM, and stored at -20°C. The third part was directly stored at -80°C for 
RNA isolation.  
 
DNA isolation  
Total faecal DNA from collected samples was isolated as described by Crielaard et al 9 with 
some minor adjustments: The samples were initially mixed with 250 μl lysis buffer (Agowa, 
Berlin, Germany), 250 μl zirconium beads (0.1 mm), and 200 μl phenol, before being 
introduced to a BeadBeater (BioSpec Products, Bartlesville, OK, USA) for twice 2 min.  
 
Faecal RNA isolation and cDNA synthesis.  
Next to DNA isolation, RNA isolation was necessary to investigate the activity of bacteria 
present in the samples. Isolation of RNA and cDNA synthesis was carried out for one 
replicate out of 5. RNA isolation through bead beating in phenol/chloroform extractions 
was performed following the protocol described by Kort et al.17 Isolated RNA was purified 
from DNA using the Invitrogen Kit (Invitrogen, Breda, The Netherlands) with a modified 
buffer (100 mM Tris/HCl pH7.5, 25 mM MgCl2, 2.5 mM CaCl2). RNA purity and 
concentration were determined on a 1.5% (w/v) agarose gel stained with ethidium-
bromide (Sigma-Aldrich).  
DNA copies (cDNA) were synthetized by incubating 2.5 μl RNA for 5 min at 60°C with 10 μl 
anneal mix containing 5 μl dNTP's [2mM] (Invitrogen), 0.1 μl RNAsin (Promega, Leiden, 
The Netherlands), 23 nl 1061-R primer (TCA CGR CAC GAG CTG ACG AC), 0.15μl 0,1 M DTT 
(Invitrogen) and RNAse free water. After cooling the samples on ice, 8 μl RT mix containing 
1 μl RNAsin (10 U.μl-1, Promega), 4 μl First Strand Buffer 5× (Invitrogen), 2 μl 0,1 M DTT 
(Invitrogen) and 0.5 μl Superscript II enzyme (200 U.μl-1, Invitrogen) were added. The 
reverse transcription took place at 42°C during 2h. Samples were inactivated at 70°C for 
10 min and stored at -20°C. cDNA was amplified and labelled with PCR as described 
further.  
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PCR amplification and PCR product purification 
Significant amounts of DNA or cDNA are needed for analysis on the microarray. A 
multiplex PCR was therefore performed on each sample (DNAs and cDNAs) with a 25 μl 
reaction mixture containing 12.5 μl 2x Multiplex PCR mix (Qiagen GmbH, Hilden, 
Germany), 0.5 μl of 16s-8-F/unibifi [25-2.5 pmol.μl-1] (AGA GTT TGA TCH TGG YTC AG / 
TGG CTC AGG ATG AAC GCT G), 1 μl 16s-1061-R [25 pmol.μl-1] (TCA CGR CAC GAG CTG ACG 
AC), 0.25 μl  Entero(Hsp60)-F- [25 pmol.μl-1] (GGT AGA AGA AGG CGT GGT TGC), 0.5 μl 
Entero(Hsp60)-R- [25 pmol.μl-1] (ATG CAT TCG GTG GTG ATC ATC AG), 5 μl of isolated DNA 
and 5,25 μl milli-Q water. The forward primers contained a 5’phospho modification while 
the reverse primers contained a 5’–C6 Cy3 modification. Only 16s-8-F/unibifi and 16s-
1061-R were used to amplify cDNAs. The program  used for amplification was as follows : 
94°C for 15 min, 30 cycles of 94°C for 30 seconds, 50°C for 90 seconds, 72°C for 80 
seconds, 1 cycle of 72°C for 2 minutes and cooled to 4°C. The PCR products were analysed 
on a 1.2% agarose gel (100V; 45 min) and stained with Serva-G (SERVA Electrophoresis, 
Heidelberg, Germany).  
The PCR products from DNA were purified using a SigmaSpin Post-Reaction Clean-up plate 
(Sigma-Aldrich) while the PCR products from cDNA were purified using autoseq G50 
columns (GE Healthcare), as described by the manufacturers. The samples obtained were 
dried by vacuum centrifugation at 60°C. A mixture of 0.5 μl lambda exonuclease (BioLabs 
inc. Frankfurt, Germany), 2 μL lambda exonuclease buffer and 17.5 μL water was added. 
Incubation took place for 30 minutes at 37°C, and inactivation during 10 minutes at 75°C. 
DNA was purified again with a SigmaSpin-2-Post-Reaction Clean-up plate (Sigma-Aldrich) 
and dried. The single-stranded products were analysed on a 1.2% agarose gel (100V; 45 
min) and stained with Serva-G (SERVA Electrophoresis). 
 
Hybridization  
Hybridization of the PCR products on the I-chip was performed as described by Crielaard 
et al9 with minor changes. Dried single-strand DNA was suspended in 45 μl DIG Easyhyb 
(Roche, Basel, Switzerland) for 20 min at 37°C and denatured for 2 min at 95°C before 
being placed on the pre-warmed microarray. Hybridization, cleaning steps and scanning 
were carried out according to the described procedure.  
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Data analysis  
Imagene 5.6 software (BioDiscovery, Marina del Rey, CA, USA) was used to analyse the 
results. Signals were quantified by calculating the mean of all pixel values of each spot and 
calculating the local background around each spot. For each spot a signal to background 
ratio (S/B), namely signal intensity, was calculated and used for further analysis. Only the 
spots with a S/B ratio larger than two were used for further analysis. This cut-off was 
selected based on the observation that negative control spots never resulted in signals 
above this cut-off (data not shown). When comparing data from all experiments, the 
minimal number of observations higher than three times above its local background for 
each spot was set to 10. This criterion was mainly used to discard data resulting from 
technical noise. The data matrix (116 targets out of 400) was analysed with Significant 
Analysis Microarray (SAM) to identify markers significantly different between predefined 
groups programs (TM4 software) and with a hierarchical clustering based on Euclidian 
distances. A Principal Component Analysis (PCA) was performed using the TM4 software 
to investigate the correlation among the bacterial fingerprints.18  
 
Quantitative PCR 
Quantitative PCR was performed to investigate the variation in the total amount of 
bacteria after different antibiotic exposures. Quantification of the total amount of DNA 
present in the samples was performed using the universal primers 16S-uni-II-F [10 pmol.μl-
1] (TCCTACGGGAGGCAGCAGT) and 16S-uni-II-R [10 pmol.μl-1] (GGACTACCAGGGTATCTA 
ATCCTGTT), and probe 16S-uni-II [5 μM] (6FAM-CGTATTACCGCGGCTGCTGGCAC-TAMRA) 
(Applied Biosystems, Bleiswijk, The Netherlands) The amplification was performed with 
5 μl DNA sample and 25 μl q-PCR mixture that contained 15 μl 2x FastStart Universal 
Probe Mastermix (Roche, Mannheim, Germany), 1 μl of each primers and probe, and 7 μl 
MilliQ water.  Total microbial faecal DNAs were diluted 1:10 before use in the q-PCR assay.  
The experiment was performed using the 7500 Fast Real Time PCR system (Applied 
Biosystems) at the following settings: 1 step of 2 min at 50°C, 1 step of 10 min at 95°C, 40 
cycles of 15 seconds at 95°C and 1 min at 60°C. Dilution of the control microbiota was 
used as quantitative standards (5 fg.μl-1 to 5 ng.μl-1).  
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Corrections of the I-chip readout 
To address the reliability of the I-chip readouts with respect to the variation in cell 
numbers, the signal intensity (S/B) obtained directly from the I-chip needed to be 
corrected based on the variation of total cells in the samples. According to literature,  the 
relative signal intensity of each target [1] (S/B of one target : total S/B) is directly 
proportional to the relative quantitative changes of the target.10 Because of this 
correlation, a correction factor [2] was calculated in our experiment on the basis of the 
total number of bacteria measured with qPCR (total number of bacteria in one sample: 
total number of bacteria in the control) and applied to the relative signal intensity of each 
target to calculate the corrected relative signal [3]:  
 
 
 
This correction factor enabled comparison of the samples in absolute abundance per 
target.  
 
Statistical analysis 
To evaluate whether two qPCR data sets were significantly different, a Student t-test was 
performed. P-values were calculated assuming equal variance and two-tailed distribution. 
Correlations were considered significant at a P-value lower than 0,001. 
 
Results and discussion 
In order to investigate the impact of antibiotics on a healthy adult intestinal microbiota, 
in vitro fermentations were performed using a screening-platform, allowing up to 96 
experimental variations at once in 1.5ml volumes. Downscaling the fermentation did not 
influence the outcomes regarding the impact of antibiotics on the microbiota as similar 
results were observed in fermentation flasks of 120ml (data not shown).  
Seven antibiotics widely-used in The Netherlands19 and in Europe20 were selected based 
on their classification and their mode of action (Table 1). A low dose (1 μg.ml-1) and a high 
dose (10 μg.ml-1) antibiotic were selected on the basis of a dose-series test performed on 
Corrected relative 
signal intensity [3] 
= Relative signal intensity [1]        x          Correction factor  [2] 
=[3] Signal intensity of one target x    Total number of bacteria in one sample
Total signal intensity                      Total number of bacteria in the control
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the screening platform. The low dose influenced either gram positive or gram negative 
bacteria, while the high dose mostly influenced both gram positive and gram negative 
bacteria (data not shown). This high dose, however, did not suppress all bacteria allowing 
a recovery of the non-affected bacteria during the fermentation time. The actual antibiotic 
concentrations used in the experiments were below the concentrations that could reach 
the colon considering an adult receiving 0.5 g to 1 g antibiotic per day and an absorption 
rate of 70 % to 90% (25 µg.ml-1 to 150 µg.ml-1).  The two selected doses were, however, in 
the range of MIC-values of currently used antibiotics21 and relevant for in vitro 
fermentations with 0.1% faecal inoculum. 
After 24h fermentation, the changes in the microbiota composition due to 1 μg.ml-1 and 
10 μg.ml-1 antibiotic treatments were monitored with a phylogenetic microarray, the I-
chip (Figure 1). The reproducibility of the impact of antibiotics (n=5), as determined by 
Pearson’s correlation (r), was good (r=0.8) to very good (r=0.98). The level of impact of the 
antibiotics was shown by a principal component analysis (Figure 2). For the 1 μg.ml-1 
treatments, data for cefadroxil, clindamycin and erythromycin predominantly clustered 
with the non-treated samples, indicating minor changes in the bacterial fingerprints. Data 
for amoxicillin, azithromycin, ciprofloxacin and doxycycline clustered separately from the 
non-treated samples, hence a stronger impact on the microbiota was present. For the 
10 μg.ml-1 treatments, 8 separate clusters could be distinguished, with each antibiotic 
treatment resulting in a separate cluster and all antibiotics clearly differing from the 
control situation. These results thus show the strong impact of these antibiotics on the 
microbiota composition. 
A more detailed description of the impact of each individual antibiotic on microbiota 
composition is presented later, but first the influence of a potential experimental bias due 
to variations in total bacterial cell numbers and the influence of nucleic acids derived from 
dead (or inhibited) cells present in the antibiotic treated samples are addressed.  
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Figure 1: Bacterial fingerprints of the non-treated and antibiotic-treated adult inoculum obtained 
with the I-Chip after 24h in vitro fermentation. Seven antibiotics were used in concentrations of 1 
μg.ml-1 (A.) and 10 μg.ml-1 (B).Targets presented in the figures have intensities which were found to 
be significantly different among sets of samples (sets based on treatment) by SAM analysis (TM4 
software). Main groups of bacteria are highlighted in colour and full name of targets can be found in 
table 2 based on their numbering. Signal compared to the background (S/B): Green: below 
detectable level, Black: medium abundance, Red: high abundance.  
Bacteroides Bifidobacteria LactobacillusClostridia Enterobacteriaceae Others
AMX AZM CFR CIP CLI DOX ERY Non-treated
A
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Figure 1 (continued): Bacterial fingerprints of the non-treated and antibiotic-treated adult 
inoculum obtained with the I-Chip after 24h in vitro fermentation. Seven antibiotics were used in 
concentrations of 1 μg.ml-1 (A.) and 10 μg.ml-1 (B).Targets presented in the figures have intensities 
which were found to be significantly different among sets of samples (sets based on treatment) by 
SAM analysis (TM4 software). Main groups of bacteria are highlighted in colour and full name of 
targets can be found in table 2 based on their numbering. Signal compared to the background (S/B): 
Green: below detectable level, Black: medium abundance, Red: high abundance.  
AMX AZM CFR CIP CLI DOX ERY Non-treated
B
Bacteroides Bifidobacteria LactobacillusClostridia Enterobacteriaceae Others
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Figure 2: Representation of the non-treated or antibiotic-treated samples in the plane defined by 
two principal components resulting from a PCA of bacterial fingerprints obtained with the I-Chip 
after 24h in vitro fermentation using adult inoculum. Seven antibiotics were used in a 
concentration of 1 μg.ml-1 (A) or 10 μg.ml-1 (B) : AMX (), AZM (), CFR (), CIP (∆), CLI (), DOX 
(), ERY (), non-treated ().  
A
B
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Reliability of the I-chip readouts when using antibiotics  
Influence of the variations in total cell numbers  
In order to investigate the influence of variations in total bacterial cell numbers on the I-
chip readout, the total number of bacteria after 24h fermentation with antibiotics was 
determined with qPCR. Figure 3 shows that the total number of cells was significantly 
reduced in case of 10 μg.ml-1 of amoxicillin, ciprofloxacin and doxycycline (p < 0,001). In 
these cases, relative comparisons between I-chip readouts from different treated-samples 
might lead to misinterpretations and, as a result, conclusions about changes in abundance 
might be incorrect. 
 
Figure 3: Total amount of DNA in non-treated and antibiotic-treated inoculum from healthy adults 
after 24h in vitro fermentation measured with qPCR. Antibiotics were applied in concentration of 
1 μg.ml-1  or 10 μg.ml-1 . Standard deviation (n=5) is shown with the error bars. * Significant 
difference versus the non-treated microbiota (p < 0.001).  
 
Table 2 deals with the hypothesis that relative values from a microarray might not be 
comparable in case of antibiotic treatment as the total number of bacteria may differ per 
sample. Based on the qPCR measurements of the total bacteria numbers, the signal 
intensity (S/B) obtained directly from the I-chip was corrected as described in the material 
and methods section. Treatment with 10 μg.ml-1 doxycycline was taken as an example. 
The three obtained readouts (S/B, relative S/B [1] and corrected relative S/B [3]) showed 
similar trends of changes in the microbiota composition. Therefore, modification of the 
microarray data is concluded not to be necessary. Similar conclusions were drawn for the 
10 μg.ml-1 amoxicillin and ciprofloxacin treatments (data not shown).  
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Table 2: Impact of doxycycline (10 μg.ml-1) after 24h in vitro fermentation on bacterial groups of 
an adult inoculum as evaluated with the signal intensity, the relative signal intensity and the 
corrected relative intensity. Formula [1], [2] and [3] are described in the material and method 
section. 
  
Family Genus species Average StDev Average StDev Average StDev
1 Alcaligenaceae unclassified_ 1.2 0.3 0.1 0.0 0.1 0.0
2 Archaea_domain 2.9 0.6 0.2 0.0 0.2 0.0
3 Archea 2.2 0.4 0.2 0.0 0.2 0.0
4 Archea 1.4 0.2 0.1 0.1 0.1 0.0
5 Bacillaceae Bacillus group 1.2 0.2 0.1 0.0 0.1 0.0
6 Bacteriales_order 2.3 0.6 0.2 0.0 0.2 0.0
7 Bacteriales_order 1.3 0.2 0.1 0.0 0.1 0.0
8 Bacteriales_order 1.2 0.1 0.1 0.0 0.1 0.0
9 Bacteroidaceae Bacteroides dorei 1.6 0.5 0.1 0.0 0.1 0.0
10 Bacteroidaceae Bacteroides dorei 1.1 0.2 0.1 0.0 0.1 0.0
11 Bacteroidaceae Bacteroides fragilis 1.2 0.2 0.1 0.0 0.1 0.0
12 Bacteroidaceae Bacteroides fragilis 1.1 0.2 0.1 0.0 0.1 0.0
13 Bacteroidaceae Bacteroides fragilis 1.4 0.3 0.1 0.0 0.1 0.0
14 Bacteroidaceae Bacteroides fragilis/uncultured 1.1 0.1 0.1 0.0 0.1 0.0
15 Bacteroidaceae Bacteroides group 1.1 0.2 0.1 0.0 0.1 0.0
16 Bacteroidaceae Bacteroides group 1.3 0.2 0.1 0.0 0.1 0.0
17 Bacteroidaceae Bacteroides massiliensis 1.3 0.2 0.1 0.0 0.1 0.0
18 Bacteroidaceae Bacteroides ovatus 2.3 0.7 0.2 0.0 0.2 0.0
19 Bacteroidaceae Bacteroides stercoris 1.1 0.1 0.1 0.0 0.1 0.0
20 Bacteroidaceae Bacteroides thetaiotaomicron 1.6 0.2 0.1 0.0 0.1 0.0
21 Bacteroidaceae Bacteroides thetaiotaomicron 1.4 0.2 0.1 0.1 0.1 0.0
22 Bacteroidaceae Bacteroides thetaiotaomicron 1.2 0.2 0.1 0.0 0.1 0.0
23 Bacteroidaceae Bacteroides thetaiotaomicron 1.3 0.2 0.1 0.0 0.1 0.0
24 Bacteroidaceae Bacteroides uncult 1.2 0.3 0.1 0.0 0.1 0.0
25 Bacteroidaceae Bacteroides uncultured 4.0 0.9 0.3 0.1 0.3 0.1
26 Bacteroidaceae Bacteroides uncultured 1.1 0.1 0.1 0.0 0.1 0.0
27 Bacteroidaceae Bacteroides uncultured 1.2 0.0 0.1 0.0 0.1 0.0
28 Bacteroidaceae Bacteroides uniformis 1.4 0.3 0.1 0.0 0.1 0.0
29 Bacteroidaceae Bacteroides uniformis 1.2 0.2 0.1 0.0 0.1 0.0
30 Bacteroidaceae Bacteroides uniformis 1.3 0.2 0.1 0.0 0.1 0.0
31 Bacteroidaceae Bacteroides uniformis 1.4 0.3 0.1 0.0 0.1 0.0
32 Bacteroidaceae Bacteroides xylanisolvens 1.4 0.4 0.1 0.1 0.1 0.1
33 Bacteroidaceae Bacteroides xylanisolvens/  finegoldii 1.2 0.1 0.1 0.0 0.1 0.0
34 Bacteroidaceae Bacteroides xylanisolvens/finegoldii 1.1 0.2 0.1 0.0 0.1 0.0
35 Bacteroidetes_phylum 25.5 3.5 2.2 0.5 2.1 0.4
36 Bifidobacteriaceae Bifidobacterium catenulatum / angulatum/ 1.2 0.1 0.1 0.0 0.1 0.0
37 Bifidobacteriaceae Bifidobacterium gallinarum 3.9 6.1 0.3 0.5 0.3 0.4
38 Bifidobacteriaceae Bifidobacterium longum 1.3 0.2 0.1 0.0 0.1 0.0
39 Bifidobacteriaceae Bifidobacterium longum 1.1 0.1 0.1 0.0 0.1 0.0
40 Bifidobacteriaceae Bifidobacterium species 1.2 0.2 0.1 0.0 0.1 0.0
41 Carnobacteriaceae Carnobacterium divergens 1.1 0.1 0.1 0.0 0.1 0.0
42 class "Clostridia" 1.2 0.2 0.1 0.0 0.1 0.0
43 Clostridiaceae Clostridium carnis 1.3 0.5 0.1 0.1 0.1 0.1
44 Clostridiaceae Clostridium carnis/ tertium/ sardiniense/ vincentii 1.2 0.1 0.1 0.0 0.1 0.0
45 Clostridiaceae Clostridium disporicum 1.2 0.1 0.1 0.0 0.1 0.0
46 Clostridiaceae Clostridium disporicum 1.1 0.1 0.1 0.0 0.1 0.0
47 Clostridiaceae Clostridium group 1.3 0.3 0.1 0.0 0.1 0.0
48 Clostridiaceae Clostridium group (7) 1.3 0.5 0.1 0.0 0.1 0.0
49 Clostridiaceae Clostridium group 2 1.2 0.1 0.1 0.0 0.1 0.0
50 Clostridiaceae Clostridium paraputrificum 1.5 0.2 0.1 0.1 0.1 0.1
51 Clostridiaceae Clostridium uncultured 1.1 0.1 0.1 0.0 0.1 0.0
52 Clostridiales_order 1.2 0.4 0.1 0.0 0.1 0.0
53 Clostridiales_order 1.2 0.0 0.1 0.0 0.1 0.0
54 Coriobacteriaceae Collinsella aerofaciens 1.3 0.4 0.1 0.0 0.1 0.0
55 Coriobacteriaceae Collinsella aerofaciens 1.2 0.3 0.1 0.0 0.1 0.0
56 Coriobacteriaceae Olsenella profusa 1.2 0.2 0.1 0.0 0.1 0.0
57 Coriobacteriaceae 2.1 0.5 0.2 0.0 0.2 0.0
58 Coriobacteriaceae 1.1 0.1 0.1 0.0 0.1 0.0
59 Desulfovibrionaceae Desulfovibrio 1.2 0.2 0.1 0.0 0.1 0.0
below detectable level <2 <0,1 % <0,1 %
low abundance 2<    <4 0,1% <  < 0,2% 0,1% <  < 0,2%
medium abundance 4 <   < 50 0,2% <   < 4% 0,2% <   < 4%
high abundance >50 >4% >4%
     * Correction factor [2] = 0.91
Signal to 
Background (S/B)
Relative S/B           
[1]
Corrected relative 
S/B                            
[3]*
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Table 2 (continued) 
  
Family Genus species Average StDev Average StDev Average StDev
60 Enterobacteriaceae Cronobacter sakazakii/  turicensis 1.3 0.2 0.1 0.0 0.1 0.0
61 Enterobacteriaceae E.coli/ Shigella 48.9 28.9 3.6 1.9 3.4 1.8
62 Enterobacteriaceae Enterobacter cloacae/ asburiae 1.1 0.2 0.1 0.0 0.1 0.0
63 Enterobacteriaceae Escherichia /shigella E.coli/shigella 245.0 13.3 18.9 2.4 18.1 2.7
64 Enterobacteriaceae Escheriachia /shigella E.coli/shigella 246.9 13.8 21.5 5.4 20.1 4.6
65 Enterobacteriaceae Escheriachia /shigella 21.9 6.1 1.8 0.3 1.7 0.3
66 Enterobacteriaceae Escherichia /shigella E.coli/ Shigella 49.2 9.4 4.6 1.7 4.3 1.5
67 Enterobacteriaceae Escherichia /shigella E.coli/shigella 48.3 24.5 4.0 1.2 3.7 1.2
68 Enterobacteriaceae 65.6 24.7 5.9 3.2 5.5 2.8
69 Enterobacteriaceae 136.1 90.3 10.4 5.6 9.9 5.4
70 Enterobacteriaceae 20.0 13.2 1.7 1.0 1.6 0.9
71 Enterobacteriaceae 1.5 0.2 0.1 0.0 0.1 0.0
72 Enterobacteriaceae 25.2 8.1 2.2 1.0 2.1 0.9
73 Enterobacteriaceae 1.3 0.3 0.1 0.0 0.1 0.0
74 Erysipelotrichaceae Coprobacillus 1.3 0.2 0.1 0.0 0.1 0.0
75 Erysipelotrichaceae Turicibacter 1.4 0.3 0.1 0.0 0.1 0.0
76 Erysipelotrichaceae 1.1 0.1 0.1 0.0 0.1 0.0
77 Erysipelotrichaceae 1.6 0.1 0.1 0.0 0.1 0.0
78 Fibrobacteraceae Fibrobacter succinogenes 1.2 0.3 0.1 0.0 0.1 0.0
79 Fusobacteriaceae Fusobacterium group 1.3 0.1 0.1 0.0 0.1 0.0
80 Fusobacteriaceae Fusobacterium 7.1 5.9 0.5 0.4 0.5 0.4
81 Gammaprotein_class 1.2 0.2 0.1 0.0 0.1 0.0
82 Incertae Sedis XI Peptoniphilus harei 0.9 0.3 0.1 0.0 0.1 0.0
83 Incertae Sedis XI Peptoniphilus harei 1.2 0.1 0.1 0.0 0.1 0.0
84 Incertae Sedis XI Peptoniphilus harei 1.1 0.1 0.1 0.0 0.1 0.0
85 Lachnospiraceae Incertae Sedis xylanophilum 2.1 1.9 0.2 0.1 0.2 0.1
86 Lachnospiraceae Roseburia cecicola/intestinalis 1.1 0.1 0.1 0.0 0.1 0.0
87 Lachnospiraceae unclassified 1.2 0.1 0.1 0.0 0.1 0.0
88 Lactobacillaceae Lactobacillus acidophilus 1.3 0.3 0.1 0.1 0.1 0.1
89 Lactobacillaceae Lactobacillus brevis / hammesii/  parabrevis 1.2 0.2 0.1 0.0 0.1 0.0
90 Lactobacillaceae Lactobacillus group 1.2 0.1 0.1 0.0 0.1 0.0
91 Lactobacillaceae Lactobacillus group 6 1.2 0.1 0.1 0.0 0.1 0.0
92 Lactobacillaceae Lactobacillus johnsonii / gasseri / taiwanensis 79.3 36.0 6.6 2.2 6.2 2.1
93 Lactobacillaceae Lactobacillus plantarum/ paraplantarum/ 30.5 13.6 2.6 1.0 2.5 1.0
94 Leuconostocaceae Leuconostoc group 2 1.3 0.1 0.1 0.0 0.1 0.0
95 Leuconostocaceae 1.3 0.2 0.1 0.0 0.1 0.0
96 Micrococcaceae Arthrobacter globiformis 1.5 0.2 0.1 0.0 0.1 0.0
97 Moraxellaceae Acinetobacter group 2.3 1.3 0.2 0.1 0.2 0.1
98 Nitrospiraceae 3.8 1.2 0.3 0.1 0.3 0.1
99 order "Lactobacillales" 1.1 0.2 0.1 0.0 0.1 0.0
100 order Bacillale 1.2 0.2 0.1 0.0 0.1 0.0
101 order Clostridiale 1.3 0.3 0.1 0.0 0.1 0.0
102 Peptococcaceae Peptococcus uncultured 1.2 0.1 0.1 0.0 0.1 0.0
103 Peptostreptococcaceae Sporacetigenium 1.1 0.1 0.1 0.0 0.1 0.0
104 Peptostreptococcaceae 1.4 0.3 0.1 0.0 0.1 0.0
105 Porphyromonadaceae Parabacteroides distasonis 1.2 0.3 0.1 0.0 0.1 0.0
106 Porphyromonadaceae Parabacteroides uncultured/ distasonis 1.2 0.4 0.1 0.0 0.1 0.0
107 Porphyromonadaceae Parabacteroides uncultured/ distasonis 1.2 0.1 0.1 0.0 0.1 0.0
108 Prevotellaceae Prevotella group 3.7 0.6 0.3 0.1 0.3 0.1
109 Prevotellaceae Prevotella group 3 1.1 0.2 0.1 0.0 0.1 0.0
110 Prevotellaceae Prevotella group 5 1.2 0.1 0.1 0.0 0.1 0.0
111 Prevotellaceae Prevotella group 7 1.2 0.1 0.1 0.0 0.1 0.0
112 Rikenellaceae Alistipes onderdonkii/shahii 1.2 0.3 0.1 0.0 0.1 0.0
113 Ruminococcaceae group 1.0 0.3 0.1 0.0 0.1 0.0
114 Ruminococcaceae Ruminococcus albus 1.2 0.2 0.1 0.0 0.1 0.0
115 Ruminococcaceae Ruminococcus flavefaciens/ callidus 1.4 0.5 0.1 0.0 0.1 0.0
116 Ruminococcaceae unclassified 1.3 0.2 0.1 0.1 0.1 0.0
117 Sphingobacteriaceae 74.8 39.1 6.1 2.6 5.7 2.6
118 Sphingobacteriales Chitinophaga 1.3 0.3 0.1 0.0 0.1 0.0
119 Staphylococcaceae Staphylococcus caprae 1.3 0.2 0.1 0.0 0.1 0.0
120 Staphylococcaceae Staphylococcus group 1.1 0.1 0.1 0.0 0.1 0.0
121 Streptococcaceae Streptococcus agalactiae/ equi 1.3 0.1 0.1 0.0 0.1 0.0
122 Streptococcaceae Streptococcus group 1.2 0.1 0.1 0.0 0.1 0.0
123 Streptococcaceae Streptococcus group 1.2 0.2 0.1 0.0 0.1 0.0
124 Streptococcaceae Streptococcus oligofermentas/  infantarius 1.5 0.5 0.1 0.0 0.1 0.0
125 Streptococcaceae Streptococcus thermophilus 1.2 0.4 0.1 0.0 0.1 0.0
126 Veillonellaceae Phascolarctobacterium faecium 1.7 0.9 0.1 0.1 0.1 0.1
127 Verrucomicrobiaceae Akkermansia muciniphila 1.5 0.4 0.1 0.1 0.1 0.1
128 Yeast Galactomyces geotrichum 1.2 0.1 0.1 0.0 0.1 0.0
below detectable level <2 <0,1 % <0,1 %
low abundance 2<    <4 0,1% <  < 0,2% 0,1% <  < 0,2%
medium abundance 4 <   < 50 0,2% <   < 4% 0,2% <   < 4%
high abundance >50 >4% >4%
Signal to 
Background (S/B)
Relative S/B           
[1]
Corrected relative 
S/B                            
[3]*
     * Correction factor [2] = 0.91
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Influence of nucleic acids derived from dead or inactive cells  
I-chip results were based on isolated DNA. DNA derived from both dead and inactive cells 
was potentially present after antibiotic-treatments and this could result in false positive 
results in our experiments. Hence, discrimination between dead and viable cells and 
between active and inactive cells was supportive in drawing reliable conclusions.  
To discriminate dead from viable cells, a treatment with propidium monoazide (PMA) was 
applied on replicates of the collected samples. PMA can bind to DNA in case the bacterial 
membrane is permeable (indicative for dead cells), and thereby inhibiting PCR 
amplification.12 The viability of cells was not checked on culturing plate since 50% to 90% 
of anaerobic bacteria from faecal sample are not cultivable. Culture independent methods 
are preferred for this type of analysis.2 Results from PMA-treated samples were compared 
to the corresponding non-PMA-treated samples. Differences between the two sets of 
samples were detected neither with qPCR on the total cell numbers (Figure 3) nor with I-
chip on the microbiota composition (fingerprints similar to the ones observed in Figure 1). 
Therefore, potentially present dead cells after antibiotic-treatments did not influence 
microarray measurements after 24h in vitro fermentation. This conclusion is in contrast 
with results from previous studies.12, 22 However, Kobayashi et al22 focused on specific 
species, which do not recover from the antibiotic treatment, while Nocker et al12 
performed measurements shortly after antibiotic addition and not after 24h fermentation. 
In our experimental set-up, the non-affected bacteria grow during 24h fermentation time 
and the error due to the presence of dead cells apparently becomes negligible. 
To discriminate actively growing cells from inactive cells, I-chip hybridizations were 
performed for both DNA and RNA isolated from the same sample (Figure 4). The 
differences between bacterial fingerprints based on DNA versus RNA especially concerned 
the bacteria present in low abundances. The signal intensities based on RNA were most 
often higher than the ones based on DNA. These differences indicate that these bacteria 
are active albeit present in low numbers, which is in line with literature reporting that 
more copies of RNA are present in one cell than copies of DNA.23 In some occasions, it was 
observed that the signal intensity based on RNA was lower than the one based on DNA 
e.g. 1 μg.ml-1 amoxicillin and 1 μg.ml-1 clindamycin. Low RNA signals as compared to DNA 
signals are the differences to be discriminated as the bacteria are present but not active. 
These differences are not dependent on the mode of action of the antibiotic: Inhibition of 
activity was also observed with amoxicillin, which is known as a bacteriolytic antibiotic 
(Table 1). Apparently, antibiotics may be bacteriolytic for the bacteria they target for, but 
may be bacteriostatic for other bacteria, as also reported earlier.3  
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Figure 4: Bacterial fingerprints of non-treated and antibiotic-treated adult inoculum obtained with 
the I-chip based on DNA vs. RNA after 24h in vitro fermentation. Seven antibiotics were tested in 
concentrations of 1 μg.ml-1 and 10 μg.ml-1. Main groups of bacteria are highlighted in colour and full 
name of targets can be found in table 2 based on their numbering. Signal to the background (S/B): 
Green: below detectable level, Black: medium abundance, Red: high abundance.   
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Overall, bacterial fingerprints based on DNA differ from the ones based on RNA. However 
these differences especially concern a low proportion of the total microbiota. Hence, in 
our study aiming at screening for major differences in the microbiota composition due to 
antibiotic treatments, no major misinterpretations are made when ignoring the presence 
of inhibited cells for any antibiotic mode of actions. 
In conclusion, the I-chip readout is not influenced by the variations in the total number of 
bacteria nor the presence of dead or inactive cells after 24h in vitro fermentation. Hence 
the impact of antibiotics on the adult microbiota can be made with this microarray and 
conclusions on biological effects can be drawn from figure 1 (p34-35).  
 
Impact of different antibiotics on the intestinal microbiota of healthy 
adults 
Seven antibiotics were tested at low dose (1 μg.ml-1) and high dose (10 μg.ml-1). The 
impact of the antibiotics on microbiota as compared to the non-treated microbiota was 
determined with the I-chip 24h after starting the exposure.  
 
Amoxicillin (Figure 1 A/B - AMX) 
At 1 μg.ml-1 antibiotic concentration, the abundance of Bacteroides remained stable, that 
of Enterobacteriaceae slightly decreased (Escherichia coli mainly) while those of 
Bifidobacterium, Lactobacillus and Clostridium decreased to an undetectable level. At 
10 μg.ml-1, the abundances of most Bacteroides species (except B. fragilis) and 
Enterobacteriaceae decreased to undetectable levels, although one outlier did not show 
significant reduction in the last group of bacteria. The abundance of Lactobacillus gasseri 
slightly increased. These results are in agreement with literature where amoxicillin is 
described as a broad spectrum antibiotic with an increasing suppression of both anaerobic 
and aerobic bacteria with increasing doses, although levels of Enterobacteriaceae are 
reported to increase but also to decrease.4  
 
Azithromycin (Figure 1 A/B - AZM) 
At 1 μg.ml-1, the abundance of a few Bacteroides species (mostly B. uniformis and B. 
vulgatus) slightly decreased while Bifidobacterium abundance was reduced to 
undetectable levels. The abundances of the other groups of bacteria remained stable. At 
10 μg.ml-1, the abundances of Bacteroides and Enterobacteriaceae were slightly lowered 
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whereas that of Clostridium was reduced to an undetectable level. The abundance of 
Lactobacillus remained stable. These results fit with literature indicating a low activity for 
AZM against gram positive bacteria and an increased activity against aerobic gram 
negative rods.24 
 
Cefadroxil (Figure 1 A/B - CFR) 
At 1 μg.ml-1, the abundances of Bifidobacterium, Clostridium and Lactobacillus slightly 
decreased, while those of the other groups remained stable. At 10 μg.ml-1, the 
abundances of B. uniformis, B. dorei, B. fragilis, Bifidobacterium, and Clostridium 
decreased to undetectable levels. The abundance of Enterobacteriaceae remained stable, 
while that of Lactobacillus brevis increased. No major effects of cefadroxil (1g, 10 days) on 
the microbiota is reported in literature,4 indicating that the absorption rate of cefadroxil 
in vivo  might be greater than 90% as assumed in the present study.  
 
Ciprofloxacin (Figure 1 A/B - CIP) 
At 1 μg.ml-1, the abundances of Enterobacteriaceae and Clostridium were dramatically 
reduced and became undetectable. At this low dose, the abundance of Bifidobacterium 
slightly increased and that of Lactobacillus remained stable. At 10 μg.ml-1, the abundance 
of Bifidobacterium decreased to undetectable levels and that of L. gasseri increased. The 
abundance of Bacteroides remained stable for the two doses tested. Strong activity of 10 
μg.ml-1  treatment is well known against Enterobacteriaceae and Clostridium4 but not the 
activity against other bacterial groups.  
 
Clindamycin (Figure 1 A/B - CLI) 
At 1 μg.ml-1, the abundances of B. fragilis and Bifidobacterium decreased to an 
undetectable level, that of L. brevis slightly increased and those of the other groups 
remained stable. At 10 μg.ml-1, the abundances of B. fragilis, B. uniformis and Clostridium 
were reduced to undetectable levels, that of Enterobacteriaceae remained stable, and 
that of L. brevis increased. In line with the observed results, Clindamycin activity is 
reported to mainly be active against anaerobic bacteria.4 Different impact per species of 
Bacteroides has been reported,25 although our data do not show survival of B. fragilis. 
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Doxycycline (Figure 1 A/B - DOX) 
At 1 μg.ml-1, the abundances of Bifidobacterium and Enterobacteriaceae were slightly 
reduced while those of B. fragilis, Clostridium and Lactobacillus decreased to undetectable 
levels. At 10 μg.ml-1, the abundances of Bacteroides and Bifidobacterium were reduced to 
undetectable levels, that of L. gasseri  increased, while that of Enterobacteriaceae did not 
further decrease as compared to the abundances observed with 1 μg.ml-1. The class of 
“Tetracycline” is not often studied.4 Only a decrease of Bifidobacterium and of the general 
microbiota diversity measured by PCR-DGGE have been reported by Saarela et al26. 
 
Erythromycin (Figure 1 A/B - ERY) 
At 1 μg.ml-1, the abundance of each group of bacteria remained stable except for the 
abundance of Bifidobacterium, which decreased to an undetectable level. At  10 μg.ml-1, 
the abundance of B. fragilis slightly decreased while the abundance of Clostridium 
decreased under the detectable level. The abundances of Enterobacteriaceae and 
Lactobacillus remained stable. These results are according to the trends reported in 
literature although a stronger impact of erythromycin towards Enterobacteriaceae and 
anaerobes has been reported.4 
 
Overview of the antibiotic impact on the human intestinal microbiota 
The impact of seven antibiotics on the human microbiota composition was now monitored 
under similar conditions in one experimental set-up. Although the interaction between 
host and microbiota are not mimicked in in vitro system, our findings for specific antibiotic 
were in general consistent with trends described in previous studies.4,25,27-30 The outcomes 
of previous studies are, however, sometimes difficult to compare among each other or 
with current data due to the use of different conditions and analytical techniques. The 
advantage of our approach is illustrated in table 3 where the straightforward comparison 
of the outcomes regarding antibiotic impact on Bacteroides, Bifidobacterium, Clostridium, 
Enterobacteriaceae and Lactobacillus is summarised.  
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Table 3: Overview of the impact of antibiotics on the main bacterial groups of adult inoculum 
measured with the I-Chip after 24h in vitro fermentation as compared to non-treated microbiota.  
  μg.ml-1 Bacteroides Bifido- 
bacterium 
Lacto- 
bacillus 
Clostridium Entero-
bacteriaceae 
AMX 1 = ↓↓ ↓  ↓↓ ↓ E.coli 
10 ↓↓ 
B. dorei  
B. uniformis 
B. thetaiotaomicron 
↓↓  ↑  
L. gasseri 
↓↓   ↓↓ 
AZM 1 ↓ 
 B. vulgatus 
B. uniformis 
↓↓ = = = 
10 ↓ ↓↓ = ↓↓ ↓ 
 
CFR 1 = ↓ ↓  ↓ = 
10 ↓↓ 
B. dorei  
B. uniformis 
B. fragilis 
↓↓ ↑↑  
L. brevis 
↓↓ = 
CIP 1 = ↑ = ↓↓ ↓↓ 
10 = ↓↓  ↑↑  
L. gasseri 
↓↓  ↓↓ 
CLI 1 ↓↓ 
B. fragilis 
↓↓  
 
↑  
L. brevis 
= = 
10 ↓↓ 
B. fragilis 
B. uniformis 
↓↓  ↑↑  
L. brevis 
↓↓  = 
DOX 1 ↓↓    
B. fragilis 
↓  ↓↓  ↓↓ ↓ 
10 ↓↓ ↓↓  ↑↑  
L. gasseri 
↓↓  ↓ 
ERY 1 = ↓↓  = = = 
10 ↓↓    
B. fragilis 
↓↓ = ↓ = 
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In general, the impact on the microbiota is antibiotic and dose dependent, even if 
antibiotics belong to the same class, as reported in literature.27 Details of the description 
are at family, genus but also species level when appropriate. Within a bacterial group, a 
specific antibiotic can have different impacts for different species (e.g Bacteroides) and 
the dose of this antibiotic can influence specific species within a bacterial group (e.g 
Lactobacillus). These differences at species level are not often considered in literature 
although predominance or absence of certain species might have an influence on the 
ecosystem and, therefore, on human health. For instance, L. gasseri that became 
predominant upon a treatment with 10 μg.ml-1 amoxicillin, ciprofloxacin and doxycycline, 
has been shown to result in a significant reduction of inflammation in IL-10- deficient 
mice.31 
For all the antibiotics except ciprofloxacin, the concentration of 1 μg.ml-1 is below the MIC 
values for the pathogens targeted. It is interesting to notice in table 3 that this low dose of 
antibiotic can already influence some bacterial groups of the microbiota. Lactobacilli, for 
instance, tends to survive antibiotic treatments. This survival of lactobacilli can be seen as 
an ability to persist through antibiotic treatment and, therefore, accentuate their probiotic 
effects or as a means to spread the antibiotic resistance genes within the gut.32 On the 
contrary, bifidobacteria seem to be very sensitive micro-organisms. All antibiotics reduced 
the abundance of this group at 1 μg.ml-1 except for ciprofloxacin, which reduced it only at 
10 μg.ml-1 concentration. As (minor) changes in the microbiota composition are reported 
to have consequences for colonic health with respect to development of resistant 
bacteria33 and may cause disturbance of colonic fermentation,34 sub-MIC dose of 
antibiotics reaching the colon should, therefore, not be under estimated with respect to 
undesired health effects. 
 
Conclusion  
To our knowledge, this study is the first to demonstrate the potential utility of coupling 
the high-throughput fermentation screening-platform to the I-chip analysis to monitor the 
effect of antibiotics on the microbiota in comparable conditions. The reliability of the 
microarray analysis was validated in case of antibiotic exposure. Errors due the variation in 
cell numbers and presence of dead cells were negligible after 24h in vitro fermentation. 
With this high-throughput approach, a detailed level of information at family, genus and 
species level was simultaneously obtained for all groups of bacteria whereas most 
previous studies focus on specific antibiotic or specific bacteria or group of bacteria. 
Although the interaction between host and microbiota cannot be mimicked completely in 
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an in vitro system, the detailed impact of seven antibiotics as obtained from one 
experimental set-up using a complex ecosystem allows comparison of the different 
antibiotics. Such detailed high-throughput evaluation could not be reached either in 
in  vitro studies using other molecular tools or in in vivo studies.  
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Chapter 3 
Impact of galacto-oligosaccharides on the gut 
microbiota composition and metabolic activity upon 
antibiotic treatment during in vitro fermentation  
 
 
Abstract 
Prebiotics are considered to have potential to reduce disturbances in the gut microbiota 
induced by antibiotics. Results in literature are, however, not consistent. The current in 
vitro study conducted in a fermentation screening-platform allowed to unambiguously 
compare the impact of galacto-oligosaccharides (GOS) on adult gut microbiota 
composition and activity upon treatment with four antibiotics at two doses. The changes 
in relative abundance of bacteria upon antibiotic treatment and the growth of 
Bifidobacterium and Lactobacillus species upon GOS addition was antibiotic and dose 
dependant. This conclusion explains discrepancies in literature and indicates that 
particular combinations of GOS-antibiotic should be studied. The combination GOS-
Amoxicillin was especially of interest as, after decrease of the level of Bifidobacterium 
spp., a recovery of mainly Bifidobacterium longum was observed and could be correlated 
to specific degradation patterns of GOS. Next to different degradation profiles of 
individual GOS oligosaccharides, an accumulation of monosaccharides and intermediate 
organic acids was observed in antibiotic-treated microbiota as compared to non-treated 
microbiota. This showed that although GOS was utilised and beneficial bacteria could 
grow for 3 out of 4 antibiotics tested, the metabolic activity of an antibiotic-treated 
microbiota was still disturbed as compared to the non-treated microbiota 
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Introduction 
Fermentation of non-digested compounds reaching the human colon requires the 
cooperation of different bacterial groups and results in the production of gases and Short 
Chain Fatty Acids (SCFAs).1 The complex microbiota and its metabolic activity are relatively 
stable in the various stages of life for each individual, but can be disrupted by e.g. 
antibiotic treatments or modulated with prebiotic supplementations.2 
In Europe, the median consumption of antibiotic was 18.3 Defined Daily Doses per 1000 
inhabitants per day in 2010. The most commonly used antibiotics were penicillins followed 
by macrolides and tetracyclines.3 These antimicrobial agents are used to treat specific 
bacterial infections, but can also kill or inhibit bacteria that are not primarily targeted, 
such as bifidobacteria and lactobacilli, within the gut microbiota.4 The extent of the impact 
of an antibiotic on the non-targeted microbial populations depends on its spectrum of 
action, mode of administration (oral vs. intravenous), dose and absorption rate.5 The 
resulting disruption of the microbiota can be the basis for the occurrence of metabolic 
dysfunctions, leading to a decrease of beneficial SCFA levels and to an increase of 
unfermented oligosaccharides.6 In 5-35% of the cases, it can also lead to antibiotic-
associated diarrhoea (AAD), with the antibiotics amoxicillin and clindamycin having the 
highest incidence.7 
Prebiotics are defined as “selectively fermented ingredients that allow specific changes, 
both in the composition and/or activity in the gastrointestinal microflora that confer 
benefits upon host well-being and health”.8 Most known prebiotics are fructo-
oligosaccharides (FOS) and galacto-oligosaccharides (GOS). The use of prebiotics to 
prevent non-antibiotic associated gut diseases is promising.9 With respect to the 
prevention of AAD, only a few studies have been performed. The results are contradictory 
regarding the efficacy to limit the risk of AAD and the impact on the microbiota 
composition.2, 10, 11 Main focus was on the number of bifidobacteria, as these bacteria are 
expected to be stimulated by the prebiotic addition. The number of bifidobacteria was 
reported to either increase,12 decrease13 or remain stable.14 Discrepancies regarding the 
effect of prebiotic addition on antibiotic-treated microbiota might be explained by the 
variability in parameters among the studies. Parameters, such as prebiotics, antibiotics, 
dosages and age of subjects are known to have a high impact on the microbiota 
composition.15 Using a fermentation screening-platform, this study aims to unambiguously 
compare the potential beneficial impact of a commercially available prebiotic, galacto-
oligosaccharides (GOS), on an adult microbiota treated with four antibiotics at two doses. 
The microbiota composition was investigated as well as the microbiota metabolic activity, 
specifically oligosaccharide degradation and organic acid production.  
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Material and methods 
Antibiotics 
Amoxicillin (AMX) (≥90%), ciprofloxacin (CIP) (≥98% HPLC), clindamycin hydrochloride (CLI) 
(impurities ≤2 mol/mol EtOH) and doxycycline (DOX) (≥98% TLC) were obtained from 
Sigma-Aldrich (St Louis, MO, USA). These antibiotics belong to four of the most widely-
used classes of antibiotics used in Europe3 and were selected based on their different 
modes of action (Table 1).  
 
Table 1: Characteristics of mostly used antibiotics in main classes frequently used in Europe. 
aAAD : Antibiotic Associated Diarrhoea   
 
Prebiotic 
Purified Galacto-oligosaccharides (GOS) with <3% (w/w dry matter) monomers and lactose 
(purified from the lactose-based prebiotic Vivinal® GOS, FrieslandCampina Domo, Borculo, 
The Netherlands) were used. Vivinal® GOS was purified because monosaccharides and 
lactose are digested and absorbed in the small intestine. For the purification, Vivinal® GOS 
was enzymatically treated with a lactase to hydrolyse the lactose into glucose and 
galactose, after which the monosaccharides were removed by nanofiltration. The degree 
of polymerisation (DP) of the purified GOS ranged from 2 to 8. 
 
Experimental set up 
In a fermentation screening-platform (96 wells of 1.5ml), selected type and dose of 
antibiotics (1 μg.ml-1 or 10 μg.ml-1) and GOS (4,2 mg.ml-1) were simultaneously added to 
the Standard Ileal Efflux Medium (SIEM) and in vitro fermented (37°C; pH 5.8) using 
Class Name Type Mode of action4 AADa risk7 
Penicillin 
 
Amoxicillin 
(AMX) 
Bacteriolytic Inhibition peptidoglycan 
biosynthesis   
High  
Tetracycline 
 
Doxycycline 
(DOX) 
Bacteriostatic Translation inhibition   Low  
Macrolide- 
Lincosamide 
Clindamycin 
(CLI) 
Bacteriostatic Translation inhibition   High  
Fluroquinolone Ciprofloxacin 
(CIP) 
Bacteriolytic Replication and 
transcription inhibition   
Low   
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healthy adult faecal inoculum (0.1% v/v) under anaerobic conditions.16 Selection of 
volunteers (n=8) and methodology to obtain and store the faecal samples were performed 
as described previously.16 Polymeric carbohydrates present in the SIEM were used as non-
prebiotic substrate in the control.16 Each fermentation was performed in triplicate. To 
investigate the microbiota metabolic activity, samples (70 µl) were collected 6 times 
during fermentation. The collection times were chosen based on a test experiment 
revealing the time range of GOS degradation. This range was between 8h and 24h 
fermentation in the control, between 16h and 32h and between 24h and 48h in the 
fermentations using 1 μg.ml-1 and 10 μg.ml-1 antibiotic, respectively (data not shown). The 
collected samples were then boiled (5 min) and stored at -20°C. To investigate the changes 
in the microbiota composition, additional samples (70 µl) were collected from the same 
well at 24h, 32h and 48h, since the fermentation rate may be slowed down by antibiotic 
addition, and stored at -20°C .  
 
Microbiota composition analysis 
The Intestinal (I)-Chip, developed at TNO (Zeist, The Netherlands), was used to investigate 
the composition of the microbiota. This DNA based microarray enabled the detection of 
more than 400 bacterial targets from the human large intestinal microbiota. Total faecal 
DNA from collected samples was isolated, amplified, purified and hybridized as described 
previously.16 The hybridization took place on a microarray constructed and validated as 
described before,17 using intestinal bacteria primers instead of oral primers. Imagene 5.6 
software (BioDiscovery, Marina del Rey, CA, USA) was used to analyse the results. Genes 
above the detectable level having a signal intensity higher than 3 (>105 bacteria) in more 
than 10 samples were used to describe the bacterial fingerprint.  
 
Total bacteria and Bifidobacterium spp. quantification using quantitative 
PCR 
Quantitative PCR (qPCR) was performed to investigate the variation in the total number of 
bacteria and of Bifidobacterium spp. during fermentation. Primers used to measure the 
total number of bacteria were the universal primers 16S-uni-II-R [10 pmol.μl-1] (GGA CTA 
CCA GGG TAT CTA ATC CTG TT) and 16S-uni-II-F [10 pmol.μl-1] (TCC TAC GGG AGG CAG 
CAG T), and probe 16S-uni-II [5μM] (6FAM-CGTATTACCGCGGCTGCTGGCAC-TAMRA). The 
primers to measure the number of Bifidobacterium spp. were 16S-Bif-F [10 pmol.μl-1]  
(GGA GCA TGC GGA TTA ATT CG), 16S-Bif-R [10 pmol.μl-1] (GAC CAT GCA CCA CCT GTG 
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AAC), 16S-Bifspec (6FAM-CTG GGC TTG ACA TGT T) (Applied Biosystems, Bleiswijk, The 
Netherlands). The amplification was performed with 5 μl DNA sample and 25 μl q-PCR 
mixture.16 Total microbial faecal DNA was diluted 1:10 to quantify the total number of 
bacteria and 1:100 to quantify the number of Bifidobacterium spp. The experiment was 
performed using the 7500 Fast Real Time PCR system (Applied Biosystems) at settings 
previously described.16 
DNA of the microbiota from the control and Bifidobacterium longum was used as 
quantitative standards for total bacteria and Bifidobacterium spp., respectively  (5 ng.μl-1 
to 5 fg.μl-1).  
 
Statistical analysis 
To evaluate whether two qPCR data sets were significantly different, a Student t-test was 
performed. P-values were calculated assuming equal variance and two-tailed distribution. 
Correlations were considered significant at a P-value lower than 0,01. 
 
GOS degradation pattern using High Performance Anion Exchange 
Chromatography (HPAEC) 
HPAEC was performed to quantify GOS degradation during the experiments. The samples 
collected were 10× diluted with Millipore water (0.42 mg.ml-1) and analysed using an 
ICS3000 HPLC system (Dionex, Sunnyvale, CA, USA), equipped with a CarboPac PA-1 
column (2 mm ID × 250 mm; Dionex) in combination with a CarboPac PA guard column 
(2 mm ID × 25 mm) and a ISC3000 ED detector (Dionex) in the PAD mode. A flow rate of 
0.3 ml.min-1 was used with the following elution profile of 0.1 M sodium hydroxide 
(solution A) and 1 M sodium acetate in 0.1 M sodium hydroxide (solution B): 0–20 min, 0–
20% B; 20–26 min washing step with 100% B; 26–41 min, equilibration with 100% A. 
Twenty µl of sample was injected each time. 
To describe the degradation of GOS over fermentation time, GOS were roughly subdivided 
based on the degree of polymerisation (DP):18 dimers (DP<3, incl. 3% monomers) eluting 
between 4.5 min and 9.7 min, medium-sized DP (3≤DP≤5) eluting between 9.7min and 
13.0min, and large DP (DP>5) eluting between 13.0 min and 18.0 min. The peak areas 
were measured to express the remaining oligosaccharides as an indication of the 
degradation rate. Degradation patterns were similar for the triplicate samples. The 
proportion of remaining oligosaccharides was quantified only in one set of samples.  
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Organic acids production using gas chromatography (GC) and high 
performance liquid chromatography (HPLC) 
A GC analysis was performed on a TRACE™ GC Ultra Gas Chromatograph system coupled 
with a FID detector (Interscience, Breda, The Netherlands) to quantify the SCFA (acetate, 
propionate and butyrate) produced during fermentation: 50µl of diluted sample (0.42 
mg.ml-1) or standards (1 mg.ml-1 to 0.125 mg.ml-1) mixed with 50 µl of 0.15 M oxalic acid 
stood for 30 min before addition of 150 µl of water. Samples (1 µl) were injected to a CP-
FFAP CB column (25m x 0.53mm x 1.00 µm) (Agilent Technologies, Santa Clara, CA, USA). 
The temperature profile was as follows:  Start at 100°C, increase to 155°C at 5°C.min-1, and 
hold at this temperature 1 min. GC data was integrated using the Xcalibur® software 
(Thermo Scientific, Breda, The Netherlands).  
HPLC was performed to quantify lactate and succinate on an Ultimate 3000 HPLC (Dionex) 
equipped with an RI-101 refractive index detector (Shodex, Kawasaki, Japan), an 
autosampler and an ion-exclusion Aminex HPX – 87H column (7.8 x 300mm) with a guard 
column (Bio-Rad, Hercules, CA, USA). The mobile phase was 5mM H2SO4 and the flow rate 
was 0.6 ml.min-1 at 65°C. Diluted samples (10µl; 0.42 mg.ml-1) and standards (10µl; 
0.125 mg.ml-1 to 1 mg.ml-1 ) were injected onto the column.  The concentration of organic 
acids was quantified only in one set of samples and expressed as µmol.mg-1 of GOS. 
 
Results 
In order to determine the potential beneficial impact of GOS on antibiotic-treated 
microbiota composition and metabolic activity (substrate degradation and SCFA 
production), in vitro fermentations using adult faecal inoculum treated with four 
antibiotics (AMX, CIP, CLI, DOX) at two doses (low : 1 μg.ml-1 or high: 10 μg.ml-1) were 
performed in a fermentation screening-platform.  
 
Impact of GOS on the microbiota composition 
Total bacteria and Bifidobacterium spp. quantification 
The total numbers of bacteria and Bifidobacterium spp. in AntiBiotic-treated MicroBiota 
(AB-MB) and in antibiotic-treated microbiota supplemented with GOS (AB/GOS-MB) as 
measured with qPCR are presented in table 2.  Overall, the total number of bacteria 
remained stable upon GOS addition. The number of Bifidobacterium spp. increased upon 
GOS addition depending on the antibiotic, dose and time.  
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Table 2: Numbers of total bacteria and Bifidobacterium spp. in adult inoculum treated with 
1 μg.ml-1 (1) and 10 μg.ml-1 (10) antibiotics with and without GOS addition as measured with qPCR 
during in vitro fermentation. Values are expressed as mean ± standard deviation of log10 (copies.g
-1 
faeces) (n=3). 
  
Total Bacteria Bifidobacterium 
  
no GOS GOS no GOS GOS 
Non-treated 
24h 11.2 ±0.1 11.0 ±0.4 7.2 ±0.2 9.9 ±0.0# 
32h 11.0 ±0.3 11.4 ±0.2 6.9 ±0.6 9.7 ±0.1# 
48h 11.3 ±0.5 11.1 ±0.1 7.8 ±0.6 9.6 ±0.1# 
AMX 1 24h 11.0 ±0.4 10.7 ±0.2 6.0 ±0.3
† 7.3 ±0.2#† 
32h 11.2 ±0.3 10.5 ±0.3 6.3 ±0.2 9.2 ±0.2# 
CIP 1 24h 11.5 ±0.1 10.3 ±0.6 7.3 ±0.1 9.5 ±0.3
# 
32h 10.8 ±0.8 10.6 ±0.3 7.2 ±0.4 9.6 ±0.3# 
CLI 1 24h 10.4 ±0.7 10.2 ±0.6 4.8 ±0.3
† 5.1 ±0.2† 
32h 10.8 ±0.6 10.1 ±0.5 4.7 ±0.4† 4.9 ±0.3† 
DOX 1 24h 10.3 ±1.0 10.8 ±0.4 7.7 ±0.8 9.8 ±0.2
# 
33h 10.2 ±0.5 11.3 ±0.2# 7.5 ±0.4 9.7 ±0.2# 
AMX 10 
24h 10.9 ±0.4 10.9 ±0.2 4.8 ±0.6† 5.8 ±0.4† 
32h 10.9 ±0.9 10.7 ±0.5 6.1 ±0.1 9.8 ±0.0# 
48h 10.7 ±0.6 10.7 ±0.4 6.1 ±0.1 9.6 ±0.2# 
CIP 10 
24h 9.3 ±0.4† 10.0 ±0.1 5.0 ±0.2† 5.1 ±0.3† 
32h 9.2 ±0.1† 9.9 ±0.2#† 5.3 ±0.1 4.6 ±0.3† 
48h 8.8 ±0.1† 10.3 ±0.2#† 4.7 ±0.1† 6.3 ±0.2#† 
CLI 10 
24h 10.7 ±0.1† 10.1 ±0.1 4.8 ±0.1† 4.8 ±0.1† 
32h 10.8 ±0.0 10.0 ±0.6 4.7 ±0.1† 4.8 ±0.1† 
48h 10.7 ±0.1 10.5 ±0.1 4.8 ±0.1† 5.6 ±0.2#† 
DOX 10 
24h 9.7 ±0.1† 9.8 ±0.4 4.7 ±0.1† 4.8 ±0.3† 
32h 8.8 ±0.8† 9.8 ±0.7 5.0 ±0.3 5.2 ±0.4† 
48h 9.2 ±0.8† 10.1 ±0.3† 4.9 ±0.1† 5.3 ±0.3† 
# significant difference  between GOS and no GOS addition (p<0.01) 
† significant difference  between non-treated and antibiotic-treated (p<0.01)  
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The increase of Bifidobacterium spp. was significant (P<0.01) for CIP/GOS-MB (+1.6 log10) 
and CLI/GOS-MB (+0.8 log10) applied with a 10 μg.ml
-1 dose, although the number of 
Bifidobacterium spp. was still below that of the non-treated microbiota (107.8 copies.g-1 
faeces ±0.6). The number of Bifidobacterium spp. upon GOS addition increased 
significantly (P<0.01) and reached a level that was similar to GOS-MB (109.6 copies.g-1 
faeces) for CIP/GOS-MB (+2.4 log10) and DOX/GOS-MB (+2.2 log10) applied with a 1 μg.ml
-1 
dose, and for AMX/GOS-MB applied with a both 1 μg.ml-1 and 10 μg.ml-1 dose (+2.9 log10 
and +3.5 log10, respectively). At low dose, the stimulation of Bifidobacterium spp. was 
quicker for CIP/GOS-MB and DOX/GOS-MB (24h of fermentation) than for AMX/GOS-MB 
(32h of fermentation). The growth of Bifidobacterium spp. for AMX/GOS-MB at both low 
and high dose is of high interest as the level of Bifidobacterium spp. was first decreased 
due to the AMX action.  
 
Microbiota fingerprinting as measured with the I-chip 
The impact of GOS on the overall microbiota composition, including specific bifidobacteria 
species, was determined using the I-chip by comparing AB/GOS-MB and AB-MB (Figure 1). 
For AB/GOS-MB, the addition of GOS did not influence the abundances of Bacteroides, 
Clostridium and Enterobacteriaceae. For the latter two bacterial groups, the abundance 
remained low upon GOS addition, which is preferable as most pathogens belong to these 
two bacterial groups. In AB/GOS-MB, an impact of GOS addition could be observed on the 
lactobacilli and bifidobacteria population at each dose of antibiotic. The increase of 
Lactobacillus spp. was dose dependant: At low dose (1 μg.ml-1), an increase of 
Lactobacillus brevis was observed upon addition of GOS after 24h of fermentation in most 
samples (excluding AMX/GOS-MB), while at high dose (10 μg.ml-1), an increase of 
Lactobacillus gasseri was observed in CIP/GOS-MB and DOX/GOS-MB. The increase of 
Bifidobacterium spp. was in line with results measured by qPCR.  
The I-chip results also showed that different species were stimulated upon GOS addition 
depending on the antibiotic treatment. For GOS-MB, a broad range of Bifidobacterium 
spp. became more abundant, mainly B. longum, B. thermophilum and B. adolescentis. For 
AB/GOS-MB, specific Bifidobacterium spp. were stimulated depending on the antibiotic 
and the dose. Using a low dose of antibiotic, mainly B. longum became more abundant for 
AMX/GOS-MB, while mainly B. longum, B. animalis and B. thermophilum for CIP/GOS-MB 
and mainly B. thermophilum, B. ruminantium and B. adolescentis for DOX/GOS-MB 
became more abundant. Using a high dose of antibiotic, mainly B. longum and B. 
thermophilum became more abundant for AMX/GOS-MB. For CIP/GOS-MB, 
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Bifidobacterium spp. were stimulated but no preferential growth of specific species were 
detected.  
As the same inoculum was used for all fermentations, it is clearly shown that within the 
same ecosystem the stimulation of specific bacteria upon GOS addition depends on the 
antibiotic used. 
 
Figure 1: Bacterial fingerprints of the non-treated and antibiotic-treated adult microbiota with and 
without GOS addition obtained with the I-Chip after 24h, 32h or 48h in vitro fermentation. 
Antibiotics were used in concentrations of 1 μg.ml−1 and 10 μg.ml−1. Signal compared to the 
background (S/B): Green: below detectable level, Black: medium abundance, Red: high abundance.   
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Metabolic activity of antibiotic-treated microbiota supplemented with 
GOS 
Degradation of the substrate GOS  
Since the growth of Bifidobacterium and Lactobacillus species was observed upon GOS 
addition in some antibiotic-treated microbiota, the degradation and utilisation of GOS 
were determined. The HPAEC elution patterns of GOS during fermentation using non-
treated microbiota are shown in Figure 2.  
 
Figure 2: HPAEC elution patterns of GOS during in vitro fermentation using non-treated adult 
microbiota. The complex mixture of GOS was roughly subdivided based on the degree of 
polymerisation (DP) (6). M: peak from the SIEM medium, G: glucose, L: lactose. 
 
A complex pattern of peaks can be observed at t=0. Few peaks were attributed to 
compounds present in the growth medium (M) and two peaks were attributed to 
glucose/galactose (G, Retention time (Rt)= 4.5min) and lactose (L, Rt= 6.3min). Other 
peaks represented oligosaccharides with different degree of polymerisation (DP) and 
isomers present in the GOS mixture.18 Over fermentation time, the different 
oligosaccharides were degraded at different rates. To visualise the degradation of GOS in 
non-treated microbiota and 1 μg.ml-1 or 10 μg.ml-1 antibiotic-treated microbiota during 
fermentation, the proportion of remaining oligosaccharides (% of peak area) is presented 
in Figure 3 for total GOS and for oligosaccharides with a DP<3, 3≤DP≤5 and DP>5.  
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Figure 3: Percentage of remaining oligosaccharides from GOS during in vitro fermentation using a 
non-treated microbiota and an 1 μg.ml-1 or 10 μg.ml-1 antibiotic-treated microbiota.  
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In GOS-MB, about 20% of the total GOS was utilised in the first 8h of fermentation and 
further utilisation occurred gradually until 24h of fermentation. For AB/GOS-MB, a lag-
time of utilisation was observed as more than 80% of GOS was still present after 16h and 
24h of fermentation when the 1 μg.ml-1 and 10 μg.ml-1 doses were used, respectively. The 
subsequent utilisation of GOS differed per antibiotic and per dose. About 40% of the GOS 
remained in CLI/GOS-MB after 34h and 48h of fermentation at low and high dose, 
respectively. On the contrary, the degradation was almost complete (<10% remaining 
GOS) for CIP/GOS-MB, AMX/GOS-MB and DOX/GOS-MB. Once the degradation started, 
the 80% remaining GOS were degraded quicker in CIP/GOS-MB (6h), as quick as in 
AMX/GOS-MB (12h) and slower in DOX/GOS-MB (17h) than in GOS-MB.   
Oligosaccharides of DP<3 were in most cases quickly utilised in 1 μg.ml-1 treated samples, 
indicating an easy utilisation by the microbiota. For AMX/GOS-MB, however, 
oligosaccharides of DP<3 accumulated at the beginning of the fermentation before being 
fully utilised within 34h of fermentation. For 10 μg.ml-1 treated samples, oligosaccharides 
of DP<3  remained present at 48h of fermentation in all cases, which is in contrast to the 
fermentation pattern of GOS without antibiotic treatment. Oligosaccharides of 3≤DP≤5 
decreased gradually in time for each dose of antibiotic. These oligosaccharides were 
present over time, probably due to a balance between further utilisation and formation. 
Oligosaccharides of DP>5 were degraded slowly in DOX/GOS-MB and quickly in AMX/GOS-
MB and CIP/GOS-MB for both doses. Overall, it can be concluded that different 
degradation profiles were observed after a same fermentation time depending on the 
antibiotic and dose used.  
 
Production of organic acids 
The degradation of GOS resulted in the production of organic acids: acetate (A), 
propionate (P), butyrate (B), succinate (S) and lactate (L) (Figure 4). For GOS-MB, the total 
amount of organic acids was 14 µmol.mg substrate-1, with a ratio of A:P:B:S:L of 
79:6:6:8:1. For 1 μg.ml-1 antibiotic-treated samples, different concentrations of organic 
acids were observed per antibiotic used. For AMX/GOS-MB, a lower total amount of 
organic acids was observed (9 µmol.mg substrate-1), mainly acetate and succinate 
(A:P:B:S:L = 44:7:5:44.0). For CIP/GOS-MB and DOX/GOS-MB, the amount and relative 
abundance of organic acids were similar to that of GOS-MB. For CLI/GOS-MB, a rather low 
amount of organic acids was observed (5 µmol.mg substrate-1), mainly acetate. For 10 
μg.ml-1 treated samples, an overall reduction of organic acids was observed (below 9 
µmol.mg substrate-1 after 48h of fermentation). Furthermore, the relative abundance of 
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organic acids is dramatically changed since it mostly consists of lactic acid and acetate, 
whereas neither propionate nor butyrate could be detected.  
 
 
Figure 4: Organic acid amount and relative concentration during in vitro fermentation of GOS 
using a non-treated microbiota and an 1 μg.ml-1 or 10 μg.ml-1  antibiotic-treated microbiota.   
  
Non-treated
1 μg.ml-1 10 μg.ml-1
AMX
CIP
CLI
DOX
0.0
5.0
10.0
15.0
20.0
0h 18h 24h 28h 32h 36h
µm
ol
/m
g 
su
bs
tr
at
e
0.0
5.0
10.0
15.0
20.0
0h 18h 24h 28h 32h 36h
µm
ol
/m
g 
su
bs
tr
at
e
0.0
5.0
10.0
15.0
20.0
0h 18h 24h 28h 32h 36h
µm
ol
/m
g 
su
bs
tr
at
e
0.0
5.0
10.0
15.0
20.0
0h 8h 12h 16h 18h 22h
µm
ol
/m
g 
su
bs
tr
at
e Lactate
Succinate
butyrate
propionate
acetate
0.0
5.0
10.0
15.0
20.0
0h 26h 28h 32h 36h 40h 48h
µm
ol
/m
g 
su
bs
tr
at
e
0.0
5.0
10.0
15.0
20.0
0h 26h 28h 32h 36h 40h 48h
µm
ol
/m
g 
su
bs
tr
at
e
0.0
5.0
10.0
15.0
20.0
0h 18h 24h 28h 32h 36h
µm
ol
/m
g 
su
bs
tr
at
e
0.0
5.0
10.0
15.0
20.0
0h 26h 28h 32h 36h 40h 48h
µm
ol
/m
g 
su
bs
tr
at
e
0.0
5.0
10.0
15.0
20.0
0h 26h 28h 32h 36h 40h 48h
µm
ol
/m
g 
su
bs
tr
at
e
 
63 
 
Chapter 3 
 
Discussion 
Using a fermentation screening platform, a straightforward comparison of the impact of 
GOS on the gut microbiota treated with four antibiotics at two doses was possible. The 
antibiotics belong to the most widely-used classes of antibiotics used in Europe. The doses 
selected (1 µg.ml-1  and 10 µg.ml-1) are in the range of MIC-values of currently used 
antibiotics.19 The changes in the microbiota composition upon antibiotic treatment 
(Figure 1) were in line with previous results 16, except for the increase of bifidobacteria 
after 1 µg.ml-1 DOX treatment. The impact of tetracycline treatment, such as doxycycline, 
on bifidobacteria has been reported to be variable due to the presence or absence of a 
resistance gene depending on the species.20 Overall, the changes resulted in changes of 
metabolic activity, even upon the use of a sub-lethal dose as 1 µg.ml-1.21  
 
Antibiotic-treated microbiota changes upon GOS addition  
In AB/GOS-MB, changes in the microbiota composition were mainly detected for the 
Bifidobacterium spp. and Lactobacillus spp., which was expected as GOS is a prebiotic 
known to stimulate specifically these bacteria.8 The growth of other bacteria which may 
utilise the partly degraded substrate present was below the detection level and co-
dependence that exists amongst members of the microbiota21, 22 was not observed. The 
changes in levels of bifidobacteria and lactobacilli were concomitant with the degradation 
of GOS and were antibiotic dependant (Table 3). The level of bifidobacteria did not 
increase in CLI/GOS-MB at both doses within 32h of fermentation, which is in line with the 
observed low degradation of GOS (about 40% remaining). Hence, partial degradation of 
GOS is likely due to the activity of lactobacilli that are known to grow on GOS, but to a 
lesser degree than bifidobacteria23 On the contrary, levels of bifidobacteria increased 
upon GOS addition in CIP/GOS-MB and in DOX/GOS-MB at low dose (1 µg.ml-1). The 
growth of these bacteria was facilitated as they were not affected by CIP and DOX (Table 
2) and could utilise GOS (Figure 3). Furthermore, the competition for GOS intermediate 
degradation products was reduced, e.g. lower levels of Bacteroides in DOX/GOS-MB.24 At 
high dose, the degradation of GOS occurred in both DOX/GOS-MB and CIP/GOS-MB, likely 
due to Lactobacillus gasseri action that were highly abundant (Table 3). Finally, levels of 
bifidobacteria, specifically B. longum, increased upon GOS in AMX/GOS-MB at both doses. 
This outcome is of high interest as the levels in the controls were low due to AMX action. 
The recovery of B. longum, therefore, reveals a potential beneficial effect of GOS addition 
in AMX-disturbed microbiota.  
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Table 3: Overview of bacteria growth, GOS degradation and ratio of SCFA and intermediate 
organic acids in non-treated and antibiotic-treated microbiota after 32h or 48h in vitro 
fermentation 
Treatment Bacteria growth  GOS degradation Ratio SCFA : 
intermediate 
OA 
Bifido- 
bacteriuma 
Lacto- 
bacillusb 
 Remaining 
GOS (%) 
Last 
remaining 
DPs 
Non-treated Log10 9.6 ±0.1 +  0% 3<DP<5 91 : 9 
AMX/GOS-MB 
1 
μ
g.
m
l-1
   
32
h 
Log10 9.2 ±0.2# 
B. longum 
--  4% DP<3 56 : 44 
CIP/GOS-MB Log10 9.6 ±0.3# 
B. longum 
B. animalis 
++ 
L. brevis 
 2% DP<3 100 : 0 
CLI/GOS-MB Log10 4.9 ±0.3 + 
L. brevis 
 35% Most 
structures 
100 : 0 
DOX/GOS-MB Log10 9.7 ±0.2# 
B. ruminatium 
B. adolescentis 
+ 
L. brevis 
 9% 3<DP<5 93 : 7 
AMX/GOS-MB 
10
 μ
g.
m
l-1
  4
8h
 
Log10 9.6 ±0.2# 
B. longum 
B. thermophilum 
--  3% DP<3 32 : 68 
CIP/GOS-MB Log10 6.3 ±0.2# ++ 
L. gasseri 
 13% DP<3 38 : 62 
CLI/GOS-MB Log10 5.6 ±0.2# --  42% Most 
structures 
80 : 20 
DOX/GOS-MB Log10 5.3 ±0.3 ++ 
L. gasseri 
 9% DP<3 0 : 100 
a as determined by qPCR (n=3). Values are expressed in Log10 (copies.g-1 faeces).  
b as determined with I-chip (++: high abundance, +: medium abundance  , --: below detectable level) 
# significant difference  between GOS and no GOS addition (p<0.01) 
DP: Degree of Polymerisation 
 
Degradation of GOS in antibiotic-treated microbiota 
An almost complete degradation of GOS was observed in three antibiotic-treated 
microbiota using a low dose. The rate of degradation of oligosaccharides with different 
DPs varied depending on the antibiotic used. This preferential degradation was linked to 
the specific growth of bifidobacteria. (Table 3). The degradation of oligosaccharides of 
DP>5 was quick for both AMX/GOS-MB and CIP/GOS-MB, and correlated with the 
stimulation of mainly B. longum. This species is known to produce a membrane-bound 
extracellular endogalactanase that liberates galacto-trisaccharides from β(1,4) galacto-
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oligosaccharides.25 It is probably due to the endo-activity of this enzyme that the 
oligosaccharides of DP>5 are readily degraded. On the contrary, for DOX/GOS-MB, a fast 
degradation of small DP followed by a subsequent degradation of larger DPs was 
observed, which is characteristic for B. adolescentis25, 26 that was stimulated. The 
correlation between GOS degradation and recovery of specific bifidobacteria species for 
specific antibiotic used indicates that preference of certain oligosaccharides by the 
microbiota is important to be considered when aiming at the recovery of this microbiota 
after an antibiotic treatment. Investigating in more detail which specific structure of GOS 
are preferentially degraded upon a specific antibiotic treatment could, for instance, ease 
the choice for an adequate synbiotic to be added during the antibiotic treatment to limit 
risk for AAD.27 Another option could be to adjust the oligosaccharides composition of a 
prebiotic mixture depending on the antibiotic treatment used in order to stimulate 
specific bifidobacteria species present in the host gut.  
 
Metabolic activity of the microbiota after antibiotic treatment 
The metabolic functions of the microbiota include the degradation of the substrate and 
production of organic acids, which are most often SCFA.28 In non-treated microbiota, the 
degradation of GOS resulted in high amount of SCFA and a low amount of intermediate 
acids as described before.13, 29 At low dose, for CIP/GOS-MB and DOX/GOS-MB, the profile 
of organic acids was similar to that of GOS-MB, indicating that the metabolic activity of the 
microbiota might be as good as in non-treated microbiota. In strongly disrupted 
microbiota, e.g. 10 µg.ml-1 AB-MB or 1 µg.ml-1 CLI/GOS-MB, monosaccharides accumulated 
and a low total content of organic acids was observed, which is consistent with literature.6 
The presence of monosaccharides that would usually be quickly utilised by the microbiota 
might be a reason for pathogen colonisation, e.g. Clostridium difficile during antibiotic 
treatment. Furthermore, a downward shift in the ratio SCFA:intermediate acids was also 
observed in our study upon antibiotic treatment (Table 3), indicating that the ability to 
convert intermediate acids to SCFA was reduced. The presence of lactate and acetate is in 
line with the degradation of GOS by bifidobacteria and lactobacilli.30 However, the 
absence of propionate and butyrate indicates that key groups of bacteria, such as 
Bacteroides and butyrate-producing bacteria, are lacking. Accumulation of succinate in 
1 µg.ml-1 treated samples revealed that the activity of mainly Bacteroides was affected, 
while accumulation of lactate in 10 µg.ml-1 treated samples suggest that the lactate-
utilising bacteria were also affected. The altered concentrations of SCFA and intermediate 
organic acids are unusual in the colon. The impact on the differences in metabolites 
produced might have consequences on colon health. 
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Conclusion  
Using a fermentation screening-platform, our results clearly revealed that the recovery of 
an antibiotic-treated microbiota upon GOS addition is antibiotic dependant and, thereby, 
explains previous discrepancy in literature. The combination of GOS-AMX appeared to be 
of high interest as a recovery of mainly Bifidobacterium longum was observed and could 
be correlated to specific degradation patterns of GOS. Furthermore, the study emphasised 
that despite the specific growth of beneficial bacteria and the concomitant degradation of 
GOS, the metabolic activity of the antibiotic-treated microbiota may still be disturbed as 
compared to the non-treated microbiota. Further in vivo research should focus on the 
impact of specific structure of GOS to prevent intestinal diseases and on the consequences 
of the altered  concentrations of SCFA and intermediate organic acids on colon health. 
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Chapter 4 
Impact of galacto-oligosaccharides and its specific size-
fractions on non-treated and amoxicillin-treated 
human inoculum 
 
 
Abstract 
The impact of galacto-oligosaccharides (GOS) and of its specific size-fractions on non-
treated microbiota (NT-MB) and on amoxicillin-treated microbiota (AMX-MB) were 
revealed using a recently described fermentation screening-platform. The Bifidobacterium 
species were highly impacted by amoxicillin and both GOS and GOS size-fractions 
stimulated their recovery. Interestingly, the level of Bifidobacterium spp. tended to be 
higher upon the addition of original GOS and low size-fractions (dimers-trimers) for NT-MB 
and of large size-fractions (tetramers to hexamers) for AMX-MB. Chromatographic 
analyses corroborated the finding that these size-fractions were preferentially degraded 
by the respective microbiota. Furthermore, new insights were obtained on the microbiota 
metabolism for AMX-MB: the amount of lactate was higher upon fermentation of low size-
fractions, while more butyrate was present upon fermentation of large size-fractions. In 
conclusion, GOS can be used in advantage to support butyrate production and the 
recovery of the beneficial bifidobacteria from amoxicillin treatment, especially  the large 
size-fractions. 
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Introduction 
Galacto-oligosaccharides (GOS) are well accepted as a prebiotic and contribute to human 
health.1 GOS are produced by trans-galactosylation of lactose by β-galactosidases from 
yeast, fungi or bacteria, resulting in complex mixtures of oligosaccharides with different 
degrees of polymerisation (DP) and glycosidic linkages.2 The DP varies from DP2 to DP8. 
Possible linkages are β(1-1), β(1-2), β(1-3), β(1-4) and β(1-6), the latter two being the most 
common ones.3 Due to the diversity of possible glycosidic linkages, various isomeric 
oligosaccharides are present in each size-fraction.3 The β-glycosidic linkages between the 
saccharide units can specifically be hydrolysed in the colon by dedicated enzymes from 
Bifidobacterium and Lactobacillus species. In pure cultures, different Bifidobacterium 
species have shown to have preferential utilisation of selected DP of GOS. For instance, 
Bifidobacterium longum subsp. infantis ATCC 15697 preferred GOS of DP4, whereas 
Bifidobacterium adolescentis ATCC 15703 utilised preferentially GOS of DP3.4 In the same 
study, Bifidobacterium longum subsp. longum DJ010A was reported to partly utilise larger 
GOS oligosaccharide. Furthermore, the type of glycosidic linkage can also influence the 
stimulation of specific species. For instance, Bifidobacterium breve 26M2 and 
Bifidobacterium lactis BB12 were shown to have preference for β(1-6) and β(1-1) linkages 
over β(1-4) linkages.5  
Prebiotics, such as GOS, have been suggested to help balancing the microbiota 
composition during antibiotic treatment and, thus, to limit antibiotic-associated disease, 
such as diarrhoea.6, 7 Antibiotic treatments are known to disturb the gut microbiota and, 
therefore, the colonic fermentation. Amoxicillin is one of the mostly used antibiotic in 
Europe. It also has one of the highest incidence (5-35%) of antibiotic-associated 
diarrhoea.8 This bactericidal antibiotic belongs to the penicillin class of antibiotics and has 
a broad spectrum of action, including an impact on bifidobacteria. In mice, it has been 
reported that the fermentation of dietary fibre fermentation as well as the subsequent 
short chain fatty acid (SCFA) production were reduced upon antibiotic treatment.9 
Similarly, the gut microbiota composition and metabolic activity were affected in an in 
vitro fermentation using human inoculum treated with different antibiotics.10 In the latter 
study, growth of specific bifidobacteria (mainly Bifidobacteria longum) was observed upon 
addition of GOS to an amoxicillin-treated microbiota. The specific growth of this species 
seemed to be correlated with a preferential degradation of the large oligosaccharides 
present in the GOS mixture.  
In the present study, the effects of GOS and the individual size-fractions of GOS on the 
microbiota composition and metabolic activity were determined for a non-treated 
microbiota (NT-MB) and subsequently for an amoxicillin-treated microbiota (AMX-MB). 
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The degradation rate and speed of the individual oligosaccharides were monitored as well 
as SCFA production and changes in microbiota composition, with an emphasis on 
Bifidobacterium spp.    
 
Material and methods 
Antibiotic 
Amoxicillin (AMX) (≥90%) was obtained from Sigma-Aldrich (St Louis, MO, USA). 
  
Prebiotic 
Vivinal® GOS (FrieslandCampina Domo, Borculo, The Netherlands) was fractionated to 
obtain a Galacto-oligosaccharides (GOS) preparation with <3% (w/w dry matter) 
monomers and lactose. For the fractionation, Vivinal® GOS was treated with a lactase to 
hydrolyse the lactose into glucose and galactose, after which the monosaccharides were 
removed by nanofiltration. The degree of polymerisation (DP) of the oligosaccharides 
present in the GOS preparation ranged from 2 to 8. 
 
Fractionation of GOS  
The oligosaccharides present in the purified GOS were fractionated by size exclusion 
chromatography (SEC). An Äkta purifier (GE Healthcare, Uppsala, Sweden) was equipped 
with three serially connected HiLoad 26/60 Superdex 30 prep-grade columns (GE 
Healthcare). The columns were maintained at 35ºC. GOS (180 mg dissolved in 1.5 mL Milli-
Q water) was applied onto the column and was eluted with 0.5% (v/v) EtOH in Milli-Q 
water at a flow rate of 1 mL/min. A refractive index RI-detector (RI-72, Showa Denko, 
Tokyo, Japan) was used to monitor the eluate. The system was controlled using Unicorn 
software. Fractions (1.9 ml) were collected, pooled according to the SEC-RI profile (data 
not shown) and subsequently freeze-dried. 
 
Experimental set up 
Using a recently developed fermentation screening-platform (96 wells of 1.5ml), the 
antibiotic amoxicillin (1 μg.ml-1) and the purified GOS or size-fractions of GOS (4,2 mg.ml-1) 
were simultaneously added to the Standard Ileal Efflux Medium (SIEM) and in vitro 
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fermented (37°C ; pH 5.8) using faecal inoculum (0.1% v/v) of healthy adults under 
anaerobic conditions.11 Selection of volunteers (n=8) and methodology to obtain and store 
the faecal samples were performed as described previously.11 To investigate the 
microbiota metabolic activity, samples (70 µl) were collected at 6 time points during 
fermentation. On basis of test experiment that determined the course of GOS 
degradation, the time range was chosen was 8h and 24h fermentation for the non-treated 
microbiota and, between 16h and 32h for the fermentations using 1 μg.ml-1 amoxicillin 
(data not shown). The samples collected were boiled (5min) and stored at -20°C. To 
investigate the microbiota composition, additional samples (70µl) were collected from the 
same well at 24h and 48h, and directly stored at -20°C. 
 
Monitoring GOS degradation  
High performance Anion Exchange Chromatography (HPAEC) was used to quantify GOS 
degradation. The samples collected were 10× diluted with Millipore water (final 
concentration: 0.42 mg.ml-1) and analysed using an ICS5000 HPLC system (Dionex, 
Sunnyvale, CA, USA), equipped with a CarboPac PA-1 column (2 mm ID × 250 mm; Dionex) 
in combination with a CarboPac PA guard column (2 mm ID × 25 mm) and a ISC5000 ED 
detector (Dionex) in the PAD mode. A flow rate of 0.3 mL.min-1 was used with the 
following gradient of 0.1 M sodium hydroxide (solution A) and 1 M sodium acetate in 
0.1 M sodium hydroxide (solution B): 0–20 min, 0–20% B; 20–26 min washing step with 
100% B; 26–41 min, equilibration with 100% A. Ten µl of sample was injected each time. 
 
Organic acids analysis 
A GC analysis was performed on a TRACE™ GC Ultra Gas Chromatograph system coupled 
to a FID detector (Interscience, Breda, The Netherlands) to quantify the SCFA production 
during fermentation:12 50µl of diluted sample (0.42 mg.ml-1) or standard (1 mg.ml-1 to 
0.125 mg.ml-1) mixed with 50µl of 0.15 M oxalic acid stood for 30 min before addition of 
150 µl of water. Next, samples (1 µl) were injected to a CP-FFAP CB column (25m x 
0.53mm x 1.00 µm, Agilent, Santa Clara, CA, USA). The temperature profile was as follow: 
start at 100°C, increase to 155°C at 5°C.min-1, and held at this temperature 1 min. GC data 
was processed using the Xcalibur® software (Thermo Scientific).  
The intermediate organic acids (lactate and succinate) were quantified on a Dionex 
Ultimate 3000 HPLC (Dionex) equipped with an ion-exclusion Aminex HPX – 87H column 
(7.8 x 300mm) combined with a guard column (Bio-Rad, Hercules, CA, USA), and an RI-101 
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refractive index detector (Shodex, Kawasaki, Japan). The mobile phase was 5mM H2SO4, 
the flow rate was 0.6 mL.min-1 and the elution temperature was 65°C. Samples (10µl - 0.42 
mg.mL-1) were injected onto the column. The concentrations of organic acids were 
expressed as µmol.mg-1 of GOS. 
 
Microbiota composition analysis 
The Intestinal (I)- Chip, developed at TNO (Zeist, The Netherlands), was used to investigate 
the composition of the microbiota. This DNA based microarray enabled the detection of 
over 400 bacterial targets from the human large intestinal microbiota. Total faecal DNA 
from samples collected was isolated, amplified, purified and hybridized as described 
previously.11 The hybridization took place on a microarray constructed and validated as 
described before,13 using intestinal bacteria primers instead of oral primers. Imagene 5.6 
software (BioDiscovery, Marina del Rey, CA, USA) was used to analyse the results. Genes 
with a signal intensity higher than 3 (>105 bacteria) in more than 10 samples were used to 
describe the bacterial fingerprint. 
 
Total bacteria and Bifidobacterium spp. quantification using quantitative 
PCR  
Quantitative PCR (qPCR) was performed to investigate the variation in the number of total 
bacteria and of Bifidobacterium spp. during fermentation. Primers used to measure the 
number of total bacteria were the universal primers 16S-uni-II-R [10 pmol.μl-1] (GGA CTA 
CCA GGG TAT CTA ATC CTG TT) and 16S-uni-II-F [10 pmol.μl-1] (TCC TAC GGG AGG CAG 
CAG T), and probe 16S-uni-II [5μM] (6FAM-CGTATTACCGCGGCTGCTGGCAC-TAMRA). The 
primers to measure the number of Bifidobacterium spp. were 16S-Bif-F [10 pmol.μl-1]  
(GGA GCA TGC GGA TTA ATT CG), 16S-Bif-R [10 pmol.μl-1]  (GAC CAT GCA CCA CCT GTG 
AAC), 16S-Bifspec (6FAM-CTG GGC TTG ACA TGT T) (Applied Biosystems, Bleiswijk, The 
Netherlands). The amplification was performed with 5 μl DNA sample and 25 μl q-PCR 
mixture.10 Total microbial faecal DNA was diluted 1:10 to quantify the number of total 
bacteria and 1:100 to quantify the number of Bifidobacterium spp. The experiment was 
performed using the 7500 Fast Real Time PCR system (Applied Biosystems) at settings 
previously described.11 
DNA of the microbiota from the control and Bifidobacterium longum was used as 
quantitative standards for total bacteria and Bifidobacterium spp., respectively (1 fg.μl-1 to 
1 ng.μl-1).  
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Results 
Fractionation of GOS and oligosaccharide identification  
GOS was fractionated based on de degree of polymerisation (DP) using SEC. Each pool 
consists majorly of oligosaccharides of one DP, with minor contamination of the preceding 
or following DP, as determined by MALDI-TOF-MS (data not shown). The composition of 
GOS (weight percentage) was 3% DP1, 12% DP2, 49% DP3, 20% DP4, 11% DP5, 4% DP6, 
<1% DP>6. Monosaccharides and oligosaccharides of DP>6 were excluded as 
monosaccharides are absorbed in the upper part of the gastro-intestinal tract and are not 
relevant for the gut fermentation, while the abundance of oligosaccharides of DP>6 was 
too low to obtain a sufficient amount needed for the fermentation experiments. The 
fractions DP2 to DP6 were further analysed with HPAEC (Figure 1A). As it can be seen, the 
complexity of the elution pattern increases with increasing DP, which confirms the 
presence of high numbers of isomeric structures present in GOS.3 The pattern of peaks 
obtained per DP was comparable to previous data3 (Figure 1B). 
 
Figure 1: HPAEC-PAD chromatograms of GOS and size-fractions of GOS obtained by SEC from this 
study (A) and from Coulier et al3 (B). Peak identification are given in Table 1. Ratio of each size-
fraction in the GOS complex mixture is indicated in figure A (weight %). 
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By comparing the two patterns, the oligosaccharides from the DP2 fraction and most 
oligosaccharides from the DP3 fraction could be identified (Table 1). For the DP2 fraction, 
β(1-2), β(1-3), β(1-4), β(1-6) as well as α- or β(1-1) linkages were identified. For the DP3 
fraction, identified structures were structures present in the DP2 fraction having an 
additional β-linked Gal, mostly at the O-4 position, added to the non-reducing terminal 
residue. For the fractions DP4 to DP6, it was more difficult to fully identify individual 
structures due to the complexity of the pattern. The different size-fractions obtained were 
now used in an in vitro fermentation to study their effect on the composition and 
metabolic activity of healthy adult microbiota with and without amoxicillin treatment. 
 
Table 1: Identities and levels of DP2 and DP3 oligosaccharides in GOS (adapted from Coulier et al).3 
Peak  
in this study 
Peak from 
Coulier et al3  
Compound wt % 
in DP2 
2.1 1 β-D-Gal-(1↔1)-α-D-Glc  + β-D-Gal-(1↔1)-β-D-Glc 
7 
2.2 2 β-D-Gal-(1→4)-D-Glc (lactose) 27 
2.2 2a β-D-Gal-(1→6)-D-Glc (allo-lactose) 15 
2.2 2b β-D-Gal-(1→4)-D-Fru (lactulose) 5 
2.3 3 β-D-Gal-(1→3)-D-Gal 1 
2.4 4 β-D-Gal-(1→4)-D-Gal 3 
2.5 5 β-D-Gal-(1→3)-D-Glc 26 
2.6 6 β-D-Gal-(1→2)-D-Glc 16 
    
3.1, 3.2, 3.3 7 + 8 ?a  
- 9 + 10 ?b  
3.4 11 β-D-Gal-(1→4)-β-D-Gal-(1→6)-D-Glc  or β-D-Gal-(1→6)-β-D-Gal-(1→4/6)-D-Glcc 
 
3.5 12 β-D-Gal-(1→4)-β-D-Gal-(1→6)-D-Glc or β-D-Gal-(1→6)-β-D-Gal-(1→4/6)-D-Glcd 
 
3.6 – 3.7 13 + 14 β-D-Gal-(1→4)-β-D-Gal-(1→4)-D-Glc  + β-D-Gal-(1→4)-β-D-Gal-(1→4)-Frue 
 
- 15 β-D-Gal-(1→6)-β-D-Gal-(1→2)-D-Glc  
3.8 16 β-D-Gal-(1→4)-β-D-Gal-(1→3)-D-Glc  
3.9 17 β-D-Gal-(1→4)-β-D-Gal-(1→2)-D-Glc  
a Total of four small peaks, all containing (1↔1) linkages in their structure. 
b Total of two small peaks, all containing (1↔1) linkages in their structure. 
c Coelution with one small unknown peak. 
d Coelution with two small unknown peaks. 
e Coeluting peaks. 
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Impact of GOS addition on the microbiota composition 
Changes in the microbiota composition during in vitro fermentation were studied by 
quantifying the levels of total bacteria and Bifidobacterium spp. and by interpreting the 
microbiota fingerprints obtained with the I-chip.  
 
Total bacteria and Bifidobacterium spp. quantification 
For the non-treated microbiota (NT-MB), the total numbers of bacteria and of 
Bifidobacterium spp. after 24h of fermentation were 109.1 and 106.2 copies.g-1 faeces, 
respectively (Table 2). Addition of GOS and its sub-fractions resulted in increase of the 
number of total bacteria after 24h of fermentation (about +0.7 log10). The addition of GOS 
and of the DP3 fraction tended to induce the highest Bifidobacterium spp. increase (about 
+3.8 log10), while the DP4 and DP5 fractions tended to induce the lowest  increase (about 
+3.0 log10). This bifidogenic effect was still visible after 48h of fermentation.  
For amoxicillin-treated microbiota (AMX-MB), the total bacteria was 107.6 copies.g-1 
faeces, so 1.5 log10 lower than in NT-MB due to the action of AMX during 24h of 
fermentation. A recovery of the total bacteria was observed after 48h of fermentation, 
reaching 108.1 copies.g-1 faeces, which was about 1 log10 lower than the total number of 
bacteria for NT-MB. Addition of GOS and its sub-fractions to the AMX-MB did not 
influence the total number of bacteria during the fermentation time studied. 
Furthermore, Bifidobacterium spp. were 1.7 log10 lower due to the action of AMX during 
24h of fermentation as compared to NT-MB. Addition of GOS and its sub-fractions induced 
growth of Bifidobacterium spp. after 24h of fermentation (about +0.9 log10). No major 
effect among the sub-fractions was observed within 24h of fermentation. After 48h of 
fermentation, however, it was clear that Bifidobacterium spp. was mostly stimulated upon 
addition of DP4 and DP5 fractions (about + 2.3 log10), while they were less stimulated 
upon addition of GOS of DP2 fraction (+1.4 log10). 
In conclusion, addition of GOS and GOS fractions stimulated the growth of bifidobacteria 
for both non-treated and amoxicillin-treated microbiota. For NT-MB, the highest growth 
was obtained upon addition of GOS and DP3 fraction. In contrast, for AMX-MB, the 
highest growth was obtained upon addition of DP4 and DP5 fractions.   
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Table 2: Numbers of total bacteria and Bifidobacterium spp. (Log10 copies.g-1 faeces) during in 
vitro fermentation using adult inoculum treated with 1 μg.ml-1 AMX with and without addition of 
GOS and size-fractions of GOS as measured with qPCR.  
 
 Total Bacteria Bifidobacterium 
  
non-treated AMX non-treated AMX 
no 
GOS 
24h 9.1 7.6 6.2 4.5 
48h 9.0 8.1 6.5 5.9 
GOS 24h 10.0 7.3 9.9 5.5 48h 9.1 8.3 9.5 7.5 
DP2 24h 10.3 7.4 9.5 5.4 48h 9.4 8.3 9.2 7.2 
DP3 24h 9.8 7.8 9.9 5.5 48h 9.1 8.5 9.4 7.6 
DP4 24h 9.3 7.2 9.2 5.3 48h 9.4 8.2 8.9 8.3 
DP5 24h 9.5 7.2 9.2 5.1 48h 9.0 8.5 9.0 8.1 
DP6 24h 9.5 7.1 9.5 5.5 48h 9.1 8.3 8.6 7.9 
 
Microbiota fingerprinting using the I-chip 
The impact of GOS and its sub-fractions on the overall microbiota composition of NT-MB 
and AB-MB was determined using the I-chip (Figure 2). The impact was observed mainly 
within the bifidobacteria population for both NT-MB and AMX-MB.  Independently of the 
addition of GOS and its sub-fractions, several Bifidobacterium spp. (B. adolescentis, B. 
angulatum, B. longum, B. thermophilum) were stimulated for NT-MB, whereas for AMX-
MB mainly B. longum was stimulated. The bifidobacteria growth occurred within 24h of 
fermentation in NT-MB and within 48h of fermentation for AMX-MB.  
For AMX-MB, the impact of the addition of GOS and its sub-fractions was also observed 
for Lactobacillus and Enterobacteriaceae. The abundance of Lactobacillus gasseri 
increased upon addition of GOS, DP2 and DP3 fractions for AMX-MB as compared to NT-
MB. The abundance of some of the Enterobacteriaceae, which were observed to decrease 
upon AMX treatment,  remain equal to the non-treated groups upon addition of DP2 and 
DP3 fractions of GOS. This observation indicates that high concentrations of small 
oligosaccharides may enhance the recovery of these potential pathogens up to a level as 
found in healthy adults, or limit the action of AMX. 
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Figure 2: Bacterial fingerprints obtained with the I-chip revealing the impact of addition of GOS 
and size-fractions of GOS on non-treated and AMX-treated (1 μg.ml-1) microbiota from healthy 
adults. Signal compared to the background (S/B): Green: below detectable level, Black: medium 
abundance, Red: high abundance.  
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Impact of GOS addition on the microbiota metabolic activity  
Changes in the microbiota metabolic activity were studied by monitoring the degradation 
of GOS and its sub size-fractions as well as by monitoring the levels of organic acids during 
in vitro fermentation. 
 
Degradation of GOS and specific size-fractions 
The degradation of GOS and its sub-fractions during fermentation with and without AMX 
treatment were monitored using HPAEC (Figure 3).  
The sub-fractions of GOS were mostly degraded (<10% remaining oligosaccharides) within 
24h of fermentation, except for the DP3 fraction (>20% remained), for both NT-MB and 
AMX-MB. The degradation rate of the sub-fractions of GOS was influenced by the 
amoxicillin treatment. For NT-MB, the oligosaccharides preferentially degraded after 18h 
of fermentation were oligosaccharides of DP2 followed by oligosaccharides of DP3 and 
DP6, and at last oligosaccharides of DP4 and DP5. At 24h of fermentation, oligosaccharides 
of DP3 were still present, most likely because of the degradation of oligosaccharides of 
DP4 to DP6. For AMX-MB, all oligosaccharides were degraded at a same speed within 24h 
of fermentation except for the oligosaccharides of DP3 that remained until 32h of 
fermentation.  
The degradation of GOS was slower for AMX-MB (20% oligosaccharides remaining) as 
compared to NT-MB (<5% oligosaccharides remaining) after 24h of fermentation. For 
AMX-MB, oligosaccharides of DP2 largely accumulated till 24h of fermentation and were 
then degraded within 32h of fermentation. About 10% of oligosaccharides of DP3 could 
still be detected after 32h of fermentation. Oligosaccharides of DP4 to DP6 were 
completely degraded within 24h of fermentation. The differences in the degradation of 
GOS and its individual sub-fractions emphasise that DP4 to DP6 fractions were 
preferentially degraded for AMX-MB independently from the presence of smaller 
structures. Hence, oligosaccharides of DP4 to DP6 appeared to be a potential successful 
substrate to stimulate a higher recovery of  certain Bifidobacterium species.  
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Figure 3: Proportion (% peak area) of remaining oligosaccharides from GOS and individual size-
fractions of GOS during in vitro fermentation using a non-treated and  AMX-treated (1 μg.ml-1) 
microbiota. Concentrations per DP present in the size-fractions or in the GOS mixture were set to 
100%.  
 
With respect to the degradation of isomeric oligosaccharides present in DP2 fraction of 
GOS, the first major difference concerns the structures β-D-Gal-(1→4/6)-D-Glc and β-D-
Gal-(1→4)-D-Fru that were completely degraded within 8h of fermentation by NT-MB 
whereas these structures were degraded last by AMX-MB (Figure 4). Another major 
difference concerned β-D-Gal-(1→4)-D-Gal that remained one of the last structure to be 
degraded by NT-MB, whereas it was degraded first by AMX-MB. The oligosaccharides with 
an α- or β[1-1] linkage were difficult to be degraded by both NT-MB and AMX-MB. With 
respect to the DP3 fraction of GOS, one of the major differences concerned β-D-Gal-
(1→4)-β-D-Gal-(1→3)-D-Glc that remained one of the last to be degraded by NT-MB 
whereas it was degraded first by AMX-MB. Also, the oligosaccharides with α- or β[1-1] 
linkage were easily degraded by NT-MB, whereas some of them were last to be degraded 
by AMX-MB.  
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Figure  4:  Proportion  (%)  of  remaining  oligosaccharides  of  DP2  and  DP3  during  in  vitro 
fermentation using a non‐treated microbiota  (A) and 1 μg.ml‐1 AMX‐treated microbiota  (B), and 
schematic representation of the preferred hydrolysed  linkages  (C).    Identification of  the  isomeric 
structures in DP2 and DP3 fractions are given in Table 1. 
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Levels of organic acids 
The  total  level  of  organic  acids  (OA),  being  intermediate  acids,  such  as  lactate  (L)  and 
succinate  (S),  and  SCFA,  such  as  acetate  (A),  propionate  (P)  and  butyrate  (B),  was 
determined to be approximately 13 to 15 µmol.mg substrate‐1 in most samples (Figure 5). 
The levels were lower (5 – 10 µmol.mg substrate‐1) for NT‐MB and AMX‐MB supplemented 
with oligosaccharides of DP2. The proportion of OA for NT‐MB was similar for GOS and its 
sub‐fractions (A:P:B:S:L = 75:6:5:11:2). One exception was that, for the DP2 fraction, more 
acetate and no propionate was detected. The proportion of OA changed upon amoxicillin 
treatment.  Succinic  accumulated  (about  3.5  times  more  than  for  NT‐MB)  while  less 
acetate was produced (about 1.5 times  less than for NT‐MB). Also, the proportion of OA 
for AMX‐MB was influenced by the DP: Butyrate was detected (around 5%) upon addition 
of oligosaccharides of DP4 to DP6 after 36h of fermentation for AMX‐MB,   while    lactate 
was detected (around 7%) upon addition of oligosaccharides of DP2.  
Overall, the proportion of OA was more influenced by the antibiotic treatment than by the 
size‐fractions of GOS present. Nevertheless,  it was clear for AMX‐MB that  lactate tended 
to be produced upon addition of small size‐fractions and butyrate tended to be produced 
upon addition of larger size‐fractions. 
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Figure 5: SCFA and intermediate organic acid levels during fermentation of  GOS and size‐fractions 
of GOS using a non‐treated and AMX‐treated microbiota (1 μg.ml‐1).    
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Discussion 
Fermentation of GOS and size‐fractions of GOS by non‐treated microbiota 
The  complex  mixture  of  GOS  was  completely  fermented  by  the  non‐treated  human 
microbiota.  The bifidogenic  effect of GOS  as observed  in many  studies14,  15 was,  again, 
confirmed.  Several  Bifidobacterium  spp.  were  stimulated,  mainly  B.  longum  and  B. 
adolescentis/angulatum.  These  species  are  quite  common  in  the  healthy  adult 
microbiota.16 The same Bifidobacterium spp. were stimulated by  the different GOS size‐
fractions.  This  contradicts  previous  studies  reporting  that  specific  size‐fractions  are 
preferentially  degraded  by  specific  Bifidobacterium  spp.4  However,  those  results  were 
based on pure Bifidobacterium cultures.  In a complex ecosystem as used  in  the present 
study, the different Bifidobacterium spp. present degrade synergically and simultaneously 
the  substrate.  Hence,  no  specific  species  is  stimulated  by  a  certain  size‐fraction. 
Nevertheless, it was clear in our study that the DP2 fraction was degraded the fastest and, 
together with DP3,  tended  to  stimulate Bifidobacterium  spp. more  as  compared  to  the 
DP4, DP5 and DP6  fractions. A preferred use of small DP oligosaccharides has also been 
seen for fructans, with FOS being faster degraded than Inulin.17 Our observations suggest 
that small oligosaccharides were efficiently used by the Bifidobacterium spp. present. The 
reported carbohydrate uptake strategy of bifidobacteria18 and the  large amount of  intra‐
cellular  enzymes  produced  by  these  bacteria18  corroborate  this  conclusion.  The 
degradation rate of GOS and the DP3 fraction were similar. Since the highest recovery of 
bifidobacteria was also  found upon  the addition of  this  fraction,  the  current mixture of 
GOS, mostly consists of oligosaccharides of DP3 (49% w/w), is, therefore, well adapted to 
support bifidobacteria growth in non‐treated microbiota.  
Beside a preference  for certain size‐fractions,  it appeared  from  this study  that, within a 
specific size‐fraction, some types of linkages are preferentially hydrolysed. The α‐ or β(1‐1) 
linkages in DP2 fractions were hydrolysed the slowest. This result indicates that enzymes 
able to hydrolyse β(1‐1)  linkages were produced by certain Bifidobacterium spp.19 These 
enzymes were, however, present in a low amount18 or had a low activity. In contrast with 
a  slow  hydrolysation  of  α‐  or  β(1‐1)  linkages  in DP2  fractions,  oligosaccharides  of DP3 
having an α‐ or β(1‐1) linkage were preferentially hydrolysed (Figure 4). Previous literature 
reported  that  this  specific  feature might help  the  action of other  β‐galactosidases.5 An 
accumulation  of  the  oligosaccharides  of  DP2   with  α‐  or  β(1‐1)  linkage was,  however, 
observed  in our  study  (data not  shown). This observation  suggests  that only  the  β(1‐4) 
linkage  between  the  two  galactoses  next  to  the  β(1‐1)  linkage  was  easily  cleaved. 
Furthermore, the β(1‐4) and β(1‐6) linkages were hydrolysed the fastest in DP2 individual 
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fraction.  For  GOS  of  DP3,  it  seems  that    β(1‐6)  branched  GOS were more  difficult  to 
hydrolyse.  This  observation  is  in  contradiction  with  previous  results  for  pure 
Bifidobacterium  cultures.5  These  authors  reported  a  preference  for  oligosaccharides  of 
DP3 with β(1‐6)  linkages over that of with β(1‐4)  linkages. The discrepancy  is most  likely 
due to the fact that the two Bifidobacterium spp. studied by these authors (B. lactis and B. 
breve) differ from the ones stimulated in our study (B. longum and B. adolescentis). 
The fermentation of GOS resulted in the production of SCFA.14, 15 Bifidobacterium spp. are 
reported  to  produce  lactate  and  acetate.20  The  diversity  of  the  SCFA  observed  is 
illustrative  for  the  synergic  action  of  the microbiota  to  degrade  and  use  intermediate 
degradation products. Only a small amount of lactate was detected, indicating that it was 
probably converted to SCFA, such as butyrate.2µ The SCFA profiles were similar upon the 
fermentation of GOS and of most GOS  size‐fractions,  indicating  the good  functioning of 
the gut microbiota.  In conclusion, GOS that mostly consists of oligosaccharides of DP3  is 
suitable  to  support  Bifidobacterium  spp.  growth  and  to  induce  butyrate  production  in 
human microbiota.  
 
Fermentation  of  GOS  and  size‐fractions  of  GOS  by  AMX‐treated 
microbiota 
The  AMX  treatment  clearly  disrupted  the microbiota  composition.  The main  bacterial 
groups that were affected constituted of Enterobacteriaceae, Clostridium, Bifidobacterium 
and Lactobacillus, as reported before.11 Addition of GOS and specific size‐fractions mainly 
stimulated  the  recovery  of  Bifidobacterium  spp.  The  recovery  of  Bifidobacterium  spp. 
within 48h of fermentation was mainly due to the increase of B. longum. This species was 
shown not  to be affected by an amoxicillin  treatment  in  infants.22 B.  longum,  therefore, 
had  a  potential  to  use  available  substrate  to  grow  in  the  absence  of  competitors.  The 
growth of this species tended to be higher upon addition of DP4‐DP6 fractions than upon 
addition  of  GOS.  Furthermore,  oligosaccharides  of  DP4‐DP6  were  shown  to  be 
preferentially degraded by  the amoxicillin‐treated microbiota. As B.  longum has already 
been reported to grow on DP5 and DP6  in a monoculture,4  it  indicates that B.  longum  is 
the main bifidobacteria  species active  in  the microbiota after amoxicillin  treatment and 
has most potential to grow. B. longum is one of the few bifidobacteria species that has a 
membrane bound endo‐galactanase.18 The fast degradation of the  large fractions of GOS 
for AMX‐MB and the fast degradation of the specific type of linkages β‐D‐Gal‐(1→4)‐D‐Gal 
suggest  that  this enzyme was active. As  the highest growth of B.  longum was observed 
upon addition of these large fractions, it is likely that mainly this micro‐organism benefits 
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from  the  degradation  products.  This  support  the  hypothesis  that  B.  longum  has  a 
mechanism to incorporate galacto‐oligosaccharides.18 Hence, we hypothesize that a faster 
recovery of B.  longum upon AMX  treatment would be possible upon addition of a GOS 
mixture enriched in oligosaccharides of DP4‐DP5 and DP6 with a linear structure.  
Other groups of bacteria were also stimulated  in AMX‐MB depending on the size of GOS 
present.  The  smaller  size‐fractions  (DP2  and  DP3)  stimulated  Lactobacillus  gasseri  and 
limited  the decrease of Enterobacteriaceae usually observed due  to  the action of AMX. 
The growth of Lactobacillus could be beneficial for the host as  it  is a reported beneficial 
group of bacteria.23 However,  limiting the decrease of Enterobacteriaceae by AMX could 
be  a  risk  for  pathogen  development  and  gut  diseases.24  Limiting  the  decrease  of 
Enterobacteriaceae upon  addition of  small  size‐fractions might be  an  indication  that  1) 
these  bacteria  can  utilise  the  substrate  themselves,  2)  they  can  cross‐feed  on  the 
degradation products released by the bifidobacteria, 3) oligosaccharides that bind to the 
bacterial cell wall24 may limit AMX action. In contrast there are indications that GOS may 
have  anti‐adhesive  activity  and  directly  inhibit  the  adherence  of  E.  Coli  to  the  host 
epithelial cell surface.25 In future research, it would be of interest to  investigate whether 
and which specific GOS oligosaccharides can bind to pathogens in more details.   
Amoxicillin treatment also disrupted the organic acid production as higher concentrations 
of  lactic  and  succinic  acid  were  observed.  An  increase  of  succinate  upon  antibiotic 
treatment was previously   reported.26 The changes  in organic acids  levels was  influenced 
more  by  the  antibiotic  treatment  than  by  the  different  size‐fractions.  It  was  striking 
though  that  lactate was higher upon  low DP addition and butyrate  tended  to be higher 
upon  larger  DP  addition.  Oligosaccharides  of  DP2  are  easily  incorporated  into 
bifidobacteria  cell  via  specific  transporters,18  resulting  in  a  high  lactate  and  acetate 
production.  The  accumulation  of  lactate  indicates  the disruption  of  the  lactate‐utilising 
bacteria  microbiota.  The  production  of  butyrate  during  fermentation  whereas 
bifidobacteria  do  not  produce  this  SCFA  is  an  indication  that  addition  of  large  size‐
fractions  stimulated  the  recovery  of  butyrate‐producing  bacteria,  most  likely  through 
cross‐feeding.  
Overall,  in a non‐treated microbiota the  level of bifidobacteria tended to be higher upon 
addition  of  original GOS  and  low  size‐fractions,  than  upon  addition  of  the    large  size‐
fractions. In an amoxicillin‐treated microbiota the addition of GOS stimulated the recovery 
of bifidobacteria, mainly B. longum and induced butyrate production. The addition of large 
size‐fractions of GOS  resulted  in a higher  recovery of bifidobacteria and higher butyrate 
level  than  the  low‐size  fractions. Hence, we  conclude  that  in particular  the presence of 
large oligosaccharides within GOS  is responsible for their beneficial effect to counter the 
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negative impact of amoxicillin on the microbiota. It is, therefore, suggested to investigate 
the  effect  of  a  GOS  enriched  with  large  oligosaccharides  on  an  amoxicillin  treated 
microbiota. 
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Galacto-oligosaccharides positively impact the gut 
microbiota of healthy adults receiving amoxicillin 
treatment  
 
Abstract 
In a double-blind randomized parallel intervention study, the effects of the intake of 
galacto-oligosaccharides (GOS) on the gut microbiota of 12 healthy adults receiving 
amoxicillin (AMX), aged 18-45 years with a normal BMI (18-25 kg.m-2), were determined. 
All subjects received AMX (375 mg; 3x per day) for 5 days and either GOS (n=6) or placebo 
(maltodextrin, n=6) (2.5 g; 3x per day) during and 7 days after the AMX treatment. Faecal 
samples were collected twice before starting the treatment and at days 2, 5, 8, 12, 19 and 
26. Due to AMX treatment, a decrease of Bifidobacterium spp., an overgrowth of 
Enterobacteriaceae and a disruption of the metabolic activity of the microbiota (increase 
of succinate and mono- and oligosaccharides in faecal samples) were observed for both 
groups. Positive effects of GOS intake were observed on the total bacteria population and 
bifidobacteria levels. The total bacteria level was significantly higher (p<0.05) directly after 
AMX treatment upon GOS compared to placebo intake. Furthermore, the bifidobacteria 
level tended to be higher (p<0.15) during and was significantly higher (p<0.05) directly 
after the AMX treatment upon GOS compared to placebo intake. The bifidobacteria 
activity and subsequent cross-feeding of other microbiota species after the AMX 
treatment was reflected through the significant increase of butyrate (p<0.05) when GOS 
was consumed as compared to placebo. Despite the low number of subjects, our findings 
confirm previous results obtained in vitro, namely that GOS intake supports the 
production of butyrate and the recovery of the beneficial bifidobacteria from amoxicillin 
treatment. 
 
Submitted for publication as: Ladirat, S. E.; Schoterman, M. H. C.; Rahaoui H.; Mars M.;  Schuren, F. 
H. J.; Gruppen, H.; Nauta, A.; Schols, H. A., Galacto-oligosaccharides positively impact the gut 
microbiota of healthy adults receiving amoxicillin treatment.   
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Introduction 
In Europe, the median consumption of antibiotics was 18.3 Defined Daily Doses per 1000 
inhabitants per day in 2010.1 The main side effect of these medicines is antibiotic-
associated diarrhoea (AAD) that occurs in 5-10% of outpatient cases and 10-35% of 
inpatient cases. Among those, the antibiotic amoxicillin (AMX) has one of the highest 
incidences.2 Prebiotics, defined as “selectively fermented ingredients that allow specific 
changes, both in the composition and/or activity of the gastrointestinal microflora that 
confer benefits upon host well-being and health”,3 have been suggested to prevent this 
common side effect of antibiotics. However, literature data concerning prevention of AAD 
is not consistent,4, 5 probably due to the variability in parameters among the studies. 
Parameters, such as prebiotics, antibiotics, dosages and age of subjects are known to have 
a high impact on the microbiota composition.6  
Recently, an in vitro study using a fermentation screening-platform allowed the 
straightforward comparison of the impact of four often used antibiotics on healthy adult 
microbiota with and without the addition of galacto-oligosaccharides (GOS), a known 
prebiotic.7 This study revealed that the recovery of bifidobacteria upon GOS addition was 
antibiotic and dose dependant. For instance, GOS did not impact the recovery of 
bifidobacteria after a clindamycin treatment, whereas GOS positively impacted the 
recovery of bifidobacteria after an AMX treatment. Further understanding of the impact of 
GOS on the gut microbiota in vivo is essential as the microbiota is considered as a key 
factor in human health.8 Besides the action of antibiotics on the microbiota composition, 
antibiotics are known to negatively impact the metabolic activity of the microbiota as 
well.9 An accumulation of monosaccharides and a high level of lactate and succinate was 
observed during in vitro fermentation using an AMX-treated microbiota supplemented 
with GOS.7 However, the metabolic activity of an antibiotic-treated microbiota upon GOS 
addition has never been addressed in vivo. Most in vivo studies investigated the effect of 
fructo-oligosaccharides (FOS) and focused on the diarrhoea frequency and prevention of 
Clostridium difficile infection.   
In this intervention study, we determined the effects of GOS intake on the microbiota of 
healthy adults during and after receiving an AMX treatment in order to investigate 
whether trends from previous in-vitro study7 represents the situation in healthy humans 
as well.  The impact of GOS on the microbiota composition was assessed by quantifying 
changes in total bacteria and bifidobacteria levels and by interpreting the microbiota 
fingerprints obtained with a phylogenetic microarray. The impact of GOS on the 
microbiota metabolic activity was assessed by monitoring the concentration of short-chain 
fatty acids, mono- and oligosaccharides in the faecal samples.  
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Material and methods 
Subjects 
Twelve subjects were recruited in Wageningen (The Netherlands) and surroundings. The 
subjects aged 18 to 40 years old, had a normal BMI (18.5 – 25.0 kg/m2) and a western diet.  
Due to the exploratory nature of this trial, no statistical examination of the number of 
participants was taken into account. Based on other studies investigating the microbiota 
functioning,10-13 the selected number of 12 volunteers is considered sufficient to validate 
whether trends from previous in-vitro results can be detected in healthy humans as well. 
This number allows a first evaluation of the response of the treatment considering 
individual variation in the microbiota.  
Subjects were excluded if they smoked, used drugs, had gastro-intestinal diseases 
themselves or in their families, travelled to Asian, African or Latin American countries in 
the last 6 months, had hypersensitivity or allergies to the products used in the study 
(amoxicillin, lactose), had history of allergies, or had hepatic disease or renal failure. 
Subjects were also excluded if they used other medications than N-acetyl-p-aminophenol 
(paracetamol) or acetylsalicylic acid (aspirin), used antibiotics in the last 3 months, had 
more than 3 antibiotic treatments in the last 2 years or consumed prebiotics or probiotics 
(a list of products was provided) in the last month before the study. Female subjects were 
also excluded if they used the contraceptive pill, were pregnant (including planning to be), 
gave birth in the last 6 months or were lactating. The study was conducted according to 
the guidelines laid down in the declaration of Helsinki and all procedures involving human 
subjects were approved by the Medical Ethics Committee (METC) of Wageningen 
University (registration number NL 42438.018.12). Written informed consent was 
obtained from all subjects. The study was registered in the U.S. national Institute of health 
clinical trial database (ClinicalTrials.gov no NCT01848535). 
  
Supplements  
The antibiotic Amoxicilline disper tablet 375 (Sandoz BV, Almere, The Netherlands) was 
provided by a local pharmacy. Amoxicillin (AMX) was investigated in this study because of 
its risk for diarrhoea and its frequent use.14 A low dose of AMX (375 mg; 3x per day) and 
the shortest duration (5 days) of treatment were chosen to limit the risks of side effects 
for the volunteers. The prebiotic Vivinal® GOS (FrieslandCampina Domo, Borculo, The 
Netherlands) was specified by the supplier to have a dry matter of 75% (w/w), of which 
59% (w/w) as galacto-oligosaccharides, 21% (w/w) as lactose, 19% (w/w) as glucose, and 
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1% (w/w) as galactose. The degree of polymerisation (DP) of the oligosaccharides within 
Vivinal® GOS ranged from 2 to 8. The dose of Vivinal® GOS (2.5 g; 3x per day) was chosen 
to be sufficient to have a bifidogenic effect and to be low enough to limit gastro-intestinal 
discomfort, such as flatulence.15 The placebo, Maltodextrin SPG 30 (powder) (AVEBE U.A, 
Veendam, The Netherlands) was specified by the supplier to comprise 6% (w/w)  glucose, 
15% (w/w) maltose, 18% (w/w) maltotriose, 8% (w/w) maltotetraose, 12% (w/w) 
maltopentaose, 17% (w/w) maltohexaose and 24% (w/w) of higher oligosaccharides. The 
degree of polymerisation was similar to that of GOS. The prepared matodextrin syrup had 
a dry matter of 75% (w/v) and a density of 1.2. The differences in sweetness and viscosity 
between the prebiotic and placebo syrups were masked upon solubilisation in 150 ml 
orange juice. 
 
Experimental design  
The study was a double blind randomized parallel intervention study comprising 12 days 
of intervention and 14 days of follow-up (Figure 1). The 12 subjects were randomly divided 
into two groups: the first group received AMX and GOS (n=6), while the second group 
received AMX and placebo (n=6). AMX (375 mg; 3x per day) was given for 5 days. GOS or 
placebo (2.5 g; 3x per day) solubilised in 150 ml orange juice was given simultaneously to 
AMX for 5 days and was continued for 7 days after the AMX treatment ended. The 
intervention products were consumed at breakfast, lunch and dinner. The effects of GOS 
or placebo intake were monitored up to 14 days after the intake ended. This follow up 
period will also enable to investigate the resilience of the microbiota after the 
intervention period.   
 
Figure 1: Scheme of the intervention study. AMX: amoxicillin, GOS: galacto-oligosaccharides, MD: 
Maltodextrin (placebo), 0* refers to samples collected at screening (1 to 7 day(s) before day 0). 
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Faecal sample collection and storage 
Faecal  samples were collected at 8 occasions: at screening (day 0*), day 0, day 2, day 5, 
day 8, day 12 day 19 and day 26. Subjects were free to deliver the faecal sample on the 
indicated day or the day after, and were free to deliver the faecal sample at home or at 
work. After delivering the first faecal sample (day 0*), the subjects had the opportunity to 
stop the study if they found the procedure too invasive. If the subjects wanted to go on 
with the study, the subjects were free to deliver the faecal sample of day 0 within 7 days 
after delivering the sample of day 0*. The subjects started the antibiotic treatment and 
GOS/placebo intake after delivering the faecal sample of day 0. Samples collected at day 
0* (1x) and at day 0 (1x) were used as baseline to estimate the individual variability of the 
microbiota composition and activity.  
At each occasion (except day 0), the subjects dropped the faecal sample in a specimen 
collection container placed on the toilet seat, collected part of the faecal sample using a 
spoon and gloves, and placed it in 1 plastic cup (120ml). The subjects filled 3 plastic cups 
using the same faecal sample up to maximum 60 ml. In case of limited faecal material 
available, the faecal sample was divided equally over the 3 cups. After collecting the faecal 
samples, the subjects placed the 3 cups in the coolest environment possible (usually 4˚C), 
phoned immediately the investigator who collected the cups within 1/2h and stored them 
at -80˚C. The first cup was used for DNA isolation, the second cup was used for measuring 
mono- and oligosaccharides and SCFA in the faeces and the last cup was used to perform a 
potential failed analysis again. At day 0, an anaerobic sachet was placed in the specimen 
collection container, roughly separated from the faecal sample by a plastic layer. The 
subjects closed the container air-tight, placed it at 4˚C, and phoned immediately the 
investigator who collected the container within 1/2h. In order to allow further 
fermentation studies, the faecal sample collected on day 0 was processed in an anaerobic 
chamber. Part of the faecal sample was divided among 3 cups as described above, and 
part was suspended in modified standard ileal efflux medium (SIEM)16 containing 12% 
(v/v) glycerol. The faecal suspension and the cups were stored at -80˚C. 
 
Stool and gastro-intestinal discomfort 
Subjects kept a diary to record compliance to the treatment, stool frequency and 
consistency, and gastro-intestinal discomfort. Compliance to the treatment was reported 
by circling ‘yes’ or ‘no’ for the intake of antibiotics and/or the orange juice at breakfast 
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(7h00-9h00), lunch (12h00-14h00) and dinner (18h00-21h00). A number was indicated to 
report stool frequency. The Bristol scale was provided and used to score the faecal 
consistency from type 1 (separate hard lumps to type 7 (watery no solid pieces). Diarrhoea 
is defined by the world health organization17 as the condition of having three or more 
loose or liquid bowel movements per day. Based on this definition, the scores on 
frequency and consistency were considered serious if subjects had ≥3 stools per day 
and/or scored ≥ type 6 on the Bristol scale. When subjects reported a serious score, the 
general practitioner was informed and decided whether the subject was withdrawn from 
the study or not. If subjects scored a type 6 stool for 3 days in a row, the subject was 
automatically withdrawn from the study and followed by the general practitioner until 
symptoms abated. The METC was informed about withdrawal. A 5-point scale from 1 (not 
at all) to 5 (very much) was used to score markers for discomfort (flatulence, bloating, 
heartburn, nausea). Free space was left to report other discomforts, medicine used and 
other remarks. 
 
DNA isolation 
The faecal sample collected in 1 cup was thawed overnight at 4˚C and homogenised by 
manual stirring. Total faecal DNA was isolated as described by Crielaard et al18 with some 
minor adjustments: The faecal sample (100 mg) was mixed with 250 μl lysis buffer (Agowa, 
Berlin, Germany) and 250 μl zirconium beads (0.1 mm) and 200 μl phenol, before being 
introduced to a BeadBeater (BioSpec Products, Bartlesville, OK, USA) for 2 min. Because of 
a high level of impurities in the faeces, the phenol extraction was performed twice. The 
DNA isolation was performed in duplicate (from the same cup) for the samples of subjects 
11 and 12 at day 0, day 5, day 12 and day 26 to investigate about the homogeneity of the 
sample collected in 1 cup. 
 
Microbiota composition analysis 
The Intestinal (I)- Chip, developed at TNO (Zeist, The Netherlands), was used to investigate 
the composition of the microbiota. This DNA based microarray enabled the detection of 
more than 400 bacterial targets from the human large intestinal microbiota. The total 
faecal DNA isolated was amplified, purified and hybridized as described previously.16 The 
hybridization took place on a microarray constructed and validated as described before,18 
using intestinal bacteria primers instead of oral primers. Imagene 5.6 software 
(BioDiscovery, Marina del Rey, CA, USA) was used to analyse the results. Genes with a 
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signal intensity higher than 3 (>105 bacteria) in more than 10 individual samples were used 
to describe the bacterial fingerprint. 
 
Total bacteria and Bifidobacterium spp. quantification  
Quantification of the number of total bacteria and of Bifidobacterium spp. in the faecal 
samples was performed as previously described using quantitative PCR (qPCR).7 
 
Water extractable carbohydrates and organic acids extraction 
Extractions of water extractable carbohydrates and organic acids were performed 
according to Albrecht et al 19 and Jonathan et al,20 respectively, with minor modifications. 
The thawed faecal samples were 20× diluted (w/v) with Millipore water (250 mg in 5 ml 
Millipore water). The diluted faecal slurry was centrifuged (3500 g, 15 min, T=4˚C). Aliquot 
of the supernatant (1 ml) was boiled (5 min) to inactivate the enzymes and filtered 
through a 0.22 µm membrane. The faecal extract obtained was used for mono- and 
oligosaccharides analysis and organic acids analysis. 
 
Monitoring mono- and oligosaccharides in faeces 
High performance Anion Exchange Chromatography (HPAEC) was used to quantify the 
mono- and oligosaccharides present in the faecal extracts. An ICS5000 HPLC system 
(Dionex, Sunnyvale, CA, USA), equipped with a CarboPac PA-1 column (2 mm ID × 250 mm; 
Dionex) in combination with a CarboPac PA guard column (2 mm ID × 25 mm) and a 
ISC5000 ED detector (Dionex) in the PAD mode was used. A flow rate of 0.3 mL.min-1 was 
used with the following gradient of 0.1 M sodium hydroxide (NaOH), 1 M sodium acetate 
(NaOAc) in 0.1 M NaOH: 0-3 min, 20-50 mM NaOH; 3-12 min, 50-75 mM NaOH;  12-15 min 
100 mM NaOH; 15-35 min 0–200mM NaOAc in 0.1 M NaOH; 35–50 min washing step with 
1M NaOAc in 0.1 M NaOH; 50-53 min 100mM NaOH; 53-68 min equilibration with 20 mM 
NaOH. Ten µl of sample was injected each time. Roughly, the monomer were considered 
to elute between 0 min and 12 min, while the oligosaccharides (including disaccharides) 
were considered to elute between 15 min and 35 min. Lactose was used as a 
quantification reference. The mono- and oligosaccharides levels were, thereby, expressed 
in mg saccharides (lactose equivalent) per gram of faeces. In the conditions stated above, 
lactose (0.01 mg.ml-1) had a peak area of 22 nC.min-1.  
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Organic acids analysis  
High Performance Liquid Chromatography was performed to quantify SCFA (acetate, 
propionate, butyrate, valerate) and intermediate organic acids (lactate and succinate) 
present in the faecal extracts. A Dionex Ultimate 3000 HPLC (Dionex) equipped with an 
ion-exclusion Aminex HPX – 87H column (7.8 x 300mm) combined with a guard column 
(Bio-Rad, Hercules, CA, USA), and an RI-101 refractive index detector (Shodex, Kawasaki, 
Japan) was used. The mobile phase was 5mM H2SO4 and the flow rate was 0.6 mL.min
-1 at 
65°C. Samples (10µl) were injected onto the column. Standards of known concentration 
(0.25 to 2 mg.ml-1) were used for quantification.  
 
Data analysis 
The significance of the difference between treatments was assessed by a Student t-test. 
The significance of the difference in time was also assessed by Student t-test to address 
the effects of AMX on the microbiota. P-values were calculated assuming equal variance 
and two-tailed distribution. Correlations were considered significant at a P-value lower 
than 0.05.  
The data matrix of bacterial fingerprints obtained with the I-chip  was analysed with 
Significant Analysis Microarray (SAM) to identify markers significantly different between 
predefined groups and with a hierarchical clustering based on Euclidian distances (TM4 
software, Rockville, MD, USA).21 Predefined groups tested were “GOS group” vs. “placebo 
group” to determine the effect of GOS and “phase 0” vs. “phase 1” to determine the effect 
of AMX in both GOS and placebo groups. The statistical analysis was performed before 
breaking the treatment codes. Due to the small group studied, we did not only look at the 
statistical significant differences, but also at individual trends. 
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Results 
Population characteristics  
Out of the 12 recruited subjects, faecal samples of 2 subjects were not analysed because 
these subjects did not comply with the treatment assigned. One subject forgot to 3 times 
drink the juices and to twice take the antibiotic tablet. The other subject forgot to once 
take the antibiotic tablet. The studied population, therefore, consisted of 5 men and 5 
women that aged 26 ± 4 years and had a BMI of 22.7 ±1.9 kg/m2. 
 
Effect of GOS on stool and gastro-intestinal discomforts 
During phase 0 (before the treatment), the mean stool frequency (1,6 ±0.5) and 
consistency on the Bristol scale (type 3.4 ±0.5) were similar for both groups. Overall, the 
frequency of defecation and consistency of faecal samples were constant over 26 days, 
and hence did not statistically differ. On an individual level, the scores on frequency and 
consistency tended to increase (up to 3 stools per day and up to a consistency of type 5 on 
the Bristol scale between days 2 and 5) during phase 1 (AMX+GOS/MD) for 3 subjects (2 
from the placebo group, 1 from the GOS group), before returning to initial values during 
phase 2 (GOS/MD). A change in the stool frequency and consistency (≥3 stools per day 
and/or ≥ type 6 on the Bristol scale) was observed for 2 subjects from the GOS group 
during AMX treatment (phase 1): One subject reported 1 loose stool of type 6 on days 2 
and 3 and the other subject reported 3 loose stools of type 6 and type 7 on days 4 and 5. 
Based on the definition of the world health organization, the latter subject had diarrhoea 
and was withdrawn from the study after day 5. The data set of this subject (days 0 to 5) 
was included in the study as it might provide insight on why the subject suffered from 
diarrhoea. 
Effects on markers for gastrointestinal discomforts, such as flatulence and bloating feeling, 
were reported were mild (maximum scores of 2 to 3 on the 5-points scales). No 
differences were seen between the GOS and placebo group.  
 
Microbiota composition 
Effects of GOS on the composition of AMX-treated microbiota were studied by quantifying 
the levels of total bacteria and Bifidobacterium spp. and by interpreting the microbiota 
fingerprints obtained with the I-chip 
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Quantification of number of total bacteria and Bifidobacterium spp. 
During phase 0 (before treatment; days 0* and 0), the number of total bacteria and the 
level of Bifidobacterium spp. were similar for both group, around 1010.3 copies.g-1 faeces 
and 109.5 copies.g-1 faeces, respectively. Individual variation of numbers of total bacteria 
and Bifidobacterium spp. before treatment can be seen in table 1. One subject in the 
placebo group presented a much lower proportion of Bifidobacterium spp. (<1%) as 
compared to the other subjects (~9%).  
 
Table 1: Number of total bacteria and Bifidobacterium spp. before treatment (Day 0* and Day 0). 
Values are expressed as mean ± standard deviation of log10 (copies.g
-1 faeces). *refers to samples 
collected at screening (1 to 7 day(s) before day 0). 
   GOS  Placebo (MD) 
Subjects  1 5 6 8 12  2 3 7 9 11 
Total bacteria  10.4 ±0.1 
10.1 
±0.4 
10.2 
±0.1 
10.5 
±0.1 
9.5 
±0.1 
 10.4 
±0.1 
10.4 
±0.1 
10.4 
±0.2 
10.4 
±0.1 
10.4 
±0.1 
Bifidobacterium  9.8 ±0.6 
9.4 
±0.1 
10.1 
±0.3 
9.7 
±0.1 
9.5 
±0.2 
 10.3 
±0.5 
9.6 
±0.1 
7.5 
±0.8 
10.0 
±0.3 
9.4 
±0.1 
 
Figure 2 shows the variation of the normalised levels of total bacteria and Bifidobacterium 
spp. along the study excluding the data set of subject 7, which was considered not to be 
representative due the low level of Bifidobacterium spp. If the data set was included, the 
trends were similar, although less significant (Suppl. Data, Figure S1). During phase 1 (AMX 
+ GOS/MD; days 2 and 5), the level of total bacteria remained similar to the level at day 0 
for both GOS and placebo groups. The level of Bifidobacterium spp. at days 2 and 5 
significantly decreased for both groups as compared to day 0 (p<0.05) due to AMX 
addition, but it tended to decrease less for the GOS group (-0.5 log10) compared to the 
placebo group (-1 log10) (p<0.15). During phase 2 (GOS/MD; days 8 and 12), the levels of 
total bacteria and Bifidobacterium spp. were significantly higher for the GOS group than 
for the placebo group (p<0.05). For the placebo group the level of Bifidobacterium spp. 
recovered to its initial value at day 12. For the GOS group, the level of Bifidobacterium 
spp. recovered to its initial value already at day 8 and was significantly higher at day 12 
than at day 0 (+0.7 log10; p<0.05). During phase 3 (follow up period; days 19 and 26), the 
increased levels of total bacteria and Bifidobacterium spp. for the GOS group returned to 
their initial levels, while the lowered level of total bacteria for the placebo group also 
returned to its initial levels.   
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Figure 2: Variation in the number of total bacteria and Bifidobacterium spp. during and after 
treatment for healthy adults receiving AMX with GOS (n=5 until day 5, n=4 after day 5) or with 
placebo (MD; n=4). Values are expressed as mean of the normalised log10 (copies.g
-1 faeces). 
Significant difference between GOS and placebo groups is indicated with * (p<0.05). Significant 
difference in time per treatment is indicated with † (p<0.05). 
 
Bacterial fingerprints of the overall microbiota 
The bacterial fingerprint of each subject during phase 1 (before the treatment; days 0* 
and 0) is given in figure 3. Similar bacterial fingerprints were obtained for the 2 baseline 
samples for each individual indicating a good stability of the microbiota within 7 days. The 
main bacterial groups present in the microbiota of each individual were Bacteroides, 
Bifidobacterium, Escherichia, Lachnospiraceae, Lactobacillus and Peptostreptococcaceae. 
On an individual level, differences could be detected for both groups at species level, 
especially for Bacteroides, Bifidobacterium, and Akkermansia. Overall, the GOS group had 
an initial microbiota that was richer in Bifidobacterium spp., Bacteroides uniformis and 
Alistipes putredinis than the placebo group (Figure 4-A). The difference in bifidobacteria 
level was solely due to the low level of bifidobacteria for subject 7. If the data set from this 
subject was excluded from the SAM analysis, no difference in the bifidobacteria level was 
detected between the two groups. 
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During the treatment, the impact on the overall microbiota is highly individual dependant. 
Some trends could be detected by SAM analysis between the GOS and placebo group as 
well as between the phases of the treatment. During phase 1 (AMX + GOS/MD; days 2 and 
5), the relative abundance of certain Lachnospiraceae was lower at days 2 and 5 than at 
day 0 (Figure 5 A-B) for both groups. The relative abundances of some Enterobacteriaceae 
were also changed: They increased significantly at days 2 and 5 than at day 0 for the GOS 
group (Figure 4 A) and for 3 out 5 subjects in the placebo group, despite not concluded as 
significant (Suppl. Data, Figure S2). As the changes of the relative abundances of certain 
Enterobacteriaceae and Lachnospiraceae were observed for both groups, they were 
probably due to the AMX action. The effects of GOS intake were detected on the level of 
Bifidobacterium spp. that were significantly higher for the GOS group than for the placebo 
group (Figure 4-B). During phase 2 (GOS/MD; days 8 and 12), the relative abundances of 
Bifidobacterium spp., B. longum and B. thermophilum were significantly higher for the 
GOS group than for the placebo group (Figure 4-C). During phase 3 (follow up period; days 
19 and 26), while the microbiota in most subjects returned to its initial composition, a 
higher level of Bifidobacterium spp., B. longum  and Bacteroides vulgatus was detected for 
the GOS group as compared to the placebo group (Figure 4-D). On an individual level, 
some bacterial groups (mainly Bacteroides) also differed from their initial levels (Suppl. 
Data, Figure S2). 
 
Metabolic activity of the microbiota 
The effect of GOS on the metabolic activity of AMX-treated microbiota was studied by 
monitoring the levels of SCFA and intermediate organic acids (OA), as well as the mono- 
and oligosaccharide (including disaccharides) levels in the faecal samples. 
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Levels of OA in faecal samples 
The levels of OA, being SCFA and intermediate OA, were measured in the faecal samples 
of subjects receiving AMX and GOS or placebo (Figure 6).  
 
Figure 6: Levels of organic acids in the faecal samples of healthy adults receiving AMX and GOS 
(n=5 until day 5, n=4 after day 5) or with placebo (MD; n=5). Values are expressed as mean of 
µmol.g-1 faeces. Significant difference between GOS and placebo is indicated with * (p<0.05). 
Significant difference in time per treatment is indicated with † for individual organic acids and with ¥ 
for total amount of organic acids (p<0.05).   
 
During phase 0 (before the treatment), the total amount of OA in faecal samples was 
similar for both groups, around 89 ±13 µmol.g-1 faeces. The molar proportion (%) of 
acetate : propionate : butyrate : valerate : succinate : lactate (A:P:B:V:S:L) was around 
59:20:16:4:0:0 for both groups. During phase 1 (AMX + GOS/MD; days 2 and 5), the levels 
of succinate and lactate tended to increase (p<0.15) for the placebo group and was 
significantly higher for the GOS group as compared to day 0 (p<0.05). The proportion of 
succinate reached up to 22% of the total OA amount. As the succinate and lactate levels 
seem to increase for both groups, it was due to the AMX action. At day 5, the level of 
lactate for the GOS group was significantly higher than for the placebo group (2±3 vs. 0±0 
µmol. g-1 faeces; p<0.05). During phase 2 (GOS/MD; days 8 and 12), the level of butyrate 
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for the GOS group at day 8 was significantly higher than for the placebo group (26 ±18 vs. 
9 ±6 µmol. g-1 faeces; (p<0.05), although not detected to be different at day 12 anymore. 
During phase 3 (follow up period; days 19 and 26), SCFA and intermediate OA levels were 
similar to their respective initial levels for both GOS and placebo groups.  
 
Mono- and oligosaccharide levels in faecal samples 
Mono- and oligosaccharide (including disaccharides) levels were measured in the faecal 
samples using HPAEC and expressed in mg saccharide (lactose equivalent) per gram of 
faeces (Figure 7). Before the treatment, the saccharide level in the faecal sample was 23 
±4 mg.g-1 faeces, of which 85% monosaccharides and 15% oligosaccharides, for both GOS 
and placebo group. Overall, the amounts, and thereby the proportion, of mono- and 
oligosaccharides remained rather stable over the study, except at day 2. At day 2, the 
levels of saccharides tended to increase for the placebo group (39 ±26 mg.g-1 faeces; 
p<0,15) and were significantly higher for the GOS group (57 ±33 mg.g-1 faeces; p<0.05) as 
compared to day 0. At day 2, the proportion of monosaccharide increased to 30% and 24% 
in the GOS and placebo group, respectively. As the level of saccharides increased in both 
groups, it was due to AMX action. Overall, no differences were detected between the 
saccharides levels of the GOS groups as compared to the placebo group. 
 
Figure 7: Mono- and oligosaccharide (including disaccharides) levels in the faecal samples of 
healthy adults receiving AMX treatment and GOS or placebo (MD) intake as measured by HPAEC. 
Values are expressed as mean of mg saccharide (lactose equivalent).g-1 faeces. Significant difference 
between in time per treatment is indicated with † (p<0.05).    
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Discussion 
Starting conditions 
Before the treatment (phase 0; days 0 and 0), subjects from both groups had a healthy 
complex microbiota composition. An individual diversity in the microbiota was observed 
at species level, as reported previously.22 The number of total bacteria (1010.3 copies.g-1 
faeces) is in the lower range of what is usually detected (109 to 1012 CFU.ml-1),23, 24 while 
the number of Bifidobacterium spp. (109.5 copies.g-1 faeces) is in line with literature.25 As a 
result, the proportion of bifidobacteria (17%) is rather high as compared to literature 
(≤10%).26 Regarding the activity of the microbiota before the treatment, the total amount 
of organic acids (102 ±15 µmol.g-1 faeces) and their relative concentration 
(acetate:butyrate:propionate:valerate of 59:20:16:4) in faecal sample were in line with 
literature, around 100 µmol. g-1 faeces total SCFA, 27 a low amount of intermediate organic 
acids and a molar ratio of acetate:butyrate:propionate of 60:20:20. 28  
 
Effect of GOS on the microbiota during AMX treatment 
Microbiota composition 
Although a low dose and a short duration of the AMX treatment were applied, changes in 
the microbiota composition were expected.29 For both placebo and GOS groups, the mean 
of total bacteria remained stable during the AMX treatment, which is in contradiction with 
previous in vivo studies.30, 31 In our study, a decrease up to 2 log10 was observed for 4 
subjects (2 subjects from each group) at different days (day 2, day 5 or day 8 after the 
treatment ended) (data not shown). This indicates that the response to an antibiotic 
treatment depends on the individual.32  
Rather than a decrease of total bacteria numbers, a shift in the bacterial composition was 
observed during the antibiotic treatment, as indicated before.33 The decrease of the 
relative abundances of Lachnospiraceae and Bifidobacterium and the increase of the 
relative abundance of Enterobacteriaceae observed for 3 out of 5 subjects in the placebo 
group due to AMX treatment are consistent with literature.29 Although no significant 
differences were found between the placebo and GOS groups, the intake of GOS to adults 
receiving the AMX treatment tended to limit the decrease of Bifidobacterium, but did not 
prevent either the decrease of Lachnospiraceae or the growth of Enterobacteriaceae. The 
low level of Lachnospiraceae as well as the higher level of Bifidobacterium for the GOS 
group as compared to the placebo group are in line with previous in vitro results.7 The 
bifidobacteria level measured in vitro at 24h of fermentation was already similar or higher 
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than the level measured at t=0, whereas the bifidobacteria level was still below the initial 
levels during the AMX treatment in the in vivo study. The difference in rate of recovery 
might be explained by the use of a diluted system in vitro. It is also possible that the level 
of bifidobacteria measured during in vitro fermentation was higher because the effect of 
AMX diminishes in time in an in vitro assay. The relative high abundance of 
Enterobacteriaceae is in contradiction with previous in vitro data.7 This discrepancy might 
be explained by a difference in the initial level of Enterobacteriaceae in vitro (low) as 
compared to in vivo (high). Possibly, the difference between the initial levels resides in the 
variability of the microbiota composition between inocula. It might also be that the pre-
culture step of the in vitro study induced a preferred growth of Enterobacteriaceae.34 
Furthermore, the discrepancy might be due to a different contact between the antibiotic 
and the bacteria in the batch system (stronger) as compared to in the colon (less severe 
because of the presence of many vilis). Eventually, the relative high abundance of the 
Enterobacteriaceae should be confirmed by quantification, as microarrays only provide 
relative changes in the composition of the microbiota. 
Overall, it can be concluded that GOS intake did not significantly prevent the changes in 
the microbiota composition observed during the AMX treatment, although GOS tended to 
limit the decrease of bifidobacteria.   
 Microbiota metabolic activity 
The disruption of the microbiota composition upon AMX was also reflected in observed 
changes in the metabolic activity. The levels of mono- and oligosaccharides as well as the 
levels of succinate and lactate tended to increase at day 2 for the placebo group as 
compared to day 0. Most probably, the bacteria metabolic activity, including enzyme 
synthesis and fermentation activity, was reduced upon antibiotic treatment, resulting in a 
lower degradation of the oligosaccharides available,35,36 an accumulation of 
monosaccharides, and a lower conversion of the intermediate organic acids into SCFA.9 
The changes in the metabolic activity was also observed upon GOS addition, as reported 
previously in vitro.7 A significantly higher levels of mono- and oligosaccharides were 
measured at day 2 as compared to day 0, reflecting the fibre-enriched diet of the GOS 
group. In addition, the fermentation of GOS by bifidobacteria was reflected by the 
significant increase of lactate for the GOS group as compared to the placebo group. As the 
cross-feeding network is disrupted due to AMX action, lactate is accumulated instead of 
being converted to SCFA, e.g. butyrate.37 In conclusion, despite an evidence for a partial 
utilisation of GOS by the microbiota, the overall metabolic activity of the microbiota was 
still majorly disturbed during AMX treatment. 
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Effect of GOS on the microbiota after AMX treatment 
After the AMX treatment, it was clear that the level of bifidobacteria was significantly 
higher in the GOS group compared to the placebo group. Bifidobacteria species produce 
lactate and acetate.37 The high level of butyrate for the GOS group compared to the 
placebo group suggests that GOS intake also stimulated the recovery of other bacteria of 
the ecosystem, probably through cross-feeding on lactate and acetate.37 The significant 
increase of the level of total bacteria for the GOS group as compared to the placebo group 
reflects the recovery of the bifidobacteria and of other groups of the microbiota, e.g. 
butyrate-producing bacteria. Overall, the recovery of the microbiota composition and 
metabolic activity occurs faster upon GOS addition than placebo after the AMX treatment 
ended. An increase of bifidobacteria in infants receiving a mixture of FOS and Inulin was 
also observed after AMX treatment.31 It, therefore, seems that the beneficial effect of GOS 
on the AMX treated microbiota becomes significant after the AMX treatment ended 
rather than during the AMX treatment. 
 
Resilience of the microbiota 
In the follow up period (3 weeks after the end of AMX treatment), the levels of total 
bacteria and of bifidobacteria as well the SCFA profile and the amounts of mono- and 
oligosaccharides in faeces returned to their initial levels. The resilience of the microbiota 
composition was reported to occur within a month in a previous study.10 In the current 
study we showed that the resilience of the microbiota metabolic activity occurs shortly 
after the AMX treatment ended, despite the microbiota composition was still altered at 
that moment. This conclusion illustrates the reported redundancy of the functionality of 
the microbiota.26 
Despite a high percentage of resilience observed on the bacterial fingerprints, individual 
differences at species level were detected, especially for the Bacteroides group. These 
differences at species level might indicate a long term impact of antibiotic on the 
microbiota.38 Long term impacts are increasing with increasing exposure events and short 
resilience time between the subsequent treatments.32   
 
Effect of GOS on stools and gastro-intestinal discomfort 
In general, no effects on gastro-intestinal discomforts were reported regarding, bloating, 
flatulence, heartburn and nausea for both placebo and GOS groups. This was expected as 
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the dose of GOS (7.5g/day) was chosen in the range where GOS has been reported to have 
bifidogenic effect but limited side effects, such as bloating and flatulence (from 2.5 to 10.0 
g/day).15 
On an individual level, the two subjects that reported one loose stool or one time 
diarrhoea belonged to the GOS group. Several factors could have caused this effect, 
among which the disruption of the microbiota by AMX treatment (low number of 
Bifidobacterium spp., increase in Enterobacteriaceae), consumption of a particular or 
spoilt product, or another change in the diet of the subjects. Another speculation could be 
that the GOS added to the fibre already present in the subjects diet, might have been too 
much to be handled by the by AMX disturbed microbiota, resulting in an osmotic 
diarrhoea.  
 
Concluding remarks 
This in vivo study revealed the potential of GOS to limit the decrease of bifidobacteria 
during an AMX treatment and to stimulate the bifidobacteria growth after the AMX 
treatment ended. Considering SCFA profiles and mono- and oligosaccharides levels in 
faeces, it was also shown that the GOS addition stimulated the recovery of the microbiota 
activity after the AMX treatment has ended rather than already during the treatment. This 
research has provided data that confirm previous results obtained in in vitro study7 and, 
thereby, justify further research involving targeted populations, such as patients, infants 
or elderly rather than healthy adults. 
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Supplementary Data 
 
 
Figure S1: Variation in the number of total bacteria and Bifidobacterium spp. during and after 
treatment for healthy adults receiving AMX with GOS (n=5 until day 5, n=4 after day 5) or with 
placebo (MD; n=5). Values are expressed as mean of the normalised log10 (copies.g
-1 faeces). 
Significant difference between GOS and placebo groups is indicated with * (p<0.05 or p=0.07 when 
indicated). Significant difference in time per treatment is indicated with † (p<0.05).  
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Research aim and approach 
Besides treating bacterial infections, antibiotic treatments also impact untargeted bacteria 
from the microbiota and, therefore, may lead to gut disorders. The side effects of 
antibiotics on the microbiota have been suggested to be reduced through the addition of 
prebiotics, which stimulate beneficial bacteria in the microbiota.1 Nevertheless, results 
were not consistent in literature and more research was necessary. This thesis aimed to 
understand whether and by which mechanisms GOS, a known prebiotic, could help to 
counter the side effects of antibiotics on the human gut microbiota. The approach was to 
screen for potential positive effects of GOS supplemented to microbiota treated with 
different antibiotics using a fermentation-screening platform. Next, the specific 
combination(s) of GOS-antibiotic that showed a positive effects of GOS on the recovery of 
the antibiotic-treated microbiota were studied in more details. The impact of GOS was 
studied on the microbiota composition as well as the microbiota metabolic activity 
disrupted with antibiotic treatments, both in vitro and in vivo. In this chapter, the main 
findings of this PhD thesis, the methodology used, and implications for further research 
are discussed. 
 
Main findings  
Effects of GOS on antibiotic-treated microbiota are antibiotic and dose 
dependant  
Part of the orally administrated antibiotics is known to reach the colon and disturbs the 
microbiota.2 The impact of antibiotics on the gut microbiota could be successfully 
monitored using an in vitro fermentation screening-platform coupled to a phylogenetic 
microarray (Chapter 2). Overall, the shift in the bacterial composition increased with an 
increasing dose, while shifts in bacterial population were also noticed upon sub-Minimal 
Inhibitory Concentrations (MIC). Next to be dose dependant,  the impact on the 
microbiota was also antibiotic dependant. The antibiotic and dose dependant shifts in the 
microbiota composition observed in vitro were similar to previous in vivo results.3 When 
GOS was added, the main impact was observed on Bifidobacterium spp. level and to a 
lesser extent on Lactobacillus spp. level (Chapter 3). This was expected as GOS has been 
demonstrated to be specifically degraded by Bifidobacterium spp. and Lactobacillus spp.4 
Lactobacilli were stimulated upon GOS addition mostly when not initially affected by the 
antibiotic treatment. It concerned L. brevis in 1 µg.ml-1 treated microbiota and L. gasserri 
in 10 µg.ml-1 treated microbiota (Chapter 3). Similarly, when the bifidobacteria level was 
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not decreased upon antibiotic exposure (Ciprofloxacin and Doxycycline), their level 
obviously increased upon GOS addition. On the contrary, when the bifidobacteria level 
was dramatically decreased upon antibiotic exposure (Clindamycin), little or no recovery 
of their level was observed in vitro upon GOS addition. A third case was striking as the 
level of bifidobacteria recovered to the initial level or higher upon GOS addition whereas it 
was first decreased due to amoxicillin (AMX) action (Chapter 3). The positive effect of GOS 
on AMX-treated microbiota was confirmed in another in vitro experiment (Chapter 4) as 
well as a human trial involving healthy adults (Chapter 5).  
Furthermore, different species of Bifidobacterium were observed to grow upon GOS 
addition depending on the antibiotic treatment, although the same inoculum was used for 
all conditions (Chapter 3). Clearly, this indicates that antibiotics impact certain 
bifidobacteria species more than others. Upon AMX treatment, B. longum was shown to 
be specifically stimulated upon GOS addition (Chapters 3 and 4). This species was also still 
present in faecal samples of infants receiving AMX, whereas in that study the level of 
other bifidobacteria was largely decreased.5 In this thesis, the (least affected) B. longum 
could, therefore, benefit from the available GOS substrate and recover beyond its initial 
level. 
Overall, it can be concluded that the recovery of beneficial bacteria as well as which 
specific species recover upon GOS addition are antibiotic and dose dependant. This 
suggests that specific combination of prebiotic-antibiotic should be considered to develop 
strategies countering the sides-effects of antibiotic on the microbiota.  
 
Correlating the microbiota composition to its metabolic activity 
Not only the microbiota composition is disrupted by antibiotic treatment, but 
subsequently the microbiota metabolic activity as well.2 In this thesis, the metabolic 
activity was investigated by monitoring both the degradation of the substrate and the 
production of organic acids. 
 
Oligosaccharide degradation 
The degradation rate of GOS was monitored during in vitro fermentation using HPAEC 
(Chapters 3 and 4). A delay in the in vitro degradation of GOS was observed upon 
antibiotic exposure (Chapter 3), which is in line with the increased level of 
oligosaccharides present in faeces of healthy adults receiving amoxicillin (Chapter 5). The 
delay in GOS degradation was also observed upon antibiotic treatments that did not 
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decrease the abundance of living bifidobacteria (Chapter 3). The latter observation 
indicates that the limited degradation of GOS is not only due to the disruption of the 
bifidobacteria population but also due to the disruption of enzyme synthesis.6 Once the 
degradation of GOS was started, the level of GOS degradation correlated with the level of 
bifidobacteria (and lactobacilli) growing (Chapter 3). Interestingly, specific size-fractions of 
GOS were preferentially degraded depending on the antibiotic used (Chapter 3) and 
within a specific size-fraction, different isomeric structures were preferentially degraded 
for AMX-treated microbiota as compared to non-treated microbiota (Chapter 4). The 
preferably degraded GOS structures correlated with the enzymes produced by the specific 
bifidobacteria species stimulated upon the antibiotic treatments (Chapters 3 and 4).  
Overall, the recovery of specific species of Bifidobacterium is concomitant to the 
degradation of particular GOS structure, indicating that the composition of the GOS 
mixture could be optimized for each antibiotic treatment.  
 
Levels of organic acids 
Fermentation of dietary compounds by the microbiota results in the production of organic 
acids (OA), being intermediate OA, such as lactate and succinate, and end-products such 
as SCFA. No or low amounts of intermediate OA are usually detected as they are 
converted to SCFA.7 Upon antibiotic treatment, the fermentation of GOS by the 
microbiota was negatively affected as indicated by the accumulation of monosaccharides 
and the decrease of the amount of SCFA (Chapter 3), which is consistent with literature.8 
The disruption of the SFCA production was in line with the level of disruption of the 
microbiota induced by the dose and the antibiotic used (Chapter 3). Interestingly, the ratio 
of SCFA : intermediate OA was shown to decrease from 10:1 in a non-treated microbiota 
to 0.7:1 in strongly antibiotic-disrupted microbiota (Chapter 3). This indicates that the 
conversion from lactate/succinate to SCFA was reduced. Different size-fractions of GOS 
could influence the type of SCFA or intermediate OA produced during in vitro 
fermentation using AMX-treated microbiota (Chapter 4). Nevertheless, the disruption of 
the SCFA and intermediate OA production occurred despite GOS addition during 
amoxicillin treatment, both in vitro and in vivo (Chapters 3-5). The altered concentrations 
of SCFA and intermediate OA are unusual in the colon and might have consequences on 
colon health. For instance, a depletion of butyrate might influence the colon epithelial 
cells as they derive 70% of their energy through the oxidation of this SCFA.9  
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In the human trial, the levels of most SCFA and intermediate OA returned to their initial 
levels after the AMX treatment ended. Interestingly, after the AMX treatment ended, a 
higher amount of butyrate was observed  for the GOS group as compared to the placebo 
group, indicating the stimulation of the cross-feeding among bacteria (Chapter 5).  
Overall, the SCFA: intermediate OA ratio during the AMX treatment is an indication of the 
level of disruption of the microbiota. GOS addition did not prevent the disruption of the 
metabolic activity of the microbiota during the antibiotic treatment in both in vitro and in 
vivo experiments, but stimulated the recovery the microbiota metabolic activity after the 
antibiotic treatment ended in vivo.  
 
Cross-feeding activity in antibiotic-treated microbiota upon GOS addition 
The degradation of GOS reflects the (recovered) activity of bifidobacteria. However, the 
accumulation of monosaccharides during the in vitro fermentation (Chapters 3-4) and 
during the AMX treatment in humans (Chapter 5) indicates that the activity of the other 
bacteria was disrupted despite the GOS addition.  
The growth of other bacterial groups was expected upon GOS addition because of cross-
feeding.10 For instance, lactate and acetate produced by bifidobacteria can be utilised by 
butyrate-producing bacteria such as Eubacterium, Roseburia.11 The growth of Eubacterium 
was detected upon GOS addition for ciprofloxacin treatment (Chapter 2). However, in 
most cases, the growth of butyrate-producing bacteria was not detected in our 
experiments despite an observed production of butyrate. Most likely, the changes in 
relative abundance of the targeted species were not detected with the microarray due to 
the low amount of these species (<1% total bacteria).11, 12 In the human trial, growth of 
butyrate-producing bacteria was observed for certain individuals independently from GOS 
or placebo intake. Quantification by qPCR of these bacteria is recommended to conclude 
about the indirect effect of GOS on butyrate-producing bacteria. 
The production of butyrate was shown to be influenced by the size of GOS added in an 
AMX-treated microbiota (Chapter 4). Butyrate production is of interest as butyrate is an 
SCFA known to have beneficial effect of colon health, such as reducing colon cancer.13 Two 
other groups of bacteria than the butyrate producing bacterial group were stimulated in 
AMX-treated microbiota depending on the size of GOS present: Enterobacteriaceae and 
Lactobacillus. The relative decreased abundance of Enterobacteriaceae observed due to 
amoxicillin treatment (Chapter 2) was not influenced by the addition of the complex 
mixture of GOS (Chapter 3), but seem to decrease less upon the addition of small size-
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fractions of GOS (Chapter 4). Also, the increase abundance of Lactobacillus gasseri was 
observed upon the addition of small size-fractions of GOS, which is in line with the 
increase of lactate production observed (Chapter 4). Changes in the abundances of 
bacterial groups upon the concentration of specific size of GOS might influence the host 
health. For instance, the growth of Lactobacillus could be beneficial for the host as it is a 
reported beneficial group of bacteria,14 whereas, limiting the decrease of 
Enterobacteriaceae by AMX could be a risk for pathogen development and gut diseases.15 
In conclusion, the disruption of the overall metabolic activity is observed despite GOS 
addition during AMX treatment, but the concentration of specific size of GOS appear to be 
of importance to stimulate other bacterial groups of the microbiota through cross-feeding.     
 
Methodological considerations 
Using in vitro models to predict in vivo responses  
Human studies are considered to be superior to study the effect of a compound on the 
microbiota and subsequent human health. Nevertheless, they are expensive, low 
throughput and face ethical restrictions.16 Furthermore, results are not easily comparable 
as responses are highly individual dependant.17 Using a fermentation-screening platform 
with a standardized pool of adult faecal inoculum (n=8) enabled the study of the effects of 
antibiotics on the human gut microbiota and the effect of GOS on antibiotic-treated 
microbiota in a high-throughput approach (Chapter 2-4). The pooled inoculum, prepared 
according to Minekus et al,18 was especially relevant in our study since it limited inter-
individual variations and increased the probability to have a larger representation of 
potential bacterial species in the human colon. Furthermore, despite the fact that the 
microbiota composition of faecal material might not be representative of the composition 
of the microbiota in the proximal colon,19 using a faecal inoculum allowed to investigate 
the effect of antibiotics and of GOS addition on a complex ecosystem taking cross-feeding 
interactions into account. Although the high-throughput approach allowed a 
straightforward comparison of the results, it also had some limitations. The main two 
limitations were (i) not mimicking the host-microbiota interactions, and (ii) influencing the 
different growth rates of the bacteria present due to the use of a diluted system. 
Nevertheless, the controls were similar among different in vitro experiments (Chapters 2-
4) indicating the reproducibility of the model system. In addition, the beneficial effects of 
GOS on amoxicillin-treated microbiota observed in vitro were evidenced in a human trial 
(Chapter 5). Despite individual variability, the bifidobacteria level recovered upon GOS 
intake and the cross-feeding activity of the microbiota upon GOS intake was reflected by 
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the significant increase of butyrate level in faecal sample after the AMX treatment. It is, 
therefore, concluded that a batch fermentation model with a pool of faecal inoculum is 
reliable to predict generic impact on the microbiota of humans.  
 
 Study design and outcome of the in vivo study 
Study design 
A double-blind randomized parallel intervention study was conducted using 12 healthy 
adults receiving amoxicillin and GOS/placebo (Chapter 5). Healthy adults were recruited 
because the risk for adverse events was considered to be lower as their microbiota is 
more mature, diverse and stable as compared to patients, infants or elderly.20, 21 The risks 
for diarrhoea do exist for healthy adults receiving amoxicillin treatment but are defined as 
“nuisance diarrhoea”, which is a frequent loose and watery stool with no other 
complications. Severe adverse such as risk for colitis, which is a potential source of serious 
progressive disease, is rare (< 0,01%).22 Furthermore, the dose selected for the in vivo trial 
(375mg 3x per day) was in the low range of commonly prescribed doses,22 therefore 
limiting the risk for side effects. An option for future research is to recruit subjects that 
need antibiotic treatments for medical reason, although the lack of a baseline 
observation, the diversity of treatment regarding dose and duration as prescribed by the 
practitioner and the rush in getting started (no real time to inform the volunteer properly) 
should be considered to have a representative and volunteer-friendly study.  
 
Outcome measured 
The outcomes of the impact of GOS on antibiotic-treated microbiota measured were the 
changes in the microbiota composition of the faecal samples, especially the changes in 
bifidobacteria level, and the changes in the microbiota metabolic activity, being 
oligosaccharides and SCFA levels in the faecal sample. Since the microbiota composition is 
known to change along the colon,19 and the SCFA produced are absorbed through the 
portal vein,13 the measurements performed using the faecal sample might not be 
representative of the microbiota as present in the proximal colon. Nevertheless, the faecal 
sample is the only accessible material that can be measured in healthy humans 
considering ethical issues.  
A high standard deviation was observed for SCFA and oligosaccharide levels in the faecal 
samples. This could be due to the fact that the diet of the subjects was not controlled. Due 
to a possible difference in the type of fibre and the fibre level in the diet of the two groups 
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the levels of oligosaccharides and SCFA measured in the faecal sample might have been 
influenced.13 Further studies should control the diet of the subjects (at least the fibre 
intake) and have a non-digestible marker to better understand the effects of GOS on the 
metabolic activity. Nevertheless, a major strength of this study is that the results can be 
easily extrapolated to the general population as the real-life situation is represented. 
Another strength of the study resides in its double blind character. The effect of GOS on 
bifidobacteria level was significantly different between the two groups despite the limited 
number of people and the uncontrolled diet. This outcome gives strong evidence that 
prebiotic can help to recover the microbiota composition after amoxicillin treatment. 
Overall, this in vivo study had a strong experimental set up and, therefore, provided data 
to justify further large studies involving targeted population.  
 
New perspectives for GOS addition to antibiotic-treated 
microbiota 
In chapters 2-4, in vitro experiments were performed using adult inoculum. In addition, 
GOS was always added simultaneously to the antibiotic treatment. Since the microbiota 
composition is changing with the host age20 and since in vivo data (Chapter 5) indicated 
that the time of addition of GOS might be of importance, supplementary studies were 
performed to investigate these issues. The results are described below.  
 
Time of GOS addition  
Upon amoxicillin treatment, the level of Bifidobacterium spp. recovered upon GOS 
addition in both in vitro and in vivo experiments (Chapters 2 to 5). The recovery was, 
however, observed after the treatment has ended in the in vivo trial, suggesting that 
supplementation GOS after an antibiotic treatment could be more beneficial than during 
the treatment (Chapter 5). In addition, it was suggested that the diarrhoea developed by 
one subject belonging to the GOS group was due to the high level of oligosaccharides in 
the colon as reflected in the faeces during the antibiotic treatment (Chapter 5). This 
observation reinforces the suggestion to supplement GOS after the AMX treatment.     
In order to investigate whether the time of addition of the prebiotic influences the 
recovery of the microbiota, an in vitro fermentation was performed in which GOS 
(4,2 mg.ml-1) was added during or 24h after a 10 µg.ml-1 amoxicillin treatment 
(unpublished results). The antibiotic effect was expected to be sufficiently diminished 
after 24h of fermentation.23  
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In table 1, it is clear that the level of Bifidobacterium spp. was significantly higher when 
GOS was added 24h after treating the microbiota with AMX (9.2 ±0.8 log10 copies.ml
-1) 
than when GOS was added simultaneously to the AMX treatment (7.5 ±0.5 log10 copies.ml
-
1), although the level of bifidobacteria was similar after 24h exposure to AMX (6.2 and 6.5 
log10 copies.ml
-1, respectively). These results confirm that the bifidobacteria activity is 
limited during the AMX treatment both with and without GOS but also suggest that the 
bifidobacteria were in a “better state” to utilise the GOS when GOS was added after the 
AMX activity diminished. The rate of degradation of GOS (Table 1) corroborates this 
suggestion as the microbiota was observed to degrade GOS faster after the AMX activity 
diminished than when GOS is added simultaneously. In addition, it was observed that the 
final concentration of SCFA was proportional to the rate of GOS degradation. The highest 
concentration of SCFA, comprising butyrate, was obtained when GOS was added after 
AMX activity diminished, while the lowest concentration of SCFA, without butyrate found, 
was observed when GOS was added simultaneously to AMX (Table 1).  
 
Table 1: Effect of the moment of GOS addition on the level of Bifidobacterium spp., percentage of 
GOS degraded and concentration of SCFA during in vitro fermentation using healthy adult 
microbiota treated with AMX (n=2). 
 
Time of 
fermentation 
Moment of GOS addition 
to AMX-treated microbiota 
During After 
Bifidobacterium spp. level 0h 6.9 ±0.2 7.0 ±0.3 
log10 (copies.ml
-1) 24h 6.5 ±0.1 6.2 ±0.2 
 
48h 7.5 ±0.5 9.2 ±0.8 
Degradation of  GOS (%) 0h* 0 ±2 0 ±0 
(based on peak area) 24h* 9 ±4 80 ±8 
 
33h* 65 nd 
 
48h* 87 ±4 nd 
Concentration of SCFA (µmol.mg-1 GOS) 48h   
               acetate  4.5 ±0.1 15.5 ±3.0 
               propionate  2.5 ±0.1 3.8 ±1 
               butyrate  NF 0.3 ±0.0 
               lactate  1.1 ±0.1 0.6 ±0.1 
               Total  8.1 20.2 
     * time after GOS addition, nd: not-determined, NF: not found  
 
Amoxicillin has a bactericidal mode of action. It inhibits the cell wall synthesis during 
bacterial multiplication. Due to an incomplete cell wall, water is absorbed into the 
bacterial cell by osmosis, leading to the lysis of the cell. As gram positive and gram 
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negative bacteria differ in their intracellular osmotic pressure as compared to external 
environment (10-30 and 3-5 times more, respectively), AMX is more effective against 
gram positive than gram negative microorganisms.24 This mechanism of action might 
explain why GOS added simultaneously to AMX is not ideal. Since GOS stimulates 
bifidobacteria growth, AMX is more likely to inhibit these growing bacteria. When GOS is 
supplemented after AMX has lost its activity (by inhibiting other growing bacterial groups), 
bifidobacteria are free of inhibitors and, hence, are able to multiply and grow. Since the 
antibiotic action reduced competitors for intermediate substrates, the growth rate of 
bifidobacteria in a AMX-treated microbiota is higher than in a non-treated microbiota. In 
conclusion, supplementing GOS to an AMX-treated microbiota helps the recovery of the 
microbiota, especially if, considering the mode of action of amoxicillin, GOS is 
supplemented after the AMX activity diminished.  
 
Age of the microbiota host 
Healthy adults were recruited because the risk for adverse events was considered to be 
lower as their microbiota is more mature, diverse and stable as compared to infant or 
elderly. 20, 21 However, amoxicillin is often used for infants25 and antibiotics in general are 
most often prescribed for elderly.26 It is, therefore, interesting to know how the age of the 
microbiota host influences the microbiota response to prebiotic upon amoxicillin 
treatment. For this purpose, in vitro fermentations were performed using faecal samples 
from babies (≤3 months old), adults (25-65 years) and elderly (≥65 years) treated with 10 
µg.ml-1 amoxicillin and supplemented with GOS (4.2 mg/ml).  
The initial composition of the microbiota differed for each age-group (Figure 1). The levels 
of Bifidobacterium spp. measured with qPCR decreased with age (40% Bifidobacterium 
spp. in babies- 13% in adults and 1,2% in elderly; data not shown), while the abundance of 
Bacteroides and Clostridium measured with the I-chip is higher for the adult and elderly 
(Figure 1), as also previously reported.27 The main impact of GOS addition to antibiotic-
treated microbiota was observed on Bifidobacterium spp. independently from the age of 
the microbiota host (Figure 1). The bifidobacteria level recovered within 24h of 
fermentation for amoxicillin-treated baby microbiota, while it recovered within 48h of 
fermentation for adult and elderly microbiota. Clearly, amoxicillin-treated baby microbiota 
benefited the most from the GOS addition. Furthermore, specific species of 
Bifidobacterium were stimulated depending on the age of the microbiota host, being 
mostly B. breve and B. indicatum in baby microbiota and B. longum in adult microbiota. 
These results are in line with the most abundant bifidobacteria species usually detected in 
faeces of different age groups.28 Interestingly, for the elderly microbiota, the abundance 
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of Clostridium disporicum and Klebsiella, which are known to be occasional or frequent 
human pathogens, respectively,29, 30 increased upon amoxicillin, independently of the GOS 
addition (Figure 1). The increase in Clostridium difficile is quite common for elderly 
subjects after an antibiotic treatment.20, 27 The higher susceptibility of elderly people to 
AAD21 seems not only to relate to the low levels of bifidobacteria, but also to the overall 
state and complex interactions among bacteria within the gut ecosystem. 
 
Figure 1: Bacterial fingerprints of the non-treated (NT) and amoxicillin-treated (AMX) microbiota 
from baby, adults and elderly and effect GOS on AMX-treated microbiota during in vitro 
fermentation. Signal compared to the background (S/B): Green: below detectable level, Black: 
medium abundance, Red: high abundance.  
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The metabolic activity of the microbiota (Table 2) was proportional to the level of 
disruption of the microbiota composition. For baby microbiota (the least disrupted by 
AMX), the degradation of GOS was the fastest and the SCFA produced were mostly 
acetate after 24h of fermentation. For adults and elderly microbiota, the degradation of 
GOS was slower (within 48h fermentation) and up to 8% succinate was produced. The 
adult and elderly microbiota were richer in Bacteroides than the baby microbiota before 
the AMX treatment (Figure 1). Despite the levels of Bacteroides for adult and elderly 
microbiota were not dramatically affected by AMX, it is likely that the Bacteroides activity 
was reduced, resulting in a limited  conversion of succinate to propionate.31 
In conclusion, supplementing GOS to an antibiotic-treated microbiota, no matter of the 
age group, seems to help to increase the bifidobacteria levels in vitro. Nevertheless, a 
higher level of bifidobacteria in elderly microbiota did not limit the growth of potential 
pathogen species, indicating that more complex interaction within the microbiota seem to 
predispose elderly population to AAD.   
 
Table 2: Influence of the age of the AMX-treated microbiota (baby, adult, elderly) on the 
percentage of GOS degraded and concentration of SCFA produced during in vitro fermentation.  
 
 
 
GOS addition to AMX-treated 
microbiota of different age 
Time of 
fermentation Baby Adult Elderly 
Degradation of  GOS     
 (% based on peak area) 0h 0 0 0 
 
12h 44 2 4 
 
24h 100 33 24 
 
48h 100 52 82 
Concentration of SCFA 
(µmol.mg-1 GOS)  
 
  
 
acetate 48h 9.8 11.4 6.2 
 propionate 48h 2.1 4.0 3.7 
 butyrate 48h 1.1 0.0 1.1 
 lactate 48h 0.0 0.4 0.0 
 succinate 48h 0.0 1.4 0.8 
 Total 48h 13.0 17.2 11.8 
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Future perspectives 
The aim of this thesis was to determine when and how GOS could counter the side effects 
of antibiotics. Overall, the results of this thesis confirmed the hypotheses: 1) The recovery 
of the microbiota upon GOS addition was antibiotic dependant and 2) the addition of GOS 
stimulated the growth of bifidobacteria and, subsequently, the functioning of the 
microbiota through cross-feeding. The detailed results provide insights on how to develop 
new strategies to counter the side effects of antibiotics.  
First, specific bifidobacteria and/or lactobacilli species were shown to recover depending 
on the antibiotic treatment and dose used. Identifying the best (highly resistant) species 
for a specific antibiotic treatment could lead to potential new probiotics effective against 
AAD. For amoxicillin treatment, it is suggested to consider the probiotic B. longum to 
decrease the rate of AAD. This probiotic, in combination with two other probiotics (L. 
rhamnosus and L. plantarum) has already been used in a clinical trial.32 Although no 
significant decrease of rate of diarrhoea was measured, the outcome of that study should 
be interpreted with caution as the rate of diarrhoea was surprisingly low, also in the 
placebo group. 
Secondly, adding GOS to antibiotic-treated microbiota had a neutral or a positive impact 
on the microbiota, independently of the age of the host. Hence, the intake of GOS should 
be considered upon receiving an antibiotic treatment. The best moment of administration 
of GOS to stimulate the growth of bifidobacteria upon treatment with a bacteriolytic 
antibiotic, such as amoxicillin, was suggested to be after the antibiotic treatment ended. 
This outcome was obtained in vitro and should, therefore, be confirmed in vivo before 
drawing strong conclusions. Although, the use of the current GOS mixture is already 
effective to recover the microbiota composition and metabolic activity upon antibiotic 
treatment, the results of this study also indicated that specific structures of GOS could 
influence the rate of recovery of the bifidobacteria. This observation provides new 
perspectives for the food industry to develop adapted mixtures of GOS or other prebiotics 
depending on the antibiotic treatment. The new mixture of GOS could be enriched in 
certain DPs, for instance enriched in large GOS for amoxicillin treatment as suggested in 
this thesis. Furthermore, new GOS structures could be developed. It is clear that breastfed 
baby have a microbiota composition that is richer in bifidobacteria and has a lower 
numbers of C. difficile and E. coli than formula fed baby,33 probably due to the 
composition of the human milk oligosaccharides. These human milk oligosaccharides have 
been shown to inhibit the adhesion of pathogenic bacteria to the epithelial surface.34 
Mimicking these structure by decorating GOS with sialic or fucosyl group could be of 
interest to limit the risks for AAD.  
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Another strategy would be to make use of synbiotics. The specific bifidobacteria species 
recovering upon a specific antibiotic treatment could be combined with the GOS mixture 
comprising the ideal composition of oligosaccharides that the species grow preferably on. 
This strategy would be especially of interest when little or no beneficial bacteria survive 
the antibiotic treatment (e.g. clindamycin). The intake of a synbiotic (FOS + B. longum or L. 
acidophilus) during a treatment of cefpodoxime proxetil successfully limited the decrease 
of lactobacilli and prevented the growth of C. difficile.35 
Finally, measuring the oligosaccharide degradation during in vitro fermentation revealed 
that some structures of GOS remain longer in time. Similarly as human milk 
oligosaccharides may limit the adhesion have of pathogenic bacteria to the epithelial 
surface,34 it could be of interest to study the anti-adhesive properties of these least 
degraded GOS in antibiotic-treated microbiota to further investigate how to reduce 
pathogen colonisation, especially C. difficile during antibiotic treatment.  
 
Overall, this thesis showed the potential of GOS to stimulate the recovery of the 
microbiota after certain antibiotic treatments. For amoxicillin-treated microbiota, the 
addition of GOS, especially the large oligosaccharides, allowed the recovery of B. longum 
and, subsequently, stimulated the activity of the microbiota through cross-feeding after 
an AMX treatment.   
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Summary 
 
The bacteria inhabiting the human gut, also called gut microbiota, have been recognised 
to play a key role in human health. The first chapter of this thesis describes the 
composition and metabolic activity of the gut microbiota and how it contributes to the 
health of the host. Then, the mostly used antibiotics in Europe and the known prebiotic 
galacto-oligosaccharides (GOS) are introduced. Both their impacts on the microbiota are 
addressed as well as how prebiotics have been considered to help preventing the negative 
side-effects of the antibiotics on the microbiota because of their bifidogenic effect. Finally, 
the chapter describes fermentation models and diagnostic tools to measure the 
microbiota composition. The discrepancies in literature regarding the effect of prebiotics 
in preventing the side-effects of antibiotics lead to the aim of this PhD thesis which is to 
investigate when and how the prebiotic GOS may counter the side-effects of antibiotics on 
the microbiota. The strategy of the thesis was to address the impact of GOS on both the 
microbiota composition and the microbiota metabolic activity disrupted with antibiotic 
treatments.  
First, the impact of seven mostly used antibiotics in Europe on adult intestinal microbiota 
was determined using a new high-throughput in vitro approach (Chapter 2). The in vitro 
fermentations were simultaneously performed using a screening-platform and the 
antibiotic-dependant shifts in the microbiota composition were investigated using a 
phylogenetic microarray. The method was shown to be reliable despite the variations in 
the number of total bacteria and the presence of dead and/or inactive cells induced by the 
antibiotic treatments. An overview of the impact of the seven antibiotics on the 
microbiota was obtained. Subsequently, 4 antibiotics were selected for further 
experiments based on their mode of action, classification and specific impact on the 
microbiota. 
In Chapter 3, the impact of the addition of the prebiotic GOS on an adult gut microbiota 
treated with the 4 selected antibiotics was investigated using the same high-throughput 
approach. In addition to the changes in the microbiota composition, the metabolic activity 
of the microbiota supplemented with GOS was investigated. The metabolic activity was 
investigated by monitoring the degradation of individual GOS components and the 
production of short chain fatty acids produced during fermentation using anion exchange 
chromatographic methods. The comparison of the results revealed unambiguously that 
the impact of GOS addition on antibiotic-treated microbiota was antibiotic dependant and 
that the recovery of bifidobacteria was concomitant to the degradation of GOS. The 
addition of GOS to amoxicillin (AMX)-treated microbiota was especially of interest as, after 
a decrease of the level of bifidobacteria due to AMX action, a the level of Bifidobacterium 
spp., mainly Bifidobacterium longum, recovered to the initial level and beyond. The results 
136 
 
 also pointed out that, despite a recovery of bifidobacteria and a degradation of GOS, the 
functionality of the microbiota was not fully recovered yet as the conversion of succinate 
to short chain fatty acids (SCFA) was limited.  
Chapter 4 focuses on the positive impact of GOS on AMX-treated microbiota described in 
chapter 3. In order to elaborate on which structures of GOS may stimulate the recovery of 
specific bifidobacteria species, GOS was fractionated based on size (molecular weight) 
using size-exclusion chromatography and the different size-fractions were in vitro 
fermented using non-treated and AMX-treated inoculum. The increase of bifidobacteria, 
especially B. longum, upon the addition of GOS after being decreased due to AMX action 
was evidenced. Interestingly, the growth of bifidobacteria and production of butyrate 
tended to be higher upon addition of large oligosaccharides (tetramers to hexamers) than 
small oligosaccharides (dimers-trimers) for AMX-treated microbiota. On the contrary, the 
growth of bifidobacteria and production of butyrate tended be higher upon addition of 
small oligosaccharides than large oligosaccharides for non-treated microbiota. Also, within 
a specific size-fraction, isomeric structures with certain types of linkages were 
preferentially utilised. β-D-Gal-(1→4)-D-Gal and β-D-Gal-(1→4)-β-D-Gal-(1→3)-D-Glc were 
the structures preferably degraded by AMX-treated microbiota whereas these structures 
remained among of the last ones to be degraded by non-treated microbiota. For the non-
treated microbiota, the linear structure β-D-Gal-(1→4)-β-D-Gal-(1→4)-D-Glc was 
preferably degraded. Overall, the results suggest that different size-fractions of GOS 
contribute to the growth of bifidobacteria species and butyrate production through cross-
feeding depending on the treatment applied, and within a size-fraction, specific isomers 
have a preferential impact.    
In chapter 5, the effects of GOS on AMX-treated microbiota were investigated in a double-
blind randomized parallel intervention study involving 12 healthy adults. The subjects 
received AMX for 5 days and either GOS (n=6) or placebo (maltodextrin; n=6) during and 
subsequently 7 days after the AMX treatment. Due to AMX treatment, a decrease of the 
number of bifidobacteria and a disruption of the metabolic activity, shown through an 
increase of succinate and oligosaccharides in faecal samples, were observed for both 
groups. A positive impact of the intake of GOS as compared to placebo was observed on 
the levels of bifidobacteria and of butyrate. The level of bifidobacteria tended to decrease 
less (p<0.15) during the AMX treatment and was significantly higher (p<0.05) after the 
AMX treatment when GOS was added as compared to placebo. The level of butyrate 
significantly increased as well (p<0.05) after the AMX treatment when GOS was added as 
compared to placebo. The increased level of butyrate reflected the recovery of the 
microbiota activity through cross-feeding. Overall, results confirm that the positive effect 
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of GOS on AMX-treated microbiota observed in vitro (Chapters 3 and 4) could be observed 
in vivo as well despite individual variability. 
In chapter 6, the in vitro results (chapters 3 and 4) related to the impact of antibiotic on 
the microbiota and the effect of prebiotics on antibiotic-treated microbiota were 
discussed in relation to the results of the in vivo study (chapter 5). After discussing some 
methodological considerations, the results obtained are put into perspective using results 
from additional in vitro experiments on the moment of administration of the prebiotic to 
the antibiotic-treated microbiota and on the age of the subjects. It is suggested that the 
positive effect of GOS on the composition and metabolic activity of the microbiota might 
be even higher if supplemented after the AMX treatment instead of during the AMX 
treatment. Furthermore, addition of GOS to AMX-treated microbiota positively influenced 
the level of bifidobacteria in the microbiota of a baby, adult and elderly person. The AMX 
treated microbiota of the baby benefited the most from GOS addition, while the AMX-
treated microbiota of the elderly person still contained a high level of potential pathogens 
despite the recovery of bifidobacteria upon GOS addition. Finally, the possible impact of 
this study on new probiotics, prebiotics and synbiotics development to prevent the 
negative side-effects of antibiotic is discussed.  
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De bacteriën die leven in de darmen van de mens, ook wel de microbiota genoemd speelt 
een belangrijke rol in de menselijke gezondheid. Het eerste hoofdstuk van dit onderzoek 
beschrijft de samenstelling en stofwisseling van de microbiota in de darmen. Ook is 
beschreven hoe de microbiota bijdraagt aan de gezondheid van de mens. Vervolgens zijn 
de veelgebruikte antibiotica, de bekende prebiotische galacto-oligosachariden (GOS) en 
hun impact op de microbiota beschreven. Hierna wordt ingegaan op gangbare fermentatie 
modellen en diagnose technieken, welke gebruikt worden om de samenstelling van de 
microbiota te bepalen. Tenslotte is beschreven hoe prebiotica met een bifidogeen effect 
de negatieve bijwerkingen van antibiotica op de microbiota helpen voorkomen. De 
verschillen in de literatuur hierover leiden tot het doel van dit onderzoek, namelijk 
onderzoeken wanneer en hoe de prebiotica GOS de negatieve bijwerkingen van 
antibiotica kan voorkomen. De aanpak van dit onderzoek richt zich op de impact van de 
prebiotica GOS op zowel de samenstelling van de microbiota als het bijbehorende 
metabolisch proces na  verstoring door het gebruik van antibiotica.  
Allereerst is in hoofdstuk 2 de invloed van zeven veelgebruikte antibiotica in Europa op de 
darmmicrobiota van een volwassene bepaald. Hiervoor is gebruik gemaakt van een 
nieuwe in vitro aanpak met een hoge verwerkingscapaciteit. Deze in vitro fermentaties zijn 
gelijktijdig uitgevoerd middels een screening platform. Vervolgens zijn de veranderingen in 
de microbiota die zijn veroorzaakt door de antibiotica onderzocht middels een 
fylogenetische microarray.  Deze methodiek is bewezen betrouwbaar voor het meten van 
het aantal bacteriën ondanks de aanwezigheid van dode en/of inactieve cellen die zijn 
veroorzaakt door de antibiotica behandeling. Met behulp van een overzicht van de invloed 
van de zeven antibiotica op de darmmicrobiota zijn vier antibiotica geselecteerd voor een 
vervolgexperimenten waarbij met name gelet werd op hun werking, classificatie en 
invloed op de darmmicrobiota.  
In hoofdstuk 3 wordt de impact van het toevoegen van de prebiotica GOS op de 
antibiotica-behandelde darmmicrobiota van een volwassene beschreven. Voor deze 
analyse zijn de 4 geselecteerde antibiotica gebruikt samen met dezelfde in vitro aanpak 
met een hoge verwerkingscapaciteit. Naast de veranderingen in de samenstelling van de 
microbiota is ook het metabolische proces in de microbiota in aanwezigheid van GOS 
nader onderzocht. Het metabolisch proces is onderzocht door het meten van de afbraak 
van specifieke GOS componenten en de vorming van korte keten vetzuren (KKVZ) als 
gevolg van de fermentatie. Hiervoor is gebruik gemaakt van 
ionenuitwisselingschromatografie. Uit de resultaten is het duidelijk dat de impact van de 
toevoeging van GOS op de microbiota afhankelijk is van de gebruikte antibiotica. Tevens 
blijkt de afbraak van GOS gerelateerd te zijn aan het herstel van de populatie 
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 bifidobacteriën. Een interessante waarneming is dat bij toevoeging van GOS aan de 
amoxicilline (AMX) behandelde microbiota de hoeveelheid bifidobacteriën in eerste 
instantie afneemt om vervolgens toe te nemen tot voorbij het oorspronkelijke niveau, 
waarbij vooral Bifidobacterium longum  domineert. De resultaten bewijzen ook dat 
ondanks de toename van bifidobacteriën en de afbraak van GOS, de microbiota nog niet 
volledig hersteld is gezien het feit dat de omzetting van barnsteenzuur naar kortketenige 
vetzuren (KKVZ) nog beperkt is.  
Hoofdstuk 4 verdiept zich meer op de positieve impact van GOS op de met AMX 
behandelde microbiota zoals beschreven in hoofdstuk 3. Om in te kunnen gaan op welke 
componenten van GOS het herstel van specifieke bifidobacteriën specifiek stimuleren zijn 
eerst alle componenten van GOS onderverdeeld op basis van grootte (moleculair gewicht). 
Hiervoor is gebruik gemaakt van gelfiltratie chromatografie. De verschillende 
componenten zijn vervolgens in vitro gefermenteerd met niet behandelde en AMX 
behandelde microbiota. Na de toevoeging van GOS is een toename van het aantal 
bifidobacteriën zichtbaar, vooral B. longum,  nadat deze eerst was gedaald door de AMX 
behandeling. Interessant is dat de groei van bifidobacteriën en de productie van butyraat 
in een AMX-behandelde microbiota hoger is bij het toevoegen van grote oligosachariden 
(tetrameren tot hexameren) dan bij kleine oligosachariden (dimeren en trimeren). In 
tegenstelling hiermee is de groei van bifidobacteriën en de productie van butyraat bij een 
niet-behandelde microbiota juist hoger bij het toevoegen is van kleine oligosachariden. 
Binnen een gekozen grootte-fractie worden structuren met bepaalde type 
glycosidebindingen met voorkeur benut. β-D-Gal-(1→4)-D-Gal en β-D-Gal-(1→4)-β-D-Gal-
(1→3)-D-Glc zijn componenten die als voorkeur worden benut door een met AMX-
behandelde microbiota. Voor de niet-behandelde microbiota wordt juist vooral de lineaire 
component β-D-Gal-(1→4)-β-D-Gal-(1→4)-D-Glc benut. De resultaten suggereren dat de 
verschillende GOS grootte-fracties bijdragen aan de toename van bifidobacteriën en 
indirect ook de butyraat productie verhogen voor zowel AMX-behandelde als niet-
behandelde microbiota.  
In hoofdstuk 5, is de invloed van GOS op met AMX behandelde microbiota beschreven 
zoals bepaald in een dubbelblinde, willekeurige en parallelle interventieonderzoek met 
twaalf gezonde volwassenen. De proefpersonen kregen GOS (n=6) of met een placebo 
(maltodextrine, n=6)  gedurende (5 dagen) en na (7 dagen) een AMX-behandeling. Door 
de AMX-behandeling is in beide groepen een afname van het aantal bifidobacteriën 
aangetoond en wijzen een toename van succinaat en oligosachariden in de ontlasting 
monsters op een verstoring van het metabolisch proces. Een positieve invloed van de 
inname van GOS in vergelijking met de placebo werd waargenomen middels de aantallen 
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van bifidobacteriën en het niveau van butyraat. Het aantal bifidobacteriën blijkt af te 
nemen (p<0.15) gedurende de AMX behandeling en is significant hoger (p<0.05) na de 
AMX-behandeling door de inname van GOS in plaats van de placebo. Het niveau van 
butyraat is na de AMX-behandeling ook significant hoger (p<0.05) door de inname van 
GOS in plaats van de placebo. De stijging van het niveau van butyraat geeft indirect het 
herstel van de microbiota weer. Ondanks de aanwezigheid van individuele variaties 
bevestigen de resultaten dat de positieve invloeden van GOS op een met AMX-
behandelde microbiota zoals in vitro gevonden (hoofdstuk 3 en 4) bevestigd worden 
middels in vivo onderzoek.  
In hoofdstuk 6, zijn de in vitro resultaten (hoofdstuk 3 en 4) naar de invloeden van 
antibiotica op de microbiota en de invloeden van prebiotica op een met antibiotica 
behandelde microbiota en vergeleken met de resultaten van het in vivo onderzoek 
(hoofdstuk 5). Na het bespreken van enkele overwegingen aangaande de gebruikte 
analysemethoden zijn de verkregen resultaten in perspectief geplaatst door gebruik te 
maken van aanvullende in vitro experimenten omtrent het moment van toedienen van 
prebiotica aan een met antibiotica-behandelde microbiota en met de leeftijd van de 
microbiota-donoren. De onderzoeksresultaten suggereren dat de positieve invloed van 
GOS op de samenstelling en metabolische activiteit van de microbiota nog hoger kan zijn 
als deze wordt toegediend na de AMX-behandeling in plaats van tijdens de AMX-
behandeling. Daarnaast heeft de toevoeging van GOS op een met AMX-behandelde 
microbiota ook positieve invloeden op het aantal bifidobacteriën in de microbiota van een 
baby, volwassene of een oudere persoon. De met AMX-behandelde microbiota van een 
baby ervaart de meeste voordelen van GOS, terwijl de AMX-behandelde microbiota van 
een oudere na een GOS toevoeging naast een hersteld niveau van bifidobacteriën nog 
steeds een hoog gehalte van potentiele ziekteverwekkers bevat. Tenslotte zijn de 
mogelijke gevolgen van dit onderzoek voor de ontwikkeling van nieuwe probiotica, 
prebiotica en synbiotica om de negatieve bijwerkingen van antibiotica te voorkomen 
besproken.  
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L’ensemble des bactéries présentes le long de l’intestin humain, aussi appelé microbiote 
intestinal, joue un rôle important pour la santé humaine. Le premier chapitre de cette 
thèse décrit la composition et l’activité métabolique du microbiote intestinal et explique 
en quoi il contribue à la santé de l’hôte. Les antibiotiques les plus utilisés en Europe et le 
prébiotique galacto-oligosaccharide (GOS) sont ensuite présentés. Chacun de leur impact 
sur le microbiote intestinal est décrit, puis un état de l’art du potentiel des prébiotiques à 
prévenir les effets secondaires des antibiotiques sur le microbiote grâce à leur effet 
bifinogénique est fourni. Enfin, ce chapitre décrit les modèles de fermentation et les outils 
de diagnostic de la composition du microbiote. Les divergences dans la littérature sur 
l'effet des prébiotiques à prévenir des effets secondaires des antibiotiques ont conduit au 
sujet de cette thèse: étudier dans quelle mesure et de quelle manière le prébiotique GOS 
peut contrer les effets secondaires des antibiotiques sur le microbiote intestinal. L’étude a 
été conduite en évaluant les effets du GOS sur la composition et sur l'activité métabolique 
du microbiote toutes deux perturbées par des traitements antibiotiques. 
Tout d’abord, l’impact de sept antibiotiques souvent utilisés en Europe a été déterminé 
sur le microbiote intestinal adulte en utilisant une nouvelle approche in vitro à haut 
rendement (Chapitre 2). Les fermentations in vitro ont été réalisées en utilisant une 
plateforme de criblage tandis que les changements de la composition du microbiote en 
fonction de l’antibiotique utilisé ont été déterminés en utilisant une puce à ADN. La 
méthode à haut rendement s'est révélée fiable malgré les variations du nombre de 
bactéries totales et la présence de cellules mortes et/ou inactives induites par les 
traitements antibiotiques. Grâce à cette méthode, un aperçu de l'impact de sept 
antibiotiques sur le microbiote intestinal a tout d’abord été obtenu. Quatre antibiotiques 
ont ensuite été sélectionnés en fonction de leur mode d'action, leur classification et leur 
impact spécifique sur le microbiote intestinal pour poursuivre l’étude. 
Dans le chapitre 3, l’impact de l’ajout du prébiotique GOS au microbiote intestinal adulte 
traité par les quatre antibiotiques sélectionnés a été étudié en utilisant la même méthode 
à haut rendement. L’impact du GOS a été étudié en évaluant les changements dans la 
composition et l’activité métabolique du microbiote intestinal. L'activité métabolique a 
été évaluée par des méthodes de chromatographie d'échange d'ions en déterminant le 
pourcentage de dégradation des composants individuels du GOS et le taux d'acides gras à 
chaîne courte produits pendant la fermentation. Les résultats ont clairement montré que 
l'impact du GOS sur le microbiote sous antibiotiques était fonction du type d’antibiotiques 
et que la dégradation du GOS était simultanée au rétablissement du niveau des 
bifidobactéries. L’ajout du GOS au microbiote traité par amoxicilline (AMX) s’est révèlé 
particulièrement performant car, après une diminution du niveau de bifidobactéries due à 
144 
 
 l’action de l’AMX, le niveau de Bifidobacterium longum est revenu à son niveau initial ou 
l’a même dépassé. Les résultats ont également souligné que, malgré le retour des 
bifidobactéries à leur niveau initial et la dégradation du GOS, la fonctionnalité du 
microbiote n’était pas encore pleinement récupérée puisque la conversion du succinate 
en acides gras à chaîne courte restait limitée.  
Le chapitre 4 se concentre sur l’impact positif du GOS sur le microbiote traité par AMX tel 
que décrit au chapitre 3. Afin de comprendre quels composés du GOS stimulent le 
rétablissement de certaines espèces de bifidobactéries, le GOS a été fractionné en 
fonction de sa taille (poids moléculaire) en utilisant la méthode de chromatographie par 
exclusion de tailles. Les fractions de tailles différentes ont été fermentées in vitro en 
utilisant un inoculum non traité et un inoculum traité par AMX. Lors de l’ajout du GOS, le 
rétablissement du niveau de bifidobactéries, en particulier celui du B. longum, a été de 
nouveau observé. Pour le microbiote traité par AMX, la croissance des bifidobactéries et la 
production du butyrate avaient tendance à être plus élevées lors de l’ajout de grands GOS 
(tétramères à hexamères) que lors de l’ajout de petits GOS (dimères-trimères). Au 
contraire, pour le microbiote non traité, la croissance des bifidobactéries et la production 
de butyrate avaient tendance à être plus élevées lors de l’ajout de petits GOS que lors de 
l’ajout de grands GOS. Pour chaque taille de GOS, les isomères de structures 
préférentiellement dégradées par le microbiote traité par AMX étaient β-D-Gal-(1→4)-D-
Gal et β-D-Gal-(1→4)-β-D-Gal-(1→3)-D-Glc. Pour le microbiote non traité, l’isomère 
préférentiellement dégradée était la structure linéaire β-D-Gal-(1→4)-β-D-Gal-(1→4)-D-
Glc. Dans l’ensemble, ces résultats suggèrent que ce sont différentes tailles de GOS qui 
contribuent à la croissance des bifidobactéries et la production du butyrate selon le 
traitement appliqué au microbiote et pour une même fraction certains isomères ont un 
impact préférentiel. 
Dans le chapitre 5, les effets du GOS sur le microbiote traité par AMX ont été déterminés 
au cours d’une étude d’intervention, randomisée, réalisée en parallèle, en double aveugle, 
contrôlée au moyen d’un placebo, sur 12 sujets adultes sains. Les sujets ont reçu de l’AMX 
pendant 5 jours et soit du GOS (n=6) soit un placebo (maltodextrine, n=6)  en simultané et 
7 jours après le traitement antibiotique. Une diminution du nombre de bifidobactéries et 
une perturbation de l'activité métabolique ont été observées pour les deux groupes en 
raison de l’action d’AMX. La perturbation de l’activité métabolique a été montrée  par une 
augmentation des niveaux de succinate et d’oligosaccharides dans des échantillons de 
matière fécale. L’effet positif de la prise de GOS par rapport au placebo a bien été observé 
sur les niveaux de bifidobactéries et de butyrate. En effet, lorsque le GOS a été ajouté, le 
niveau de bifidobactéries avait tendance à moins diminuer au cours du traitement d’AMX 
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(p<0,15) et était significativement plus élevée après le traitement d’AMX (p<0,05). Le 
niveau du butyrate a augmenté de manière significative après le traitement AMX lorsque 
GOS a été ajouté (p<0,05). Cette augmentation du niveau de butyrate reflète la reprise 
d’activité du microbiote au moyen d’une alimentation croisée. D’un point de  vue général, 
les résultats confirment que les effets positifs du GOS sur un microbiote traité par AMX 
observés dans les essais in vitro (Chapitres 3 et 4) sont aussi observés dans le test in vivo.  
Dans le chapitre 6, les résultats des essais in vitro (chapitres 3 et 4) et de l'étude in vivo 
(Chapitre 5) sont discutés. Après avoir pris en considération des aspects méthodologiques, 
de nouvelles perspectives ont été dégagées en fonction de résultats d’expériences in vitro 
complémentaires. Ces expériences complémentaires ont montré que l’impact du GOS sur 
le microbiote sous traitement antibiotiques pouvait être influencé par le moment 
d'administration du prébiotique au microbiote et par l'âge des hôtes du microbiote 
inoculé. En effet, les effets positifs du GOS sur la composition et l’activité métabolique du 
microbiote étaient supérieures lorsqu’il été ajouté après le traitement d’AMX et non pas 
pendant le traitement d’AMX. D’autre part, l’ajout du GOS au microbiote traité par l’AMX 
a stimulé le niveau des bifidobactéries aussi bien pour les microbiotes d’un bébé, d’un 
adulte et d’une personne âgée, mais à des niveaux différents. Le microbiote du bébé s’est 
entièrement rétabli du traitement d’AMX avec du GOS alors que le microbiote d’une 
personne âgée présentait un niveau de bactéries potentiellement pathogènes élevé 
malgré le rétablissement des bifidobactéries dû à l’ajout du GOS. Enfin, ce chapitre 
présente les implications possibles de cette étude sur le développement de nouveaux 
probiotiques, prébiotiques et symbiotiques pour contrer les effets secondaires négatifs 
des antibiotiques.    
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